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DRPH INTEGRATING STATEMENT 
 
Introduction 
I began Doctor of Public Health (DrPH) studies at the London School of Hygiene & Tropical 
Medicine (LSHTM) in October 2005. I chose the DrPH over a PhD because the DrPH was designed 
for those of us whose career plans involved a broader range of global public health activities 
than academic research alone. DrPH training consisted of three components: (i) a taught 
component of three compulsory doctoral-level modules and three elective masters-level 
modules of five weeks each; (ii) an organisational attachment of 3-6 months and research report 
of not more than 12,000 words; and (iii) a research project of approximately eighteen months 
and thesis of not more than 50,000 words.  
 
Due to unavoidable work and life commitments during the past twelve years, I took several years 
of formal and informal study interruptions. This potentially makes me one of the longest-
enrolled research degree students in LSHTM’s history. University regulations have since 
changed, to force timely completion by students like me who encounter unanticipated 
difficulties. In hindsight, a PhD would have been a more straightforward option.  
 
Taught component 
The first two compulsory doctoral modules completed were 4005/4006 (now reorganised as one 
five-week module 5002): Evidence-Based Public Health Practice. The aim was ‘to enable students 
to locate, assess, synthesize, present and use research-based information to improve public 
health in a range of settings.’ These modules focused on applying research evidence to public 
health policy-making and examining the processes involved, from collecting appropriate 
evidence through agenda setting to how changes occur in policy and practice. This was similar 
to modules I had taken during my MSc, but provided greater depth, and I have since been able 
to apply elements learnt to my own teaching and research projects.  
 
The third compulsory five-week doctoral module completed was 4004: Leadership and 
Organisational Management, since renamed 5001: Understanding leadership, management and 
organisations. Its aim was ‘to provide students with opportunities to explore a range of issues 
and theories relating to management, leadership and organisations, to consider the application 
of these theories in public health organisations and to their own management practice, and to 
develop an understanding of themselves as leaders and managers in public health.’ This module 
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focused on organisational management theory and practice, e.g. strategic and change 
management, and personal leadership development. I learnt a number of useful skills, including 
how to implement and interpret managerial analyses (e.g. SWOT analysis). I was able to apply 
this to the organisational attachment report and subsequent teaching and consultancy work. It 
also helped in applying an evaluation framework to the interventions included in this thesis (i.e. 
Chapter 7). 
 
The three MSc modules I completed as part of my coursework were: (i) PH208: Financial 
Management; (ii) 3141: Vector Sampling, Identification & Incrimination; and (iii) 1807: Principles 
and Practice of Health Promotion. I chose module PH208 as the topic was not sufficiently 
covered in the doctoral modules and have since been able to apply some of the skills developed 
in consultancy work and to the costing sections of Chapter 3. I chose module 3141 to improve 
my ability to identify and differentiate malaria vectors, which was extremely useful on its own, 
and I was able to apply some of it to chapter background sections (e.g. Chapter 1). I chose 
module 1807 to deepen my knowledge of health promotion theory and methods, some of which 
were applicable to Chapter 5 on insecticide-treated net purchasing and the discussion (Chapter 
7). Completion of three elective MSc modules is no longer required, which could help speed 
completion of the degree. 
 
I additionally attended three MSc modules to strengthen my technical and theoretical grounding 
in specific subject areas necessary to the thesis, which could not be included as course modules 
due to timing and prerequisites. These were: (i) 1103: Introduction to Health Economics; (i) 1501: 
Economic evaluation; and (ii) 3189: Ethics, Public Health & Human Rights. Module 1103 was a 
prerequisite for module 1501, and could not be taken the first year as timing conflicted with 
doctoral modules, while the latter helped provide the necessary analytical skills to complete 
Chapter 3. Module 3189 helped with the analysis of equity and humanity considerations in 
Chapter 7.  
 
As an unforeseen benefit of being a self-funded student and later academic staff-member, I had 
opportunities to develop, organise, and teach on a number of other MSc modules, several of 
which were relevant to my DrPH studies. For example, I organised PHM101 Basic Epidemiology 
and PHM104/IDM403 Health Management for three years and GHM104 Issues in Global Health 
Policy for a year. I co-organised SM3457 Designing Disease Control Programmes in Developing 
Countries for four years and taught on SM3196 Analysis & Design of Research Studies and 
SM1402 Conflict & Health. Additionally, I co-authored the second edition of Introduction to 
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Epidemiology with Ilona Carneiro1, developed the textbook and module for PHM214 Conflict & 
Health2, and coordinated development of the distance learning MSc course in Global Health 
Policy. These additional teaching and development opportunities deepened my understanding 
of broader contextual, programmatic, and policy issues, which related to the thesis topic.  
 
Organisational and Policy Analysis (OPA) project 
For my organisational attachment, I worked at the Malaria Consortium in London for six months 
supervised by Global Technical Director Dr Sylvia Meek. Established in 2003, the Malaria 
Consortium describes itself as “one of the world’s leading non-profit organisations specialising 
in the prevention, control and treatment of malaria and other communicable diseases among 
vulnerable populations.” As my primary deliverable, we prepared a technical report on malaria 
financing mechanisms for the All-Party Parliamentary Malaria Group now the All-Party 
Parliamentary Group on Malaria and Neglected Tropical Diseases (APPMG)3. The Rt. Honourable 
Hilary Benn, then Secretary of State for International Development, launched the report on 15 
March 2007 at the Palace of Westminster.  
 
This second APPMG report used evidence presented to the group during the previous year to 
advocate for mobilising US$3.2 billion annually from all donors to meet the malaria-related 
Millennium Development Goals and Abuja targets for the 82 most-affected countries. It 
recommended creating and/or strengthening global financing mechanisms (e.g. Aid Guarantee 
Facility, Affordable Medicines Facility, International Finance Facility, debt conversion, UNITAID, 
air ticket solidarity levy) to fill the gap between existing funding, reported as US$600 million for 
2004, and the US$3.2 billion estimated as necessary to meet global targets3. 
 
My professional attachment report, now called an organisational and policy-analysis report, was 
titled Piloting advocacy evaluation. Its aim was examine how the Malaria Consortium could 
measure its effectiveness in international advocacy, using its role in development of the malaria 
financing report as a case study4. The APPMG report was aimed at influencing policy change on 
aid financing through data-driven advocacy, while the implicit social-change purpose was 
improving the lives of the poorest in Africa. Data were collected by participant-observation, key 
informant interviews, and document review. Data were analysed thematically, informed by an 
adaptation of the Anne E Casey Foundation framework proposed by Reisman et al5-7.  
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DrPH research thesis  
As a self-funded student and lone parent, I was not able to travel to collect my own data. 
Therefore, I drew from existing operational research data from HealthNet International (now 
Health Works) in Afghanistan and Pakistan, an organisation for which I had worked and with 
which I had completed my MSc research. Completion of the thesis required a range of 
quantitative and qualitative analytical skills, given the diversity of the datasets available. I 
prepared each results chapter for submission as an article, allowing the thesis development 
process to serve a dual purpose.  
 
Conclusions 
Despite the challenges and frustrations I encountered, successful completion of this degree will 
definitely be worthwhile. I believe that the very circuitous route that I have taken to reach this 
stage, while I would not recommend it to others, has contributed to making me a more capable 
global public health researcher and leader. The objective of initiating the DrPH programme at 
LSHTM was to develop future global public health leaders, recognising that strong research skills 
are necessary but insufficient and the abilities to translate research evidence into meaningful 
engagement with diverse audiences and the leadership to inspire and manage large initiatives 
and teams, were equally vital. This is still an idea that I support and I think that the DrPH course, 
including my many tangents, has equipped me well for the next stages in a global health career.  
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ABSTRACT 
 
Increased global attention and funding has provided opportunities to strengthen malaria 
control. One cross-border control programme researched a range of prevention and treatment 
interventions over twenty years to reduce the malaria burden for Afghans in Pakistan and 
Afghanistan. Malaria in these areas is unstable and seasonal. Primary vectors include Anopheles 
culicifacies, An. fluviatilis, and An. stephensi. Objectives were to evaluate malaria control 
interventions in refugee settlements in Northwest Pakistan and returnee settlements in Eastern 
Afghanistan. Findings offer lessons for programmes in other fragile and conflict-affected 
settings, while helping inform regional and global malaria control efforts. 
 
A mixed-methods study design included two study sites. The northwest Pakistan site covered 
248 camps on malarious land near the Afghan border. The eastern Afghanistan site covered 200 
villages near Jalalabad. As the national border separating study sites was relatively porous and 
both populations mobile, there were no notable sociodemographic differences between sites. 
Notable differences related to national malaria control policies, infrastructure, and priorities. 
Data were collected as part of operational research by HealthNet-Transcultural Psychosocial 
Organisation (HNTPO) between 1990 and 2005. Economic and quantitative data were analysed 
using Microsoft Excel™ and Stata®11-14. Qualitative data were analysed thematically using 
inductive and deductive coding.  
 
Cost-effectiveness analysis of adding indoor residual spraying to case management in Pakistan 
(1990-95) showed favourable incremental cost-effectiveness ratios per case prevented and 
DALY averted. A clinical trial of extended-dose chloroquine in Pakistan (1998) showed that while 
increasing chloroquine dosage reduced recrudescence, approximately 50% failure was still too high 
for first-line treatment. Qualitative analysis of men’s and women’s perspectives on malaria 
prevention during the Taliban regime in Afghanistan (2000), showed women and men had 
similar knowledge, while lack of money was a major disincentive to ITN purchasing. Clinical and 
epidemiological analysis of pregnant and reproductive-age women in Afghanistan (2004-2005), 
showed malaria prevalence was much lower than anaemia prevalence in pregnancy and women 
were well-informed about malaria risks, but their autonomy was limited. 
 
Key findings are discussed in relation to the study framework, providing overall lessons, 
implications, and potential limitations. 
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CHAPTER 1 INTRODUCTION  
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Overview 
The aim of this thesis is to assess several interventions implemented by the malaria control 
programme provided for Afghans during the period 1990 to 2005, primarily considering 
effectiveness, but also aspects of efficiency, equity, and humanity. The thesis is divided into 
seven chapters. Chapters 1 and 2 cover background and methods. Chapters 3 to 6 cover sub-
study results. Chapter 7 draws on sub-studies and an evaluation framework to synthesise key 
results and provide overall discussion and conclusions.  
 
This introductory chapter provides background context. The first section summarises relevant 
malaria control policies and strategies. The second section describes malaria epidemiology and 
control efforts in Pakistan and Afghanistan, focusing on refugee settlements in Khyber-
Pakhtunkhwa (KPK) province, formerly Northwest Frontier Province (NWFP), Pakistan and 
returnee settlements in Nangarhar Province Afghanistan. The third section describes the 
evaluation framework and research approaches selected. The fourth section examines the 
potential value of using operational data to inform policy and practice. The final section provides 
aim and objectives. 
 
Malaria control policy and strategies 
Malaria Control era achievements (1990-1999) 
At the beginning of the 1990s, there were an estimated 300-500 million malaria cases and 1.5-
2.7 million deaths annually8. Multidrug-resistant falciparum malaria was spreading, since its 
detection in Southeast Asia in the 1980s, threatening control efforts in other parts of the world9. 
The successes of the Global Eradication Campaign (1956-1969) had not been sustainable and a 
deteriorating situation convinced the World Health Organization (WHO) Executive Board to 
propose a Ministerial Conference on Malaria to mobilise the international community and 
affected countries to intensify malaria control efforts8. The Ministerial Conference on Malaria 
Control, held in Amsterdam in 1992, adopted a World Declaration on the Control of Malaria and 
Global Malaria Control Strategy that was confirmed by the World Health Assembly in 1993, and 
by the forty-ninth Session of the United Nations General Assembly in 19948. This strategy 
differed from eradication era approaches in that it was grounded in the primary healthcare 
approach and called for flexible, decentralized programmes, based on disease rather than 
parasite control; strengthening of national capacities; and the rational and selective use of 
effective malaria control tools supported by operational research8. However, due to insufficient 
financial and human resources, the objective of reducing malaria mortality by at least 20% from 
the 1995 level in at least 75% of affected countries by the year 2000, was not achieved8. 
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Millennium Development Goal era achievements (2000-2015) 
Malaria gained increasing global attention during the Millennium Development Goal (MDG) 
period of 2000-2015, leading to significantly increased political commitments, expanded 
regional collaboration, availability of substantial and more predictable financing, and improved 
control interventions10. Between 2000 and 2015, increased control efforts contributed to a 41% 
reduction in malaria case incidence and a 62% reduction in malaria deaths globally11. The 
estimated number of malaria cases globally declined by 19% from 262 million in 2000 (range 
205–316 million) to 212 million in 2015 (range 149–303 million), while estimated numbers of 
deaths declined by 49% from 839,000 (range 653,000-1.1 million) to 429,000 (range 236,000-
635,000)11. Countries and territories considered endemic for malaria reduced from 108 to 91 
during this period11.  
 
The malaria-specific target C of MDG 6, ‘to have halted and begun to reverse the incidence of 
malaria globally by 2015,’ was achieved, with 57 countries meeting the World Health Assembly 
and Roll Back Malaria Partnership (RBM) target of reducing malaria incidence by 75% by the end 
of 201512. Similarly, with global malaria incidence estimated to have decreased by 37% and the 
global malaria mortality rate estimated to have decreased by 60% between 2000 and 2015, 
substantial progress was made towards the World Health Assembly target of reducing the global 
malaria burden by 75% and the RBM target of reducing global malaria deaths to near zero by 
201512.  
 
Sustainable Development Goal era initiatives (2016-2030) 
With the ending of the MDGs in 2015, and the transition to the era of the Sustainable 
Development Goals (SDGs) covering the years to 2030, affected countries and the international 
community have begun setting new malaria control goals and targets13. WHO’s Global Technical 
Strategy for Malaria 2016-2030 (GTS) and RBM’s Action and investment to defeat malaria 2016–
2030: for a malaria-free world (AIM) succeed the Global Malaria Action Plan: for a malaria-free 
world 2008–2015, with the aim of ensuring that global malaria trends remain on a downward 
trajectory10, 11, 13.  
 
The malaria-related SDG Target 3.3, ‘by 2030 to end epidemics of AIDS, tuberculosis, malaria, 
and neglected tropical diseases, and combat hepatitis, water-borne diseases, and other 
communicable diseases’ relates to SDG 3 ‘Ensure healthy lives and promote wellbeing for all at 
all ages’11. WHO equates achieving this malaria component with attaining GTS and AIM targets 
by 2030, to: (i) reduce malaria incidence and mortality rates globally by at least 90% compared 
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with 2015 levels; (ii) eliminate malaria from at least 35 countries in which malaria was 
transmitted in 2015; and (iii) prevent re-establishment of malaria in all countries currently 
malaria free11.  
 
Malaria burden and the increased importance of vivax malaria 
WHO has indicated that the main ongoing and emerging challenges in malaria control for the 
next decades are gaps in intervention coverage, health system weaknesses and resource 
constraints, insecticide and antimalarial resistance, slower transmission declines in high-burden 
countries, and increasing vivax malaria risks11.   
 
Despite major improvements, malaria remains a significant concern globally. Almost 3.3 billion 
people in 91 countries are still estimated to be at risk11, 13. Malaria remains a leading infectious 
cause of death worldwide, along with respiratory infections, human immunodeficiency virus 
(HIV), diarrhoeal diseases, and tuberculosis13. Recent estimates indicated 212 million malaria 
cases (range 148-304 million) and 429,000 deaths (range 235,000–639,000) in 201511. Most 2015 
malaria cases (88%) and deaths (92%) were estimated to have occurred in the WHO African 
Region, followed by the WHO South-East Asia Region (10% and 6% respectively) and the Eastern 
Mediterranean Region (2% of both cases and deaths), which includes Afghanistan and 
Pakistan11. 
 
Of the five Plasmodia species known to infect humans14, Plasmodium falciparum followed by P. 
vivax causes an estimated 90% of human malaria infections worldwide11. P. falciparum is most 
prevalent on the African continent and responsible for most malaria deaths. However, P. vivax 
has a wider geographical distribution, because it survives in higher altitudes and cooler climates 
and has a dormant hypnozoite liver stage that enables it to persist for extended periods in the 
absence of Anophelines, e.g. during winter, and cause relapsing symptoms months later11, 12. 
About 4% of estimated cases globally, and 41% outside the African continent, are caused by P. 
vivax 11.  
 
Most researchers and policy-makers focus on P. falciparum in sub-Saharan Africa, which is 
responsible for approximately 90% of both global malaria cases and global malaria mortality11, 
13, 15-17. However, as the global malaria burden reduces, this focus is beginning to broaden. 
Malaria still poses a significant burden to populations in parts of Asia and South America, partly 
because vivax malaria is not as benign as was once thought18-26. Vivax malaria remains a 
significant public health issue in many parts of the world, including countries such as Afghanistan 
and Pakistan, causing an estimated 13.8 million cases globally in 201511. Most vivax cases occur 
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in the WHO South-East Asia Region (58%) and Eastern Mediterranean Region (16%), with over 
75% of global cases estimated to occur in just four countries, i.e. Ethiopia, India, Indonesia, and 
Pakistan 11.  
 
Severe vivax cases and deaths have been reported from all endemic regions. In 2015, the total 
number of vivax malaria deaths globally was estimated at 3,100 (1,800-4,900) with 86% 
occurring outside sub-Saharan Africa11. Thus, the importance of vivax malaria appears to be 
growing, though information on population-attributable risks of severe disease and death due 
to P. vivax remains sparse, with further research required20, 26, 27. The four countries accounting 
for most vivax cases also accounted for 81% of estimated vivax deaths in 2015 (i.e. Ethiopia, 
India, Indonesia, Pakistan)11.  
 
Malaria control funding and cost-effectiveness estimates    
The increased global commitment to malaria control is particularly noticeable in international 
and domestic funding increases. Average global commitments to malaria control in the 1990s 
ranged below US$100 million annually, increasing to an estimated US$0.3 billion in 2003, US$1.7 
billion in 2009, and US$2.9 billion in 201511. In 2015, the United States was the largest single 
international malaria control funder, accounting for approximately 35% of global funding, 
followed by the United Kingdom (16%), and France (3.2%)11. Approximately 45% of international 
funding is channelled through the Global Fund to Fight AIDS, Tuberculosis and Malaria11. 
Spending on malaria control commodities, e.g. artemisinin-based combination therapies (ACTs), 
rapid diagnostic tests (RDTs), insecticide treated mosquito nets (ITNs), insecticides and 
equipment for indoor residual spraying, was estimated to have increased from US$40 million in 
2004 to US$1.6 billion in 2014, and accounted for 82% of international malaria spending in 
201411, 12. Domestic spending through national malaria control programmes in endemic 
countries, while still a relatively small proportion of total funding, increased to US$612 million 
in 2015 with malaria patient care another US$332 million11. 
 
WHO estimated that a cumulative 1.3 billion fewer malaria cases and 6.8 million fewer malaria 
deaths occurred globally between 2001 and 2015 than would have occurred had incidence and 
mortality rates remained at 2000 levels11. Malaria interventions are highly cost-effective, and 
with an estimated 70% of the cases averted between 2001 and 2015 due to malaria 
interventions, they provide some of the highest returns on public health investment10, 11, 13. 
When the Copenhagen Consensus Center initially ranked development options across all sectors 
by cost-effectiveness, malaria control investments were ranked among the top four 
development priorities17. Again, as part of the Post-2015 Consensus, halving global malaria 
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infections was identified as one of the 19 most cost-effective development targets across 
sectors28. In malaria-endemic countries, efforts to reduce and eliminate malaria are increasingly 
viewed as high-impact strategic investments for public health, poverty alleviation, equity, and 
development10, 11. Malaria elimination is being attempted in areas of unstable transmission, with 
the ultimate goal of global elimination encouraged by economic modelling estimates such as 
those done by the Copenhagen Consensus Center, increased investments in new control 
technologies, and initial successes in areas of Viet Nam and Zanzibar28, 29. An increasing number 
of countries are moving towards elimination, with only 13 countries estimated to have fewer 
than 1,000 malaria cases in 2000 and 19 countries estimated to have achieved this in 201511. 
 
To achieve global targets, WHO estimated that annual global investments in malaria control and 
elimination need to increase to US$6.4 billion annually by 2020 to achieve a 40% reduction in 
malaria incidence and mortality rates, increase to US$7.7 billion by 2025 to achieve a 75% 
reduction, and increase to an estimated US$8.7 billion by 2030 to achieve a 90% reduction10, 11. 
However, current malaria funding, calculated at US$2.9 billion for 2015, remains far short of 
required estimates11. For example, while international funding for malaria control outside of 
Africa rose steeply from less than US$17 million in 2000 to US$300 million in 2010, the amount 
committed falls short of the resources required to achieve universal access to life-saving malaria 
prevention and control measures outside sub-Saharan Africa, estimated at approximately US$3 
billion per year11, 30.  
 
Malaria control strategies and interventions  
Increased funding has brought significant changes in antimalarial drug policies from 
monotherapies and limited ITN distribution to ACTs, mass distribution of ITNs, and 
corresponding declines in malaria incidence28. The Global Technical Strategy for Malaria 2016-
2030 is built on three pillars: (1), to ensure universal access to malaria prevention, diagnosis, 
and treatment; (2), to accelerate efforts towards elimination of malaria and attainment of 
malaria-free status; and (3), to transform malaria surveillance into a core intervention10. The 
core WHO-recommended control interventions advocated under Pillar 1 are quality-assured 
vector control, chemoprevention, and diagnostic testing and treatment10, 11. Elements of these 
interventions, specifically cost-effectiveness of indoor residual spraying, effectiveness of 
extended dosage chloroquine, acceptability of chemoprevention in pregnancy, and purchasing 
of ITNs are assessed in later chapters.  
 
WHO now recommends implementing prevention and case management interventions in a 
complementary way: (i) prevention strategies based on vector control, and chemoprevention if 
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appropriate, and (ii) universal diagnosis and prompt effective treatment of malaria in public and 
private health facilities and at community level10. These interventions are time-tested and 
recommendations are not dramatically different from the WHO Global Malaria Programme 
recommendations for 2005-2015 to scale-up three primary interventions to help achieve Abuja 
Declaration and MDG targets: (i) diagnosis of malaria cases and treatment with effective 
medicines; (ii) distribution of ITNs to achieve full coverage of populations at risk of malaria; and 
(iii) indoor residual spraying (IRS), including, where indicated, the use of dichloro-diphenyl-
trichloroethane (DDT)17, 31-33.  
 
The two most broadly applicable vector control interventions are ITNs, particularly long-lasting 
insecticidal nets (LLINs), and IRS. Preventive treatment interventions, which currently target 
falciparum malaria, suppress existing infections and prevent the consequences of parasitaemia 
10. The most widely researched is intermittent preventive treatment (IPT) of pregnant women. 
Universal diagnostic testing of all suspected cases requires parasitic confirmation by quality-
assured microscopy or RDT, to prolong the effectiveness of WHO-recommended antimalarials, 
particularly ACTs10. Of the estimated 663 million cases averted globally between 2001-2015 due 
to malaria control interventions, 69% (range 63-73%) were estimated averted due to ITN usage, 
21% (range 17-29%) due to ACT treatment, and 10% (range 6-14%) due to IRS11, 12.  
 
Insecticide-treated mosquito nets for malaria prevention 
Considerable published research demonstrates the effectiveness and cost-effectiveness 
(efficiency) of ITNs and LLINs for malaria control in a variety of epidemiological settings34-48. 
Sleeping under ITNs has been shown to reduce malaria incidence and case fatality by an average 
of 50% and 20% respectively with average cost-effectiveness ratios of international $35-100 per 
disability adjusted life-year (DALY) averted at 95% coverage11, 49. ITN effectiveness against P. 
vivax incidence appears similar once relapses are accounted for, though DALY-based cost-
effectiveness ratios are less informative due to much lower mortality rates for P. vivax of well 
below 1%27, 50-54. Real effectiveness and cost-effectiveness are lower, as ITN coverage rarely 
reaches 95%. However, most malaria endemic countries have adopted policies promoting 
universal access to ITNs, which has significantly improved coverage11. For example, WHO reports 
that an estimated 54% of Africans slept under ITNs in 2015 compared to 2% in 2000, though 
coverage of children under five (at 68%) remained below universal targets11, 12.  
 
Indoor residual spraying for malaria prevention 
IRS has regained some of its former popularity in the past two decades. IRS, mainly using DDT, 
eliminated malaria as a public health issue in large areas of Asia, Europe, and the Americas 
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during the 1950s55. Despite continued controversy over the use of DDT for in-house spraying, a 
significant body of literature exists on the epidemiology and cost-effectiveness of IRS39, 42, 56-86. 
IRS protective efficacy is roughly 50%, though a Cochrane review put the range at 6-93% (the 
wide range appeared to be due to the limited number of studies meeting review criteria) and 
indicated that IRS may be more effective in unstable/seasonal transmission settings, such as 
many areas of South Asia87. Costs per person-year protected were calculated at about US$3-4, 
though this varied considerably with transmission levels and insecticide used47, 86, 88. However, 
IRS arguably requires significant technical capacity, structured programmes and sustainable 
financing, and implementation lags behind that for ITNs55. Additionally, transitions from 
pyrethroids to more expensive carbomates due to insecticide resistance, have contributed to 
reductions in spraying from a global peak of 5.7% coverage of populations at risk in 2010 to 3.1% 
in 201511. Approximately 116 million people are currently protected by IRS worldwide11, 12.  
 
Intermittent preventive treatment in pregnancy for malaria chemoprevention 
Chemoprevention among vulnerable groups is a key element of WHO’s multipronged strategy 
to reduce the global malaria burden10. WHO-recommended malaria chemoprevention includes 
IPT of pregnant women (IPTp), IPT of infants (IPTi), and seasonal chemoprevention for children 
under 5 years, to suppress existing infections and prevent the consequences of parasitaemia10. 
At the time of the studies included here, IPTp was still being assessed in a variety of settings 
including South Asia, though it is now only recommended in areas of moderate-to-high malaria 
transmission in sub-Saharan Africa89, 90. 
 
Microscopy for malaria diagnosis 
Accurate parasitic diagnosis and prompt treatment with effective antimalarials remain 
successful for case management, though clinical diagnosis and usage of ineffective first-line 
treatment drugs persist in many resource-constrained settings, including among private and 
informal providers in Pakistan and Afghanistan91-94. Diagnostic confirmation by quality-assured 
microscopy or RDT before treatment became an official WHO recommendation in 2010, 
strengthened in the current global technical strategy as universal diagnosis10, 11. However, the 
proportion of suspected cases receiving a diagnostic test at public facilities has remained 
relatively steady at around 65% in WHO’s Eastern-Mediterranean region11. While microscopy 
requires more infrastructure and training than RDTs do, the lack in some malaria parasites of 
histidine rich protein 2 (HRP2, the most common target antigen used in RDTs to detect P. 
falciparum) first reported in 2010 in Peru and detected more broadly since, demonstrates the 
ongoing value of quality-assured microscopy11. However, WHO now recognizes that testing and 
safe radical treatment of vivax malaria requires two diagnoses: (i) the presence of P. vivax 
Howard N: Malaria control for Afghans (1990-2005) 20 Chapter 1 
parasites and (ii) glucose-6-phosphate dehydrogenase status, due to the risk of haemolytic 
anaemia in some populations, including those in South Asia10. 
 
Antimalarials for treatment     
WHO now recommends that after diagnostic confirmation, all patients with uncomplicated P. 
falciparum malaria should be treated with quality-assured ACTs and, in areas where 
chloroquine-susceptible P. vivax is present (e.g. Pakistan and Afghanistan), uncomplicated non-
falciparum malaria should be treated with either chloroquine (with primaquine for radical cure 
where feasible) or an ACT known to be effective in the area10. Prolific research programmes have 
contributed extensively to global malaria case-management policy and literature, with the 
original advocacy push for ACTs originating in Thailand95, 96. With artemisinin resistance 
confirmed in Cambodia in 2009 and observed in a further four Mekong sub-region countries, 
monitoring therapeutic efficacy and molecular markers of drug resistance and developing new 
antimalarials continue to be priorities10, 11. The economic literature related to malaria case-
management is relatively extensive, particularly on diagnosis, drug resistance, and usage of ACTs 
in sub-Saharan Africa58, 61, 63, 96-111.   
 
Equity and humanity in malaria control  
Malaria disproportionately affects the poorest, though causal mechanisms are complex112. Thus, 
equity has received increased attention in control programmes and research in the past 
decades110, 113-124. WHO defines equity as the absence of avoidable or remediable differences 
among groups of people, whether defined socially, economically, demographically, or 
geographically. Equity is a concept that combines equality, social justice, and fairness125. It thus 
involves more than just equality of health determinants, but also overcoming inequalities that 
infringe on human rights norms and fairness126, 127. Achieving health equity requires creating fair 
opportunities for health and eliminating gaps in health outcomes between different social 
groups125. As with most health equity literature, that for malaria control has focussed on 
distributive justice (e.g. access to interventions such as ITNs or diagnosis and treatment by those 
in need)118, 128-133 and horizontal equity (e.g. all people in equivalent circumstances are treated 
equally) or vertical equity (e.g. those deemed at greatest need, such as biologically and 
economically high-risk groups, receive targeted support)110, 113, 117, 118, 121, 122, 134-137.  
 
Humanity is a multidimensional concept that lacks a specific definition in the context of health 
services provision, but generally draws from the four principles of biomedical ethics, e.g. 
autonomy, justice, beneficence and non-maleficence, with dignity sometimes included as 
well125, 138. Recent ethical reviews have considered aspects of humanity in malaria control 
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implementation and research, noting this as an area of growing interest and importance139-142. 
Humanity is increasingly considered, though not always explicitly highlighted, in the malaria 
case-management literature143-145. Perhaps unsurprisingly, most focus has been on autonomy 
and non-maleficence in clinical drug trials146-149. However, justice is particularly relevant in 
situations where resources are constrained (e.g. health systems in Pakistan and Afghanistan) to 
help determine the range and quality of interventions provided so as to ensure humane and safe 
treatment125.  
 
Malaria among Afghans in Afghanistan and Pakistan 
While global strategies are an important starting point, lessons learned at national and sub-
national levels must be incorporated and applied. A specialist international technical NGO has 
been working with national malaria control programmes and available partners to research and 
implement the control tools and strategies described above to successfully reduce the malaria 
burden among 3 million Afghan refugees in Pakistan and communities of returnees in 
Afghanistan, for over twenty years150, 151. Programmatic experiences and data can offer lessons 
for current global malaria-control agendas51, 150, 152-154. 
 
The malaria control programme for Afghans 
HealthNet International (now Health Works), a Dutch NGO working to support health systems 
strengthening and health services delivery in areas affected by war or disaster, was started as 
an initiative from Médecins Sans Frontières (MSF) in 1992 to bridge the gap between emergency 
relief and structural development. Artsen zonder Grenzen (MSF-Holland) initiated a malaria 
control programme for Afghan refugees in Pakistan in 1989, which was handed over to the newly 
created HealthNet International in 1992. In 2005, HealthNet International merged with the 
Transcultural Psychosocial Organization (TPO), becoming HealthNet-TPO (HNTPO) and gaining 
psychosocial and mental health care expertise in addition to its core work reinforcing healthcare 
systems and the prevention, diagnosis, and treatment of infectious diseases. In 2017, HNTPO 
changed its name to Health Works, to make itself ‘more appealing’ without changing its core 
mission155. This thesis will refer to the organisation as HNTPO to retain consistency and because 
the former name remains familiar at the time of writing and most appropriate for the time-
period covered.  
 
The HNTPO programme supporting Afghans began as a response to a falciparum and vivax 
malaria epidemic in refugee camps of Northwest Frontier Province in Pakistan, renamed Khyber 
Pakhtunkhwa (KPK) province in 2010. Pakistan had a long history of malaria control, initiating 
eradication in the 1960s, switching to the control agenda in 1975-1985, and joining the RBM 
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movement in 2006156. However, malaria control for refugees was primarily the responsibility of 
UNHCR and humanitarian NGOs157. Once the initial epidemic in northwest Pakistan was 
controlled, the HNTPO programme then shifted to focus on reducing malaria in eastern 
Afghanistan152. Malaria control has a long history in Afghanistan dating back to formation of the 
Directorate General of Preventive Medicine and Primary Health Care in 1948115, 152, 153, 158-179. 
Early vector control focused on DDT spraying and An. superpictus was almost eradicated by 
1970179. However, after the Soviet invasion, the national malaria control programme weakened 
and almost ceased functioning, while health infrastructure was destroyed during decades of 
war179-183. After the fall of the Taliban in 2001, the Afghan Ministry of Public Health (MoPH) and 
donors worked to improve health indicators quickly by contracting out basic health services to 
non-governmental providers184-186. While formal subcontracting of health services was a 
relatively new initiative in low-income countries, HNTPO has supported the majority of malaria-
control activities in Afghanistan since 1991151, 185, 187.   
 
HNTPO programme principles have been to apply appropriate control techniques and strategies 
on a large scale after operational research demonstrated efficacy, cultural acceptability, and 
safety152. The programme has emphasised research capability and developed several innovative 
control tools, some of which are now being tested outside the region, e.g. insecticide treated 
materials, cattle sponging162, 188, 189. HNTPO maintained detailed records, recording 
epidemiological and entomological efficacy, social awareness, costs, and the evolution of 
operational strategy. Thus, it is possible to analyse data retrospectively on prevention and case-
management interventions. Efficacy findings have already had influence on regional malaria 
control policy, for example first-line treatment regimens and ITNs for vector control190, 191.  
 
Research approach and framework 
Major questions in public health intervention evaluation generally involve prevalence, causes 
and effects of supply and demand, relations between prevention and treatment, and 
interdependences with other sectors, including education, business, and technology192. As such, 
it has not yet needed its own research methodology, instead adapting theories and methods 
from existing disciplines192. Thus, the research approaches used in designing and analysing the 
sub-studies come from epidemiology and social sciences, e.g. economics.  
 
Evaluating public health interventions  
As the sub-studies included are topically and methodologically diverse, and conducted over 
varying time-periods, a programme evaluation framework was chosen to help guide analysis. 
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Details of how the evaluation framework was selected are provided in the sub-section entitled 
‘Study design and framework selection’ in Chapter 2.  
 
Evaluation frameworks draw from quantitative and qualitative research approaches, enabling a 
broader understanding than might be possible from any one method193. Trochim defined 
evaluation as ‘the systematic acquisition and assessment of information to provide useful 
feedback about some object’194. The Organisation for Economic Co-operation and Development 
(OECD) Development Assistance Committee (DAC) Criteria, often cited in the evaluation 
literature, add relevance, efficiency, impact and sustainability to analysis of effectiveness195. 
Public health intervention evaluation should thus be ‘a systematic method of collecting, 
analysing and using data’ to ‘improve and account for public health actions by involving 
procedures that are useful, feasible, ethical, and accurate’196, 197. While each evaluation cannot 
include all aspects suggested in the literature, the sub-studies included were diverse enough to 
enable consideration of aspects of effectiveness, efficiency, equity, and humanity within the 
malaria programme, represented in Figure 1125, 198.  
 
Relevant evaluation types 
The health programme evaluation literature is substantial. Health programme evaluation can 
include over thirty-five different evaluation types - such as needs assessment, accreditation, 
audit, cost-benefit, effectiveness, efficiency, pluralistic, goal-based, process, or impact199. 
Almost thirty years ago, Hopkins noted a distinction between formative and summative 
evaluations that continues today, with the specific type selected depending on needs, skills, 
time-frame, and resources200. For example, if the evaluation asks whether a specific strategy is 
a good way to prevent malaria then formative evaluation helps implementers do it better in 
their specific context, process evaluation lets implementers describe how they are doing it, and 
outcome/impact evaluation tells stakeholders whether implementers did what was intended or 
not.  
 
Table 1 shows several common types of evaluation under which studies in results chapters 3-6 
fit. The top section on formative evaluation shows the original purpose of each study, while the 
lower section shows how summative secondary analysis of the study data included in this thesis 
now fits.  
  
Howard N: Malaria control for Afghans (1990-2005) 24 Chapter 1 
Table 1. Common evaluation types and purposes 
Evaluation types Purpose  Relevant chapters 
Formative During -  to strengthen or improve what is evaluated Initial analysis 
Needs 
assessment 
for determining what the need is, how great, and how it 
might be addressed (i.e. gaps between current and 
desired conditions) 
 
Ch 6 
Developmental  for assessing ongoing programmes during their 
construction to implement improvements 
 
Ch 4 
Process  for investigating the process of programme delivery, 
including alternative procedures 
 
Ch 3 
Pluralistic  For examining stakeholder perspectives, influence, and 
involvement 
 
Ch 5 
Audit  For assessing validity, reliability and internal control to 
improve programme or organisational quality 
 
NA 
Summative  After - to examine the effects or outcomes of what is 
evaluated 
Secondary analysis 
re-examining data to 
address new questions 
or with new methods 
Outcome  For measuring change in outcomes (e.g. disease rates, 
behaviours) against objectives that may or may not be 
due to the programme (e.g. investigates whether 
interventions caused demonstrable effects on 
specifically defined target outcomes 
 
Ch 4, 5 
Impact For measuring the extent to which programme activities 
changed outcomes, consistent with objectives (i.e. 
assesses the overall or net effects - intended or 
unintended - of the programme) 
 
Ch 3, 6 
Economic For examining costs and consequences in standardised 
economic terms 
 
Ch 3 
Meta-analysis for integrating outcome estimates from multiple studies 
to provide summary judgement on an evaluation 
question 
NA 
 
NB: Adapted from http://www.socialresearchmethods.net/kb/intreval.htm and 
http://info.k4health.org/inforeports/BCCtools/7.shtml  
 
Evaluation framework selected 
The malaria control programme for Afghans consisted of multiple interventions during 1990 to 
2005 (e.g. indoor residual spraying, insecticide treated mosquito nets, diagnostics, treatment 
drugs), multiple settings (e.g. acute humanitarian support for refugee camps in Pakistan and 
chronic-emergency support for villages in Afghanistan), and multiple funding sources, 
programme targets, and outcome measures. However, the goal remained to reduce the malaria 
burden among vulnerable Afghan populations in Pakistan and Afghanistan. 
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Each sub-study contributes indicators and associated baseline and targets to an overall 
outcome-based evaluation of selected HNTPO interventions. Such a multi-method approach is 
supported by the literature on evaluation of complex interventions - those "made up of various 
interconnecting parts”201 – and the British Medical Research Council framework for the 
development and evaluation of complex interventions to improve health was used as a 
theoretical guide202. It is worth noting that this thesis does not attempt to assess the whole 
HNTPO programme for Afghans, as data for such an evaluation were not available. Thus, only 
the relevant interventions were assessed.   
 
The framework selected (Figure 1) was for an outcome evaluation and considered the four 
dimensions of effectiveness, efficiency (cost-effectiveness), equity, and humanity proposed by 
Black and Gruen in Smith et al and again in Tsang and Cromwell125, 198. 
 
Figure 1. Conceptual framework for four-dimensional evaluation 
 
NB: Developed from Black and Gruen125, 198, 203 
 
Effectiveness 
The epidemiological methods used in analytic and experimental studies help determine 
programme effectiveness through examining hypothesised relationships, statistical 
associations, and causality198, 204. Social sciences (e.g. economics, anthropology, psychology) 
contribute methods of determining and interpreting effectiveness, such as multilevel regression 
modelling, to health research205.  
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Efficiency 
Improving public health programme and intervention efficiency in resource-constrained settings 
requires comparison and prioritisation of interventions that provide the greatest benefit per unit 
of cost206. Without systematic analysis of costs and outcomes, identifying relevant alternatives 
is difficult207. Economic analysis has become increasingly popular among donors and aid agencies 
in low-income countries as implementing agencies must increasingly demonstrate value-for-
money. The analytic perspective or viewpoint chosen can be that of the individual, provider, 
health system, or society, with each having important implications for interpretation as what is 
good value for the individual or provider may not be for society and vice versa207. While costs 
are analysed in a common format, benefits (outcomes) are approached in several ways206, 207. 
Key economic exposure measures used here were total, average, and incremental cost, while 
outcome measures used included cases prevented and disability-adjusted life years (DALYs) 
averted. The main economic method used, cost-effectiveness analysis, enables comparison of 
interventions to determine maximum health gain for given expenditure125.  
 
Equity 
Equity encompasses fairness, justice and equality, and is generally assessed in health in terms of 
opportunities or outcomes125. Horizontal equity refers to equal treatment for equal needs, while 
vertical equity refers to unequal treatment for unequal needs (e.g. preferential treatment for 
pregnant women and under-five children)125, 198, 208. Measuring the equity of an intervention 
involves comparing selected inputs, processes and outputs between selected groups and by 
clinical need, e.g. the capacity to benefit from the intervention125, 209. Needs vary according to 
various geographical, socioeconomic, ethnic, gender, age, and co-morbidity factors and can be 
estimated using standardised techniques, such as indices and socioeconomic classifications (e.g. 
residential area or asset indices210) or co-morbidities (e.g. Charlson Index211), and direct or 
indirect standardisation (e.g.  standardised mortality ratios)125, 204.  
 
Mooney outlined seven measures of equity: (i) equality of expenditure per capita, (ii) equality 
of inputs per capita, (iii) equality of input for equal need, (iv) equality of access for equal need, 
(v) equality of usage for equal need, (vi) equality of marginal met need, and (vii) equality of 
health212. Most published literature on equity in health focuses on distributive justice (e.g. 
access, usage, health service financing), rather than on whether these inequalities are unfair or 
unjust125, 208.   
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Humanity 
Providing healthcare in northwest Pakistan and Eastern Afghanistan, or other dangerous 
resource-constrained settings, necessitates consideration of humanity issues to avoid these 
being superseded by efficiency considerations213, 214. Evaluating humanity in public-health 
programming minimally involves consideration of the three 1979 Belmont Report ethical 
principles (i.e. autonomy, justice, beneficence), expanded by Beauchamp & Childress to four: (i) 
autonomy, the right to informed choice, (ii) justice, the right to fair treatment, (iii) beneficence, 
choosing to do good, and (iv) non-maleficence, avoiding harm138, 215. Dignity, the right to respect, 
is often added125, 216, 217.  
 
Operational data for informing policy and practice 
All data for this thesis came from operational research datasets. Operational public health 
research consists of “investigating strategies, interventions, instruments, or knowledge that can 
enhance the quality, coverage, effectiveness, or performance of health systems, health services, 
or disease control programmes”218. Coming from military and industrial modelling, as the 
discipline of applying advanced analytical methods to decision-making, operational research has 
been widely used in the commercial sector but remains less developed in health programmes218. 
It can be used directly to inform policy, as it is designed for improving programme outcomes, 
assessing the feasibility of new approaches or interventions, and advocating policy change219. By 
showing what works and what does not in various contexts, operational research can provide 
evidence to help policy-makers adapt health interventions and services for maximum public 
health benefit220.  
 
Research that does not tangibly affect policies and practices is particularly ineffective and 
wasteful in resource-constrained settings, such as Afghanistan and Pakistan, in which disease 
burden is high221. Operational research in low-income countries thus has a key role in filling the 
gap between what is known from research and what is done with it, referred to by Zachariah 
and others as the implementation, or ‘know-do,’ gap221. The two main approaches to 
operational research are analysing secondary data and conducting primary research218. 
Operational research can thus include a range of study designs, primarily categorised as: (i) 
descriptive, including cross-sectional and qualitative; (ii) case-control; and (iii) retrospective or 
prospective cohorts219, 222. 
 
Unlike basic science research and most randomised controlled clinical trials that primarily 
address efficacy questions, operational research should have direct and practical relevance for 
policy and practice219. However, large amounts of routine data that are collected within health 
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systems and by non-governmental organisations remain underused, neither fully analysed nor 
widely disseminated, thus reducing the potential effect of research on policy and practice220. 
Operational research could have a much larger role than it currently does in influencing policy 
and practice, if more operational data were analysed and reported as has been attempted in 
this thesis and related publications89, 115, 223-225.  
 
There is an ethical imperative for ensuring that operational data that are collected are not 
wasted. Operational research ethics is based on four principles of duty: (i) to alleviate suffering, 
(ii) to show respect for human beings, (iii) to be sensitive to cultural differences, and (iv) not to 
exploit the vulnerable219. None of these principles can be achieved if data are not fully used.  
 
Aim and objectives 
The study aim was to assess interventions implemented by the malaria control programme 
provided for Afghans during the period 1990 to 2005, using existing secondary operational data 
and primarily considering effectiveness, but also considering aspects of efficiency, equity, and 
humanity. It was not possible to conduct a full programme evaluation given the nature of the 
available data. Thus, findings on individual interventions were treated as indicative of 
programme capacity and discussed qualitatively in Chapter 7. 
 
Each results chapter (Chapters 3-6) includes specific objectives for individual sub-studies. The 
overall objectives of this DrPH research were to (i) evaluate whether malaria control 
interventions provided for Afghans were effective and efficient, according to standard 
definitions provided, using epidemiological and economic analysis methods on data gathered in 
refugee camps in KPK Pakistan and villages in eastern Afghanistan between 1990 and 2005; (ii) 
discuss the equity and humanity of programme interventions, according to standard definitions, 
using social science data gathered between 2000 and 2005; and (iii) consider implications for 
malaria control policy and practice specific to each sub-study and broader lessons that could 
inform future research.   
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CHAPTER 2 METHODS  
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Overview  
The four sub-studies in chapters 3-6 each include specific and more detailed methods sections. 
This chapter provides an overview of methodological approaches used. The first section details 
the two study sites and population. The second section describes study design and framework 
selection. The third section discusses secondary dataset selection and issues around using 
secondary data. The fourth section describes methods used in reviewing the literature for each 
sub-study. The fifth section discusses data collection. The sixth section discusses data analysis, 
including quantitative and qualitative measurement of exposures and outcomes. The final 
section describes ethics considerations. 
 
Study sites and population  
Both Afghanistan and Pakistan are geographically part of South Asia, which includes one fifth of 
the global population and covers approximately 5.1 million km² (i.e. 11.5% of the Asian continent 
and 3.4% of global land-surface area)226. The other South Asian countries are Bangladesh, 
Bhutan, India, Maldives, Nepal, and Sri Lanka. South Asia is important for health policy and 
practice because: (i) with 1.7 billion people, it is the most populous and densely populated 
geographical region globally; (ii) it has the highest number of the world’s poor, at approximately 
500 million; and (iii) it is one of the world’s least stable sub-regions, with all eight countries 
regularly ranking below average on global fragility indices and Afghanistan and Pakistan 
routinely among the worst performers227, 228. Not only does this consume substantial global 
resources for development and humanitarian assistance, peace-keeping, and stabilisation, but 
continued sub-regional tensions have been leveraged globally (e.g. entrenching extremist 
ideologies, as a ‘training ground’ for global terrorism, nuclearisation228).  
 
More positively, South Asia is increasingly important to the global economy, due particularly to 
the economic rise of India. The sub-region is covered by two economic cooperation agreements, 
the South Asian Association for Regional Cooperation (SAARC) established in 1985 and 
incorporating Afghanistan in 2009, and the South Asia Free Trade Agreement (SAFTA), which 
incorporated Afghanistan in 2011228. At its most basic, improved community health and disease 
control contributes to individual security, which in turn increases national and regional stability 
and prosperity229, 230.   
 
Politically and culturally, the two countries are often included as part of the ‘Middle East’ of 
predominantly Muslim-majority countries. For example, public health guidance and policy for 
both countries is managed through WHO’s Eastern Mediterranean Regional office, which covers 
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22 countries and territories in the Middle East, North Africa, and Horn of Africa 231. Aside from 
the obvious geopolitical importance, malaria research in Afghanistan and Pakistan is relevant to 
global practice for two major reasons.  
 
First, malaria epidemiology in South Asia is considerably different from that in sub-Saharan 
Africa or Southeast Asia, where most malaria research has been conducted, and thus requires 
different control approaches and priorities. Despite global improvements, Pakistan was one of 
five high-burden countries in Asia that did not achieve the malaria-related MDG or World Health 
Assembly targets by the end of 201511, 30. The malaria burden in Afghanistan has decreased more 
than that in Pakistan, but increased violence and conflict and potential reductions in funding 
continue to threaten gains made.  
 
Second, experiences in strengthening malaria prevention and treatment services in these 
conflict-affected settings can provide important lessons for the next stages in malaria control. If 
current efforts are sustained or increased, and malaria transmission continues to decline 
globally, more adults will be at risk as lower malaria exposure means immunity is not acquired; 
malaria may become increasingly concentrated in marginalised hard-to-reach populations or 
border areas, potentially worsening existing inequities; transmission intensity may become 
increasingly heterogeneous and migration from or to higher-transmission areas will increase the 
risk of outbreaks; antimalarial and insecticide resistance is likely to increase; and P. vivax may 
become increasingly important, as it can tolerate a wider variety of environments and is harder 
to control30.  
 
Each of these potential global concerns have been considered or researched, though obviously 
on a smaller scale, as part of the twenty-five year malaria control and research programme for 
Afghans in the border areas of northwest Pakistan and Eastern Afghanistan.  
 
Figure 2 shows the two countries and the 1896 ‘Durand line’ border between them, bisecting 
the traditional Pashtun tribal area, shown as a shaded area on both sides of the border. As in 
many regions where modern national boundaries have divided traditional tribal lands, Pashtuns 
on both sides of the border often have more affinity with each other than with the rest of their 
respective nations.  
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Figure 2. Map of Afghanistan and Pakistan including border area 
 
Source: Wikipedia Commons. 
https://upload.wikimedia.org/wikipedia/commons/5/50/Durand_Line_Border_Between_Afghanistan_And_Pakistan.jpg 
 
Pakistan is a lower-middle-income country with a semi-industrialised economy and growing 
services sector. Since separating from India in 1947, Pakistan has had a series of civilian and 
military governments and been affected by regional and civil conflicts232. Healthcare is overseen 
by the Ministry of Health (MoH) at the federal level and by health departments at provincial 
levels233. Primary healthcare facilities include basic health units, rural health centres, primary 
healthcare centres, dispensaries, first aid posts, mother and child health centres, and lady health 
visitors233. 
 
Afghanistan is a low-income country with very poor human development indicators. A series of 
coups, beginning in 1973 with the overthrow of King Zahir Shah, were followed by years of civil 
war that devastated the country234. Healthcare, overseen by the Afghan MoPH since 2001, has 
been significantly reconstructed since the fall of the Taliban in the same year. During the study 
period, most primary health services were provided by informal providers, charitable 
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organisations, and a few NGOs183, 186. According to MoPH data, only 9% of Afghans had access to 
health services in 2003, while as much as 67% had access in 2016 to the Basic Package of Health 
Services and Essential Hospital Services in over 2,200 health facilities in all 34 provinces235. 
 
The Basic Health Unit or Basic Health Centre was the smallest and simplest community-based 
primary healthcare facility in Pakistan (BHU) and Afghanistan (BHC) during the study period, as 
differentiated from community health-worker services that were normally provided from home. 
BHU/BHCs focused on immunization, sanitation, malaria control, and maternal and child health. 
Services normally included antenatal, delivery, and postpartum care; routine immunizations; 
management of childhood diseases; treatment of malaria and tuberculosis; and identification, 
referral, and follow-up care for those with mental and physical disabilities. BHU/BHC catchment 
populations were approximately 15,000-30,000, depending on local geography and population 
density233, 236. BHU/BHCs typically had 7-13 staff, usually including a male nurse or health 
assistant; a female community, auxiliary, or nurse midwife; a community health/nutrition 
supervisor; a sanitary inspector; a lab technician/microscopist; a drug dispenser; 1-2 lady health 
visitors; 1-2 vaccinators, a guard, and a cleaner233, 236. BHU/BHCs also supervised the community 
health-workers and birth-attendants working from home in their catchment areas233, 236.  
 
The health systems of both Pakistan and Afghanistan are a mix of public and private, formal and 
informal, modern and traditional medicine237. Thus, in addition to government/NGO facilities, 
many Afghans attended informal and for-profit providers during the study period237, 238. Reasons 
included easier access, preferred treatments, and better availability of drugs and ‘doctors’237. 
Private healthcare was not adequately regulated at the time of research, and many spent 
significant sums for wrong or insufficient diagnoses and treatments237, 239.    
 
Study site and population in northwest Pakistan 
The United Nations High Commissioner for Refugees (UNHCR) has responsibility for Afghan 
refugee camps and informal settlements in Pakistan. Pakistan was not a signatory to the 1951 
Refugee Convention or the 1967 Protocol Relating to the Status of Refugees and the temporary 
stay of registered Afghan refugees in Pakistan was regularised by means of Proof of Registration 
cards 240. Afghan refugees in Pakistan were never a homogeneous group, instead arriving and 
leaving in conflict-inspired waves starting with the Soviet invasion and war of 1979-1989. 
Pakistan hosted the majority of Afghan refugees globally, which peaked at approximately 5 
million in the 1980s due to its ‘open-door’ policy 241. Most (60-80%) were housed in 340 camps 
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or settlements in NWFP (now KPK1) along the Afghan-Pakistan border157. Most (85%) were ethnic 
Pashtuns, while 15% were Uzbeks, Tajiks or other ethnic minorities 240.  
 
While most urban refugees and economic migrants lived in slum areas of Pakistan's major cities, 
low-income rural refugees in KPK camps were sited on marginal or waterlogged land capable of 
supporting extensive mosquito breeding 242, 243. Malaria in Pakistan is typically unstable and 
seasonal, with major transmission post monsoon, i.e. August to November. Anopheles stephensi 
and An. culicifacies were considered primary malaria vectors, while An. fluviatilis, An. 
superpictus, and An. subpictus were also known vectors 242, 244. The initial malaria epidemic in 
Pakistan, for which UNHCR requested specialist technical support, was caused by the influx of 
three million non-immune Afghans to KPK refugee camps and informal settlements. In 1991, at 
the height of the epidemic, approximately 150,000 cases of vivax and 40,000 cases of falciparum 
malaria were diagnosed and treated annually 224.  
 
The UNHCR malaria control programme in KPK followed WHO guidelines as part of integrated 
housing, education and health services for refugees. Implementers were the governmental 
Project Department for Health (PDH) and local and international non-governmental 
organizations (NGOs). From 1985, AZG provided health support to the camps, including malaria 
control until HNTPO took on this role. From 1992, HNTPO was funded to monitor malaria 
incidence, train technical staff, supervise malaria diagnosis, and organise vector control.  
 
The malaria epidemic was eventually controlled by improving the quality of both diagnostic and 
treatment services in 200 BHUs and laboratories, improving refugee health awareness through 
basic malaria-focussed health education campaigns, and primarily by reviving annual targeted 
IRS usage in traditional mud-brick houses and nomad tents245. IRS was conducted by refugee 
workers at the onset of peak falciparum transmission (July-August) in camps reporting malaria 
incidence above 0.5% for falciparum or 3.0% for vivax. Malathion and later permethrin were 
used. BHUs provided case management, which was free to service-users. Positive cases received 
first-line treatment in accordance with national guidelines. By 1995, annual numbers had fallen 
to 30,000 vivax and 4,500 falciparum cases respectively in an estimated population of 1.2 million 
refugees. However, malaria remains a significant public health concern in Pakistan, which is 
listed as a major focal point in the WHO-EMRO region 11.  
 
                                                             
1 As most research data were gathered prior to 2010, this document will use both ‘NWFP’ for historical accuracy, and  
‘Khyber Pakhtunkhwa’, or KPK to aid clarity.  
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Figure 3. Map of Pakistan's Khyber-Pakhtunkhwa Province (NWFP) and Federally 
Administered Tribal Areas (FATA), showing districts 
 
Source: Wikipedia Commons. https://commons.wikimedia.org/wiki/File:Map_showing_NWFP_and_FATA.png  
 
Study site and population in eastern Afghanistan 
In contrast to the situation in northwest Pakistan, the 1990s malaria resurgence in eastern 
Afghanistan resulted from repatriating infected refugees to a fragile conflict-affected country in 
which health infrastructure and malaria control services had ceased to function. Many former 
refugees resettled in and around Nangarhar Province (Figure 4). Similarly to northwest Pakistan, 
primary vectors in this area were An. culicifacies, An. superpictus, and An. stephensi, while An. 
fluviatilis and An. pulcherrimus were found nationwide246. Malaria transmission was from June 
to September in Nangarhar Province, and malaria was hyper-endemic in rice producing areas85. 
An. stephensi breeds in residual water, while An. superpictus favours mountain lakes. An. 
superpictus and An. fluviatilis are exophilic and exophagic, while other species are generally 
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endophilic and endophagic. Small species, such as An. stephensi, can penetrate untreated 
mosquito nets and have a flight radius of 1-2 kilometres246.  
 
Before Afghanistan’s extended conflict, malaria was almost eliminated as a public health issue 
through vertical governmental IRS and chloroquine (CQ) treatment52, 152, 246. As control 
infrastructure deteriorated during over thirty years of conflict malaria rates increased, peaking 
during the mid-1990s152, 246. From 1992, eastern Afghanistan became stable enough to establish 
a network of NGO-supported clinics, standardize training and monitoring of microscopists and 
clinical staff, and distribute ITNs and insecticide retreatment.  
 
Malaria prevalence in Afghanistan is heterogeneous, believed to be endemic in areas below 
2,000 meters elevation and highly prevalent in river valleys under rice cultivation152. 
Transmission seasons vary throughout the country, and the population is effectively non-
immune to malaria225. While malaria incidence has reduced significantly in the past fifteen years, 
malaria remains a health concern in Afghanistan11, 224, 247, 248. Large areas of Afghanistan are 
malaria endemic due to both P. vivax (approximately 70-90% of infections) and P. falciparum150, 
246. Approximately 60% of the population - nearly 25 million people - are considered at risk11. 
Malaria outbreaks have re-emerged as a concern since 2001 (e.g. in Kundoz, Takhar, and 
Badakhshan provinces) due to refugees returning from neighbouring countries, intensified rice 
cultivation close to populated towns, and insufficient coverage of vector-control measures249, 
250. WHO estimated that approximately 300,000-510,000 malaria cases occurred in 2015, more 
than 30% of them in eastern Afghanistan11.  
 
HNTPO coordinated malaria control in eastern Afghanistan from 1992, extending its malaria 
operations from Peshawar Pakistan to Jalalabad Afghanistan152. As no effective government 
seemed likely to evolve in Afghanistan during the nineties, malaria control efforts were quite 
different from those in KPK refugee settlements. Instead of working through or creating a 
vertical programme, HNTPO attempted to encourage self-sufficiency and personal or 
household-level protective measures. Despite initial donor scepticism, HNTPO introduced ITNs 
on a broad scale. Over 200,000 family-size ITNs were sold at subsidized prices, covering almost 
1 million inhabitants. Few Afghans had used mosquito nets previously and this was one of the 
largest programmes of its kind in the South Asian or Middle-East regions until creation of the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) in 2002 enabled free mass 
distribution of ITNs.  
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Figure 4. Nangarhar Province Afghanistan, showing districts 
 
Source: Wikipedia Commons https://commons.wikimedia.org/wiki/File:Nangarhar_districts.png 
 
During the mujahedeen (1992-1996) and Taliban (1996-2001) eras, HNTPO focussed on 
interventions shown through operational research to be effective, popular and not requiring 
significant government involvement or inputs52, 153, 188, 246, 251. Government infrastructure and 
external support remained minimal until well into the US-led occupation (2001-2014) and is 
arguably still weaker than had been anticipated when the Taliban first fell 248. In South Asia, both 
IRS and ITNs have been shown to be effective for malaria control39, 52, 251-254. However, 
sustainability of prevention efforts requires effective government structures to either stimulate 
local production of necessary supplies and equipment or regulate supply and distribution, which 
has not yet occurred in Afghanistan. 
 
Study design and framework selection 
A mixed-methods study design was chosen, including economic analysis of routine cost and 
outcome data (Chapter 3), epidemiological analysis of clinical, laboratory, and socioeconomic 
data (Chapters 4 and 6), and qualitative analysis of interview and focus group data (Chapter 5). 
 
A review of evaluation literature for public health and healthcare was conducted, described 
below in the Literature review sub-section, to identify relevant work undertaken and potentially 
suitable frameworks to guide analysis and interpretation. A number of potential evaluation 
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frameworks were identified, predominantly from the healthcare literature. The most notable, 
which were considered for use, were: (i) Donabedian’s seminal work, including his 1988 use of 
programme evaluation theory to assess quality of healthcare through structure, process, and 
outcomes and his 1966 dimensions of effectiveness, efficacy, efficiency, acceptability, 
legitimacy, and equity255, 256; (ii) the 1991 OECD-DAC dimensions of effectiveness, efficiency, 
relevance, sustainability, and impact; (iii) the 1999 US Centers for Disease Control and 
Prevention (US-CDC) Framework for Program Evaluation in Public Health, which considers utility, 
feasibility, propriety, and accuracy257; (iv) Black and Gruen’s dimensions of effectiveness, 
efficiency, equity, and humanity for assessing healthcare services258; and (v) the 2006 OECD 
framework dimensions of effectiveness, cost/expenditure, responsiveness, needs, safety, and 
accessibility259. 
 
Table 2. Comparing evaluation frameworks 
Framework Focus  Domains included Strengths  Weaknesses  
Donabedian 
(1966) 
Clinical 
services 
 Acceptability 
 Effectiveness 
 Efficacy 
 Efficiency 
 Equity 
 Legitimacy 
 Widely recognised. 
 Includes equity 
explicitly.  
 Focused on clinical care. 
 Available data and research 
focus is on effectiveness 
rather than efficacy.  
 Legitimacy would be 
challenging to assess with 
available data.  
OECD-DAC 
(1991) 
Development 
assistance 
 Effectiveness 
 Efficiency 
 Relevance 
 Sustainability 
 Impact  
 Widely recognised 
and reasonably 
comprehensive. 
 Does not explicitly include 
equity or humanity. 
 Impact data not available. 
 Relevance and sustainability 
hard to measure.  
US-CDC 
(1999) 
Public health 
programmes 
 Accuracy  
 Feasibility 
 Propriety 
 Utility 
 Designed for public 
health programmes.  
 The interpretation of some 
domains is not obvious.  
 Overly complex for this 
purpose. 
Black and 
Gruen 
(2005) 
Health 
services 
 Effectiveness 
 Efficiency 
 Equity 
 Humanity 
 Broadly applicable. 
 Understandable and 
relevant, yet flexible. 
 Only one to include 
humanity explicitly.  
 Minimal guidance on 
thresholds, e.g. for 
humanity indicators. 
OECD 
(2006) 
Healthcare   Accessibility 
 Effectiveness 
 Cost/Expenditure 
 Needs  
 Responsiveness 
 Safety 
 Explicitly includes 
safety and 
responsiveness. 
 
 Only includes equity in 
terms of access and need.  
 Responsiveness would be 
difficult to assess with 
available data.  
Kruk et al 
(2010) 
Health 
services 
 Effectiveness 
 Efficiency 
 Equity 
 Includes the three 
key domains. 
 Broadly applicable. 
 Does not improve on Black 
and Gruen, as it excludes 
humanity. 
 Domains treated as 
qualitative themes.  
Reeve et al 
(2015) 
Health 
services 
 Accessibility 
 Appropriateness 
 Continuity 
 Effectiveness 
 Efficiency 
 Responsiveness 
 Improves on Black 
and Gruen by 
including 
appropriateness and 
continuity 
(sustainability). 
 Only includes equity in 
terms of access and does 
not include humanity.  
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Black and Gruen’s framework was selected as it included the three key domains of effectiveness, 
efficiency, and equity, and was the only framework to include humanity. It was recognised from 
the beginning that equity and humanity would be more difficult domains than effectiveness and 
efficiency to assess with the secondary data available. However, the attempt seemed 
worthwhile as a contribution to evaluation approaches using operational research data in 
complex settings.   
 
The initial literature review, conducted prior to 2008 DrPH review, was updated prior to thesis 
finalisation, and two additional relevant frameworks considered: (i) Kruk et al’s use of 
‘Effectiveness, Equity, and Efficiency’ to review the contribution of primary care in low and 
middle-income countries260; and (ii) the more comprehensive health services evaluation 
framework developed by Reeve et al for rural and remote communities in Australia (Figure 
12)261. Neither were selected as Kruk et al’s framework did not progress from Black and Gruen’s, 
while Reeve et al’s framework additionally included structure, process, outcome, and key 
foundations (i.e. sustainability, quality of care, national performance indicators, community 
health determinants) that required considerably more time and external data to the programme 
than were available.  
 
Dataset selection and secondary data usage issues 
Dataset selection 
Despite the wealth of operational datasets collected by HNTPO, most had already been 
published or were maintained by someone intending to analyse and publish them. Thus, only a 
limited number was available for potential inclusion in this thesis research. Potential datasets 
consisted of: (1) cost-effectiveness data of the malaria programme in KPK camps from 1990-
1995; (2) cost-effectiveness data of ITNs and IRS in KPK camps in 1991-1994; (3) clinical trial data 
of extended-dose CQ in KPK camps in 1998; (4) cost-effectiveness data of IRS with lambda-
cyhalothrin versus malathion in KPK camps in 1996; (5) cost data of static versus mobile 
distribution of ITNs in Nangarhar province in 1997; (6) clinical trial data of CQ versus SP 
chemoprophylaxis in KPK camps in 1998; (7) semi-structured interviews and cross-sectional 
household survey data of malaria knowledge, prevention and treatment practices, and ITN 
usage in Nangarhar in 2000; and (8) clinical survey, cross-sectional survey, and case-control data 
of malaria and pregnancy in Nangarhar in 2004-2005. 
 
A minimum of three datasets were required for inclusion, while a maximum of five could have 
been included with some loss of depth. To provide the broadest view of the malaria control 
programme in both countries, a range of study types and topics in both study settings were 
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necessary. Thus, the eight datasets were checked against binary selection criteria (Yes/No), and 
the six that were of satisfactory or good quality were ranked from best to worst per criterion as 
shown in Table 3.  
 
Table 3. Dataset selection criteria and ranking 
Criteria  Datasets  Ranking (best to worst)a   Score valuesb Includedc   
Data quality      
  Good  5; 7 7; 5 [6;5] 7 
  Satisfactory   1; 2; 3; 8 8; 1; 3; 2 [4;3;2;1] 8; 1; 3 
  Unsatisfactory   4; 6 Excluded  Excluded Excluded 
Addresses framework     
  Effectiveness  1; 2; 3; 4; 6; 7; 8 1; 3; 8; 2; 7 [6;5;1;0;0] 1; 3; 8; 7 
  Efficiency 1; 2; 4; 5 1; 5; 2 [6;5;1] 1 
  Equity 1; 2; 7; 8 7; 1; 8; 2 [6;5;1;0] 7; 1; 8 
  Humanity  7; 8 7; 8 [6;5] 7; 8 
Type      
  Epidemiological 3; 6; 8 3; 8 [6;1] 3; 8 
  Economic 1; 2; 4; 5 1; 5; 2 [6;1;0] 1 
  Qualitative  7 Included [6] 7 
Setting      
  Pakistan 1; 2; 3; 4; 6 1; 3; 2 [6;5;0] 1; 3 
  Afghanistan  5; 7; 8 7; 8; 5 [6;5;0] 7; 8 
Time-period     
  1990-1999 1; 2; 3; 4; 5; 6 1; 5; 3; 2 [6;5;1;0] 1; 3 
  2000-2005  7; 8 7; 8 [6;5] 7; 8 
NB: aDatasets were ranked ‘best to worst’ from left to right according to selected criteria. bEach dataset was assigned a numerical 
score from 6-0 according to how well it achieved each criterion, and scores for each criterion were summed to provide a total for 
each dataset. cThose datasets included in thesis research are shown in this column in-line with the criteria they satisfy.   
 
Two datasets failed quality criteria and were immediately excluded (Datasets 4 and 6), while 
only one dataset was qualitative and so immediately included (Dataset 7), though it would have 
achieved the second highest score of ‘36’ anyway. The remaining five were ranked by score: 
(Dataset 1) 38; (Dataset 8) 22; (Dataset 3) 19; (Dataset 5) 16; and (Dataset 2) 2, with the top 
three highest scoring datasets being included with Dataset 7. Dataset 5 scored well enough to 
be included, but was not as strong an economic dataset as Dataset 1 and did not contribute to 
any criterion not already covered by included datasets, and was thus deemed unnecessary. 
Thus, a total of four datasets were included (i.e. Datasets 1, 3, 7, and 8 were used in Chapters 3, 
4, 5, and 6 respectively). 
 
Data issues 
The obvious advantages of using secondary data were time and cost savings, and the potential 
for new and additional insights combined with the ethical benefit of ensuring that data involving 
human subjects were analysed and disseminated and therefore not wasted. However, the main 
methodological challenges, compounded by the age of some datasets, were inappropriateness 
of some data variables and lack of control over data quality. First, secondary data could not 
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always answer research questions directly and thus questions had to be adjusted to fit the data 
available. Second, it was not always easy to determine how data were collected or what quality 
assurance procedures had been used and some assumptions were required that were detailed 
in specific sub-studies. Third, missing and incongruous data could not always be checked with 
data collectors or original paper files and similarly assumptions were required that were 
described in sub-studies. Fourth, more effort was required to ensure results were relevant to 
the issues of today than would have been the case, for example, with data collected within the 
past eighteen months.  
 
Each dataset had to be assessed to determine original purpose, collection methods, collection 
period, types of variables, ethics considerations and any local approval process, and data 
consistency and accuracy. Despite the age of some datasets, most of this information was 
available (primarily because these issues were considered during the selection process 
described above). Data quality (e.g. consistency and accuracy) were hardest to determine 
directly. However, HNTPO had an established reputation for epidemiological research, economic 
data were collected by an LSHTM researcher who was still employed at the School, and 
qualitative data were collected by another LSHTM researcher - who was still employed at the 
School - and the DrPH candidate. Thus, original principal investigators were able to answer a 
number of questions that could not be determined from quality checks on variables. It is worth 
noting that when most of these data were collected, ethics approval was not routinely required 
for operational research. Therefore, one of the first steps was to apply for retrospective ethics 
approval for these datasets and overall approval for secondary analysis. These approvals 
provided further assurance that study approaches, data collection, and analyses complied with 
ethical principles.    
 
Literature reviews  
Multiple sources were searched to increase comprehensiveness. First, a review of relevant peer-
reviewed published literature was conducted in the main electronic databases, e.g. PubMed, 
EMBASE, Science Citations, Social Science Research Network (SSRN), ISI Web of Knowledge, 
Health Economic Evaluations Database (HEED), and Cochrane Central and specialised registers. 
Second, a purposive online review of relevant documentary sources was conducted. Search 
engines Google (https://www.google.co.uk/) and Google Scholar (https://scholar.google.co.uk/) 
were used to access additional academic, non-academic and grey literature, including global and 
regional policy documents, conference proceedings, study reports, evaluation reports, website 
information, presentations, online tutorials, organisational data, and news articles. As the 
quality of this data varied considerably, it was only included for context or if the methodology 
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was cited in an academic publication. Third, a purposive hand-search of publications and 
reference lists from the HNTPO control programme was conducted.  
 
To identify and support the evaluation framework, a review of evaluation literature published 
between 1990 and 2015 was conducted for public health, healthcare, humanitarian aid, complex 
interventions, and development sectors. PubMed, Popline, SSRN, and ISI Web of Knowledge 
were searched for relevant journal publications. Search terms included ‘evaluation’, ‘public 
health,’ ‘malaria control,’ ‘effectiveness,’ ‘efficiency,’ ‘equity (equity of access),’ and ‘humanity 
(autonomy, beneficence, non-maleficence, dignity, justice),’ adapted to the MESH headings for 
each database. A Google search, and snowballing of relevant article reference lists, was also 
conducted.  
 
Separate literature reviews were conducted for each sub-study, though a number of 
publications were relevant to more than one chapter.  
 
The first study in chapters 3, assessing cost-effectiveness of adding malaria prevention to case 
management for Afghan refugees, drew on health economics literature. A search of PubMed, 
SSRN, and HEED databases was conducted. Initial broad search terms, adapted to database 
MESH headings, included ‘cost-effective,’ ‘cost’, ‘economic,’ ‘incremental cost effectiveness 
ratio’, or ‘CEA’ and ‘malaria’ or ‘Plasmodium falciparum’, ‘Plasmodium vivax,’ ‘disease control,’ 
‘Pakistan,’ ‘Afghan’ and ‘refugee.’  
 
Chapter 4, assessing CQ resistance among refugees in Pakistan, related to the epidemiological 
literature on drug resistance and access to effective diagnosis and treatment drugs. PubMed, 
EMBASE, and Cochran registers were searched using initial broad search terms, adapted to 
database MESH headings, including ‘chloroquine resistance,’ ‘ECQ’ and ‘pfcrt,’ or ‘pfmdr1,’ 
‘Pakistan,’ ‘Afghanistan,’ and ‘refugee.’  
 
Chapter 5, assessing malaria-related perceptions and behaviours among Afghans under the 
Taliban, related to the social science literature (particularly in South Asia) on health education, 
behaviour change, gender, equity, and humanity. PubMed, SSRN, and Google Scholar were used. 
Initial broad search terms, adapted to database MESH headings, included ‘qualitative,’ 
‘social/socio*,’ ‘knowledge attitudes and practices’ or ‘KAP,’ and ‘ITN’ or ‘malaria,’ ‘risk 
perception,’ ‘behaviour,’ ‘gender,’ ‘women’ or ‘female,’ and ‘Afghanistan.’ 
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Chapter 6, assessing prevalence, clinical indicators, and women’s perceptions of malaria in 
pregnancy, relates to the epidemiological literature on malaria in pregnancy (particularly in 
South Asia) and the social science literature on behaviour change and equity. PubMed, SSRN, 
Cochran databases, and Google Scholar were used. Initial search terms, adapted to database 
MESH headings, included: ‘malaria’ or ‘vivax’ and ‘pregnancy’, ‘antenatal,’ ‘prenatal’, ‘perinatal’, 
‘postnatal/postpartum,’ ‘risk perception,’ ‘women,’ and/or ‘Afghanistan.’ 
 
Data collection 
All primary and secondary datasets were collected as part of HNTPO’s operational research from 
1990 to 2005. Economic data for Chapter 3 were collected by a consultant in 1996 as part of a 
retrospective review of UNHCR’s health programme for Afghan refugees from 1990 to 1995. 
Drug resistance data for Chapter 4 were collected for an open-label double-blind randomised 
controlled trial of CQ treatment for uncomplicated falciparum malaria in Pakistan refugee 
camps, conducted by HNTPO research staff in 1993 to help inform programme antimalarial 
policy. Socioeconomic data for Chapter 5 were collected by the DrPH investigator when working 
for HNTPO in 2000 to determine service-user preferences, knowledge and practices so as to help 
inform ITN programme expansion. Clinical and knowledge, attitudes and practices (KAP) data 
for chapter 6 were collected from women of reproductive age as part of a Unicef and WHO-
funded study of malaria in pregnancy conducted by the DrPH investigator and HNTPO staff in 
2004-2005 to help inform national Safe Motherhood policy. 
 
Data analysis  
Economic data were analysed using Excel™. Quantitative socioeconomic and clinical data were 
analysed using Stata® versions 11-14. Qualitative data were analysed manually using thematic 
coding.  
 
Epidemiological measurement of occurrence and association 
Epidemiological measures of occurrence, association and impact include incidence, prevalence, 
and odds1. Disease occurrence was measured through incidence rates and point prevalence198, 
262. Association of interventions with outcomes was measured through odds ratios, using logistic 
regression tested statistically using χ2 for categorical data and t-tests for continuous data263.  
 
The likelihood that findings were due to chance was minimised in sub-study design. Statistical 
tests of significance, based on probability theory (e.g. the null hypothesis of no difference 
between groups), increased the likelihood that associations were not due to chance. The 
conventional p-value of <0.05 and 95% confidence intervals were used (i.e. 95 of 100 times 
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observed differences were other than those expected by chance and true values between upper 
and lower confidence limits). A statistical power of 1-β=0.80 was used, a priori or post-hoc, to 
determine whether a meaningful association could be observed for expected effect sizes or 
specific sample sizes, given specified significance levels. Sample sizes were calculated using Stata 
or EpiCalc.  
 
Internal validity was addressed in sub-study design and analysis. Selection bias was limited 
through randomised selection or allocation where feasible and distribution measurement of 
case-mix variables (e.g. age, sex, residence). Information bias was limited through standardised 
data collection and measurement, and blinding where feasible. Confounding was addressed at 
sub-study design stage by collecting data on a priori confounders. The effects of confounding 
and interaction were controlled for in analysis by restriction, stratification, or multivariate 
regression techniques. External validity was increased at selection, by ensuring study samples 
were as representative of the wider population as possible. Bradford Hill’s criteria were used to 
infer evidence of causality264. Of these nine criteria, four (temporality, strength and consistency 
of association, and dose-response relationship) appeared to provide strongest evidence265. 
 
Economic measurement of cost and utility 
Economic costs encompass the value of forgone opportunities, resulting from engaging 
resources in any activity207. Cost-effectiveness analysis, such as in Chapter 3, is used to 
determine technical efficiency. It examines the costs and consequences of alternate 
interventions (i.e. IRS added to case management versus case management alone) expressed 
per unit of health outcome. A societal perspective was chosen, as it is the most comprehensive 
economic perspective (i.e. including all others) and therefore preferred when data are sufficient 
to allow for it. Economic measures used for costing included direct, indirect, fixed and variable 
costs, discounting, and time preference, while outcome measures included utility values and 
disability-adjusted life years (DALYs)207. Data concerns were addressed using sensitivity analysis.  
 
Social science measurement of equity and humanity 
The equity measure initially chosen was equity of usage, which is a function of supply and 
demand (i.e. supply, by providing equal services for equal need, and demand, by requiring those 
with greatest need to choose to use services)125, 198. It appeared to be the most relevant 
allocational definition, as using a definition encompassing health equity would have been 
beyond the anticipated scope of a malaria-control programme212. The humanity measures 
initially chosen were autonomy (based on perceived independence and informed choice) and 
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dignity (based on perceived fair and respectful treatment). Justice was also considered, within 
equity of usage.  
 
Both qualitative and quantitative social science methods were used. Quantitative methods, such 
as household surveys, were used to describe social phenomena such as malaria knowledge, 
attitudes and reported practices, and to test theories (e.g. that Afghans purchase ITNs to protect 
themselves from malaria). Qualitative methods, such as in-depth interviews (IDIs), were used to 
generate and explain social data (e.g. why children are prioritised for sleeping under ITNs). 
Measures used include comparative (i.e. items were compared directly with each other – “Do 
you prefer CQ or SP for malaria treatment?”) and non-comparative (i.e. each item scaled 
independently – “How do you feel about using malaria treatment during pregnancy?”) scaling266, 
267.   
 
Ethics 
Ethics approval for secondary analysis of data-sets was granted by the Research Ethics 
Committee of the London School of Hygiene & Tropical Medicine (LSHTM), reference number 
5508. Approval for specific sub-studies was granted by the relevant coordination bodies in 
Pakistan and Afghanistan. Studies conducted in KPK refugee camps (i.e. Chapters 3 and 4) were 
developed with inputs and coordination from UNHCR, which supported the malaria control 
programme financially, and received local ethics approval from UNHCR and Pakistan MoPH 
authorities. The clinical trial in Chapter 4 was also registered with ClinicalTrials.gov, reference 
number NCT01019408. Studies conducted in Nangarhar Province Afghanistan (i.e. Chapters 5 
and 6) were funded by UNHCR, WHO and UNICEF Afghanistan. The sub-study in Chapter 5 was 
conducted when there was no functioning national ethics review committee in Afghanistan and 
thus received local approval from UNHCR, WHO and the acting governor for the Taliban in 
Jalalabad. The epidemiological and KAP study in Chapter 6 received approval from Afghan MoPH 
authorities.  
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Abstract 
Introduction  
Financing of malaria control for displaced populations is limited in scope and duration, making 
cost-effectiveness analyses relevant but difficult. This study analyses cost-effectiveness of 
adding prevention through targeted indoor residual spraying (IRS) to case management in 
Afghan refugee settlements in Pakistan during a prolonged malaria epidemic.  
 
Methods 
Taking a societal perspective, provider and household costs of vector control and case 
management were collected from provider records and community survey. Health outcomes 
(e.g. cases and DALYs averted) were derived and incremental cost-effectiveness ratios (ICERs) 
for cases prevented and DALYs averted calculated. Population, treatment cost, women’s time, 
days of productivity lost, case fatality rate, cases prevented, and DALY assumptions were tested 
in sensitivity analysis. 
 
Findings 
Malaria incidence peaked at 44/1,000 population in year 2, declining to 14/1,000 in year 5. In 
total, 370,000 malaria cases, 80% vivax, were diagnosed and treated and an estimated 67,988 
vivax cases and 18,578 falciparum and mixed cases prevented. Mean annual programme cost 
per capita was US$0.56. The additional cost of including IRS over five years per case prevented 
was US$39; US$50 for vivax (US$43 in years 1-3, US$80 in years 4-5) and US$182 for falciparum 
(US$139 in years 1-3 and US$680 in years 4-5). Per DALY averted this was US$266 (US$220 in 
years 1-3 and US$486 in years 4-5) and thus ‘highly cost-effective’ or cost-effective using WHO 
and comparison thresholds.  
 
Conclusions 
Adding IRS was cost-effective in this moderate endemicity, low mortality setting. It was more 
cost-effective when transmission was highest, becoming less so as transmission reduced. 
Because vivax was three times more common than falciparum and the case fatality rate was low, 
cost-effectiveness estimations for cases prevented appear reliable and more definitive for vivax 
malaria.  
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Background 
Despite almost two decades of radically increased public funding and significant gains, malaria 
control remains challenging as resistance develops to existing insecticides and antimalarials 268-
271. WHO recommends an integrated control approach of early diagnosis and treatment, vector 
control, epidemic surveillance and response, and improved information systems 10, 268, 272. 
Despite these advances, financing of malaria control for populations displaced by crises and 
conflicts is by definition limited in scope and duration 137, 248. Cost-effectiveness analyses, by 
comparing costs and consequences of alternative interventions, can increase effective 
programme management, but are particularly difficult to conduct in complex, resource-
constrained settings. Thus, no studies were found exploring full operational costs or cost-
effectiveness of integrated malaria control in refugee settings or including epidemic 
transmission, and minimal published cost-effectiveness research was found for malaria 
prevention in South Asia 39, 54. 
 
Parts of Afghanistan and KPK province, Pakistan remain malaria endemic 160, 249, 273, 274. 
Breakdown of control infrastructure during decades of conflict led to a high annual malaria 
burden for Afghanistan during 1990-2010 152, 248, 273. Inflows of over 3 million Afghan refugees to 
Pakistan in the 1980s and 1990s led to increased transmission in newly-settled areas 85, 150, 153, 
275. Refugee populations were particularly vulnerable, due to being predominantly non-immune 
and settled in areas prone to Anopheline breeding 85, 171, 243, 275, 276. To inform future refugee 
programme design and implementation, data from the 1990-1995 epidemic were 
retrospectively evaluated, as primary healthcare services in settlements changed relatively little 
over this chronic emergency period. 
 
This study aimed to determine whether adding targeted malaria prevention using IRS to case 
management using quality-assured microscopy and national first-line treatment was a better 
use of limited resources than case management alone during five years of epidemic malaria 
control in Afghan refugee settlements in Pakistan. Objectives were to: (i) calculate costs of the 
integrated control programme and vector control and case management components; (ii) 
determine costs per malaria case and death prevented, year of healthy life gained (YHLG), and 
disability-adjusted life-year (DALY) averted; and (iii) calculate incremental cost-effectiveness 
ratios (ICERs) for integrated control relative to case management alone. 
 
Methods  
Study design 
Following Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines 
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277, an intervention study design was selected to determine the cost-effectiveness of adding a 
vector control intervention to existing malaria case management, using a societal perspective. 
A societal perspective requires that costs related to all stakeholders (e.g. health 
system/programme, government and private providers, service-users) are included, so that 
cost-effectiveness calculations account for costs and benefits for the whole of society and 
‘reflect broad public interest’278. Programme implementation costs, outcomes (i.e. cases and 
deaths prevented, YHLG, DALYs), and cost-effectiveness (ICERs) were calculated.  
 
Study site and population 
The study population resided in Afghan refugee settlements near the Afghanistan-Pakistan 
border. In Year 0, a population of almost 2.5 million Afghan refugees was supported by 193 BHUs 
(the lowest level of primary healthcare facility) in over 100 settlements in KPK (Table 1a). By Year 
5, this had dropped to 1.2 million refugees supported by 71 BHUs. As the refugee population 
declined and NGOs reduced activities, numbers of operational BHUs reduced by nearly two-
thirds.  
 
Refugee populations were non-immune and constantly changing, having originated in areas 
where malaria was previously controlled and engaging in considerable cross-border movement. 
Refugee settlements were sited on marginal land and housing was rapidly constructed from 
mud-brick, lacking piped water or sewerage. UNHCR provided integrated housing, education, 
and health services for refugees. The UNHCR malaria control programme responded to a late 
1980s malaria epidemic and operated for over fifteen years. Implementers were governmental 
Project Department for Health (PDH) and local and international NGOs. HNTPO, a specialist 
technical NGO, conducted research and provided technical support, quality-assured malaria 
microscopy training, monthly field laboratory monitoring, malaria surveillance, vector control, 
and evaluation.  
 
Intervention 
The UNHCR-subsidised intervention consisted of: (i) case management through strengthening 
malaria diagnosis and treatment at BHUs in all settlements during years 0-5; and (ii) vector 
control using annual IRS in a sub-set of higher-incidence settlements during years 1-5. Case 
management, conducted by BHU health-workers, consisted of diagnosis by quality-assured 
microscopy and treatment of malaria cases according to national guidelines275. Microscopy was 
the only diagnostic method used. Continuous training and quality checks, through bimonthly 
monitoring of each BHU laboratory (i.e. experienced microscopists checked a randomly-selected 
series of negative and positive malaria slides from each microscopist), maintained a diagnostic 
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accuracy of above 98%275. RDTs were not available at test sites, but it was deemed unlikely by 
investigators that their usage would have improved the level of accuracy achieved. Positive 
cases received a 3-day course of CQ as first-line treatment, with primaquine (PQ) administered 
as a gametocytocidal drug for falciparum malaria and as a 5-day course for vivax malaria, though 
this was later abandoned as a trial demonstrated insufficiency for radical treatment279. UNHCR 
procured CQ locally and primaquine internationally. All cases were recorded for surveillance 
purposes and asked to return for a follow-up slide, with most doing so, and treatment failures 
receiving sulphadoxine-pyrimethamine (SP). National guidelines have since changed for 
confirmed falciparum malaria, to more effective and more expensive SP-artesunate therapy 280, 
and this substitution was modelled in sensitivity analysis.  
 
IRS vector control was conducted by refugee workers, supervised by implementing partners, in 
an annual campaign held before the onset of peak annual transmission (July-August). Refugee 
settlements were spatially discrete, ranging from approximately 5,000 to 30,000 population, and 
separated from local Pakistani villages. Settlements were generally quite densely populated. 
Though density sometimes varied, it was not difficult for the malaria control programme to 
identify spatially the perimeters of each settlement and houses within them, all of which were 
eligible for IRS. IRS targeting was based on a threshold reported malaria incidence rate per 
settlement of above 5 falciparum cases per 1,000 person-years or 30 vivax cases per 1,000 
person-years in the previous year. Pumps and insecticide were donated by UNHCR. The 
organophosphate insecticide malathion and the pyrethroid lambdacyhalothin were used for IRS 
(Table 1a). All services were provided free to end-users. 
 
Effectiveness calculations  
Effectiveness measures used were cases prevented, deaths prevented, YHLG, and DALYs 
averted. YHLG were reported because DALYs were very low due to low recorded mortality and 
for comparison with studies not reporting DALYs. Malaria incidence per 1,000 population was 
estimated from BHU-diagnosed malaria cases, as 87% of refugees surveyed reported using BHUs 
for healthcare85, 281. Population figures were taken from biannual UNHCR records and 
crosschecked with HNTPO data, NGO family registrations, and spraying records, but potentially 
over-represented due to population mobility. As population estimates affected incidence 
calculations, a reduced population set was included in sensitivity analysis. 
 
Cases prevented by vector control were calculated in sprayed settlements as ‘the number of 
actual cases’ minus ‘the number of cases that would have occurred in the absence of spraying’. 
Unsprayed settlements were used for controls and matched with sprayed settlements with 
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similar populations and incidence rates from the same district, using randomised controlled trial 
principles. As some unsprayed settlements had lower incidence rates, which could have 
underestimated cases prevented, a higher transmission reduction was tested in sensitivity 
analysis. Inversely, the inherent variability in caseloads between villages and over years could 
have overestimated cases prevented, and a lower transmission reduction was also tested in 
sensitivity analysis.  
 
Cases prevented by case management could not be calculated readily, as no counterfactual 
settlements without case management existed. Thus, the worst-case scenario was used in which 
case management prevented no additional cases and thus had no impact on transmission, with 
higher estimates modelled in sensitivity analysis.  
 
Deaths prevented were calculated as the product of the number of falciparum cases prevented 
multiplied by the case fatality rate (CFR). This enabled comparison across vector control and 
case management and derivation of YHLG. Vivax CFR was estimated as zero. A falciparum CFR 
of 0.71% (i.e. 44 deaths out of 6,210 falciparum cases) for Afghan refugees was obtained from 
two years of mortality data in study settlements in Hangu district282. As household deaths were 
seldom reported and not directly attributable to malaria, and CFR data were collected during 
epidemic conditions, both a higher CFR and lower non-epidemic CFR were tested in sensitivity 
analysis.  
 
Years of healthy life gained (YHLG) summed morbidity and mortality gains from cases prevented. 
Mean days of illness per episode, obtained by household survey, were 12 for vivax and 18.4 for 
falciparum. Mean age at death for falciparum, obtained from BHU records, was 16.4 years. Age-
disaggregated life expectancy data were obtained from WHO life tables for Afghanistan over the 
study time-period 283 and used for calculating years of life lost, as it was anticipated based on 
discussion with local experts that these rates would be more similar to refugee death rates than 
would those for the host population. Calculations using BHU and Afghan life table data were 
compared and found to be similar. However, it is worth noting that neither could be assumed 
to be completely accurate, but instead seen as the best available to model years of life lost, and 
results should be interpreted accordingly. Morbidity gains per case averted were calculated as 
mean days ill multiplied by percentage of nonfatal cases (i.e. 1 minus CFR). Mortality gains per 
case averted were calculated as: ‘life expectancy at age of death’ minus ‘mean age at death’ 
multiplied by 1 minus CFR. A 3% discount rate was used, to capture present valuation of future 
benefit or harm 284, as its common usage in other studies improved comparability 285-287. YHLG 
were obtained by dividing day results by 365. 
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DALYS averted were calculated for falciparum and vivax combined according to WHO methods, 
with 3% discounting, 0.053 disability weighting for moderate infectious disease, and uniform 
age weighting 288, 289, as: ‘years of life lost to malaria mortality plus years of malaria-related 
disability in the absence of the intervention’ minus ‘years of life lost to malaria mortality plus 
years of malaria-related disability in the presence of the intervention’. Major DALY assumptions 
(i.e. discount rate, age weighting, disability weighting, life expectancy, CFR) were tested in the 
sensitivity analysis.   
 
Cost calculations 
Using a standard ingredients approach, total costs were calculated over five years for the whole 
control programme and for vector control and case management components individually. 
Provider cost data were collected from UNHCR, HNTPO and four implementing partners 
providing healthcare services covering 80% of settlements. Shared provider costs, associated 
with both vector control and case management (i.e. malaria inspectors and supervisors, 
administrative and finance staff, general health-staff, overheads, storage, transport) were 
allocated per programme component. Household cost data were estimated by facility exit 
survey. The survey was conducted by two male CHWs, experienced in interviewing, of 623 
malaria outpatients at four BHUs in Naguman, Kotki, and Azakhel settlements, to calculate 
weighted average household costs. Settlements were purposively selected to represent lower, 
middle, and higher-income households. Data collected on: (i) malaria species diagnosed; (ii) 
travel and waiting times for BHU providers; (iii) travel and waiting times for non-BHU providers; 
(iv) payments at non-BHU providers; and (v) time and productivity lost from illness were used to 
estimate direct and indirect household costs per malaria episode.  
 
Total annual case management costs were estimated as: (‘provider cost per case’ plus 
‘household cost per case’) multiplied by ‘number of cases diagnosed and treated annually’. Case 
management costs per strain and per year were calculated as: (‘number of positive slides 
recorded’ multiplied by ‘cost per case diagnosed and treated’) plus (‘number of negative slides 
recorded’ multiplied by ‘cost per slide’), with mixed cases assumed to incur falciparum costs and 
negative results costed as: slide plus reagent plus ‘microscopist time per slide’. Provider costs 
for case management summed direct costs from all participating providers. Specific costs were 
laboratory technicians, microscopes, slides and reagents, antimalarials, training, and 
monitoring. Shared costs were allocated as described above for vector control. Household costs 
for case management summed direct and indirect costs for service-users, which were estimated 
per episode by the exit survey then multiplied by numbers of cases to estimate total annual 
Howard N: Malaria control for Afghans (1990-2005) 53 Chapter 3 
costs. Direct costs were costs incurred through treatment. Indirect costs were costs incurred 
through travel and the value of time lost from regular activities, due to illness, and due to caring 
for those ill. Service-user costs per case were: ‘direct costs’ plus ‘indirect costs’ plus ‘carer costs’ 
plus ‘productivity lost to morbidity or mortality’.  
 
Direct household costs were: ‘average per-case test and treatment costs for non-BHU providers’ 
plus ‘average per-case travel costs’. Estimated travel costs for patients and carers were: ‘travel 
costs to and from a facility’ multiplied by ‘number of journeys per person per episode’. As 
polypharmacy was common among private providers, meaning malaria patients received non-
essential tests and drugs they would not have incurred without malaria infection, these were 
included as direct costs.  
 
Indirect household costs were: (‘travel time to and from facilities’ multiplied by ‘number of 
journeys per person per episode’ plus ‘time per person spent in facilities waiting and consulting’ 
plus ‘additional non-productive time spent ill’) multiplied by ‘time value for patients and carers’. 
Time spent ill was estimated from survey data as 12 days for vivax and 18.4 days for falciparum 
malaria. As this was potentially overestimated, a lower estimate was tested in sensitivity 
analysis. Time, for both service-users and carers, was valued as ‘time in days’ multiplied by ‘daily 
wage’ multiplied by ‘% in paid employment’ using the average daily wage of US$1.65 paid by 
PDH and estimating that 34.7% of adult refugees (i.e. 65% of men, 1% of women) earned wages 
based on HNTPO interview data290. As this estimation undervalued women’s unpaid domestic 
work, higher estimations were tested in sensitivity analysis. For cost of death an adapted human 
capital approach was used to estimate potential life-long productivity losses as data did not 
allow for willingness-to-pay estimations. Estimated length of productive life was calculated by 
subtracting 16.4 years, the mean age at death from falciparum malaria, from median Afghan life 
expectancy using an Afghan life table, as no life table was available for Afghan refugees 291. 
Productivity valuation was: ‘discounted value of future income’ multiplied by ‘the value of one 
year of income’ multiplied by ‘case fatality rate’. A discount rate of 3% was assumed and 
productivity lost to mortality estimated using both epidemic and non-epidemic case fatality 
rates (CFR). While non-working children could not be disaggregated, malaria was most frequent 
in working ages. Carers were normally women or unemployed householders, thus replacement-
cost valuation using the generalist daily wage paid to refugee labourers (i.e. US$1.65) was 
selected. 
 
Total annual vector control costs summed provider and service-user costs associated with vector 
control. Costs for participating providers were entomologists, spray-personnel, spray pumps, 
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protective gear, and insecticide. Implementing partners provided specific and shared cost data 
(e.g. overheads, vehicles, personnel) from expenditure records, budget files and staff interviews. 
As malaria control was part of integrated health-service delivery, shared support cost allocation 
differed by provider. Cost allocation approaches were: (i) personnel costs multiplied daily wages 
by estimated time in post; (ii) annual training was calculated as (number of trainees for NWFP 
programme/number of trainees for all programmes) multiplied by (total training costs); 
transport and overheads were split by number of operational sectors weighted by numbers of 
malaria staff or similar indicator of programme size; and monitoring costs were estimated from 
HNTPO interviews. Household costs associated with vector control, estimated by provider 
interview, summed time lost to women’s unpaid work during house preparation, time waiting 
for IRS/drying, and post-spraying house reorganisation, based on replacement cost of a 
domestic worker. Household costs were very small and thus treated as zero for simplicity.  
 
Annual per-capita case management costs were calculated by dividing total case management 
costs by total recorded settlement population. Annual per-capita vector control costs were 
calculated by dividing total vector control costs by the total recorded population of settlements 
sprayed. 
 
All costs were converted to US$2015 constant prices using Pakistan’s national GDP deflator and 
International Monetary Fund statistics292-294. Capital costs were annualised using the World Bank 
discount rate for Pakistan of 10% and expected useful lifespan (i.e. BHU buildings and 
microscopes at 20 years, vehicles at 10 years, and computers, photocopiers, and spray pumps 
at 5 years).  
 
Cost-effectiveness calculations  
Cost per case prevented by vector control was calculated as: ‘total programme and household 
costs of vector control and case management’ divided by ‘total number of malaria cases 
prevented’. No cases were prevented by case management in the main analysis, so costs were 
calculated as zero. The incremental cost-effectiveness ratio (ICER) for cases prevented by vector 
control was then calculated as difference in cost divided by difference in effect: (‘total 
programme and household costs of vector control and case management’ minus ‘total 
programme and household costs of case management alone’) divided by (‘number of cases 
prevented by the whole programme’ minus ‘number of cases prevented by case management 
alone’). Costs and ICERs for malaria deaths prevented, per YHLG, and per DALY averted were 
calculated similarly. The WHO cost-effectiveness threshold for DALYs of 3 times Pakistan’s GDP 
per capita in year 0, i.e. US$1,436 (range US$537-US$3,864), was used because preference 
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elicitation data were unavailable and it remains an established threshold295, 296. However, given 
criticisms of the WHO threshold by Shillcutt and others297, 298, Wood et al’s threshold values for 
Pakistan, i.e. US$87-US$669, were also compared299.  
 
Sensitivity analysis  
A univariate sensitivity analysis was conducted, as probabilistic analysis would have been 
difficult without cost and effect distributions. Inputs for major assumptions of population, 
malaria treatment costs, valuation of women’s time, days of productivity lost to illness, CFR, 
cases prevented, and DALY assumptions were varied and resulting costs compared with 
effectiveness outcomes. To test the effects on the ICER for cases prevented of:  
1. increasing falciparum treatment costs, a higher estimate using SP+Artesunate was tested;  
2. reducing population size, an additional annual incidence set was calculated using a 
population of one-half recorded size; 
3. varying cases prevented by vector control, both increased and reduced rates of 50% were 
tested85, 300;  
4. increasing cases prevented by case management above zero, rates of 30% and 50% were 
tested111; 
5. reducing days of productivity lost to malaria illness, lower estimates from Nepal (i.e. 7.9 days 
for vivax, 10.9 days for falciparum) were used253; 
6. reducing valuation of women’s time, two additional daily rates of $1.00 and $0.00 were 
used. 
 
To test the effects of varying DALY assumptions on the ICER for DALYs averted: 
 the 3% discount rate was compared with a rate of 5% and 10%301;  
 uniform age weighting was compared with non-uniform weighting;  
 disability weighting of 0.053 for an acute moderate infection episode was compared with 
0.005 for a mild episode and 0.254 for post-acute consequences as estimated for the 2010 
Global Burden of Disease289;  
 historic Afghan life expectancy was compared with a 2014 Afghan life table283; and  
 the 0.71% CFR was compared with a possible non-epidemic estimate of 0.05% (an estimated  
midrange CFR for Pakistan for 2003-2013302) and a doubled epidemic estimate to account 
for potential underreporting of deaths, as there was no required death registration. 
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Ethics 
Local ethics approval for operational research was provided by UNHCR Pakistan office. Approval 
for retrospective data analysis was provided by the LSHTM research ethics committee (reference 
5508). All patient data were anonymised prior to inclusion.  
 
Results  
Epidemiology and response 
Figure 5 shows malaria incidence in refugee settlements rose from 34 per 1,000 person-years in 
year 0 to a peak of 44 per 1,000 person-years in year 2, then declined steadily to 14 per 1,000 
person-years in year 5. Table 4a shows annual population, malaria incidence, and programme 
responses. At baseline in year 0, 193 health facilities provided case management for 2.4 million 
refugees (0.8/10,000 population). The number of facilities peaked in years 2-3 with 1.0/10,000, 
decreasing to 0.6/10,000 in year 5. From year 1 onwards, high-incidence settlements also 
received IRS, peaking in year 3 with 50% (77/155) of BHU catchment settlements covered and 
reducing to 41% (29/71) of remaining settlements in year 5. Programme effectiveness and cost-
effectiveness results are reported for years 1-5 only, as year 0 did not include IRS. 
 
Figure 5. Malaria incidence per thousand in KPK refugee settlements, Year 0 to Year 5 
 
 
Effectiveness analysis 
Cases and deaths prevented: Table 4b shows that over years 1-5, an estimated 67,988 vivax cases 
(annual average 13,598), 18,578 falciparum and mixed-infection cases (annual average 3,716), 
and 132 deaths (annual average 26) were prevented through IRS.  
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Table 4. Epidemiology, programme effectiveness, and cost-effectiveness by year 
a. Epidemiology  Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 
Population 2,402,726 2,386,726 1,832,077 1,541,577 1,298,006 1,236,325 
P. vivax cases 65,410 85,560 63,909 54,096 28,898 15,815 
P. falciparum cases 16,121 12,984 16,495 7,376 3,941 1,895 
Mixed falciparum cases 829 282 253 133 15 122 
Total cases 82,360 98,826 80,657 61,605 32,854 17,832 
Vector control response (%)       
 Number of settlements sprayed 
with malathion  
0 64 (100) 76 (100) 39 (51) 19 (56) 13 (45) 
 Number of settlements sprayed 
with lambda-cyhalothrin 
0 0 (0) 0 (0) 33 (43) 15 (44) 13 (45) 
 Number of settlements sprayed 
with permethrine  
0 0 (0) 0 (0) 5 (6) 0 (0) 3 (10) 
   Total settlements sprayed 0 64  76 77  34 29  
 Case management response       
 total BHUs 193 190 180 155 101 71 
 per 10,000 population 0.80 0.80 0.98 1.01 0.78 0.57 
       
b. Effectiveness indicators Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 
Cases prevented             
   P. vivax ..           13,979         19,406            21,181         11,769         1,653  
   P. falciparum/mixed  ..             3,106           6,144              7,754           1,087            487  
  Total cases   17,085   25,550   28,935   12,856   2,140  
Deaths prevented ..                 22                44                   55                 8                3  
Years healthy life gained       
   P. vivax ..                460              638                 696              387              54  
   Discounted P. vivax ..             460            619            656           354            48  
   P. falciparum ..                949           1,878  2,370              332            149  
   Discounted P. falciparum ..             949         1,823   2,234            304           132  
DALYs averted ..            2,511  3,756            4,253               1,890                315  
       
c. Cost-effectiveness indicators Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 
Cost per case prevented       
   P. vivax ..     US$142        US$88             US$85          US$106         US$539  
   P. falciparum/mixed  ..       US$641         US$278         US$233      US$1,152      US$1,829  
Total cases  ..    US$116          US$67             US$63           US$97            US$416  
Cost per death prevented  ..   US$90,224  US$39,182      US$32,886    US$257,576   US$116,415 
Cost per YHLG  ..    US$1,412        US$679           US$590        US$1,741         US$4,383  
Cost per discounted YHLG   US$1,412   US$700   US$626   US$1,903   US$4,948  
Cost per DALY averted ..     US$792     US$455        US$426        US$662       US$1,033  
 
YHLG: Days of healthy life gained per case prevented were 12 for P. vivax, 111 for P. falciparum. 
Per case estimates were multiplied by cases prevented and then by 365 to obtain a total 2,235 
YHLG for vivax prevention (annual average 447) and total 5,678 YHLG for falciparum prevention 
(annual average 1,136). Discounted YHLG totalled 2,138 (annual average 428) for vivax 
prevention and 5,443 (annual average 1,089) for falciparum prevention (Table 4b).  
 
DALYs averted: Disability-adjusted life-years averted were estimated as 0.147 per case 
prevented for total cases, thus accounting for vivax and falciparum morbidity and mortality. This 
was then multiplied by cases prevented to obtain a total of 12,725 DALYs averted (annual 
average 2,545) during years 1-5 (Table 4b).  
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Cost analysis 
Total costs: Programme costs totalled US$8.9 million (US$1.5 million annual average) for the full 
six years (years 0-5) and US$7.7 million (also US$1.5 million average) for the five years included 
in cost-effectiveness analysis. UNHCR funded approximately 56% overall with remaining costs 
divided between HNTPO (i.e. 12% overall) and NGO service-providers (i.e. 32% overall). HNTPO 
and NGO service-providers’ proportional contributions shifted, from 6% and 50% respectively in 
year 0 to 26% each in year 5. Figure 6 shows an overall decline in costs from US$1.3 million at 
baseline to US$890,623 in year 5, with two peaks in years 1 and 3. Case management was 
proportionately higher at US$5.6 million (62%), decreasing from US$1.3 million annually (100%) 
at baseline to US$438,765 annually (49%) in year 5. Vector control totalled US$3.4 million (38%), 
peaking in year 3 at US$852,477 (47%). Service-user case management expenditures totalled 
US$27,861 (0%), decreasing with the epidemic curve from US$7,025 (1%) at baseline to 
US$1,117 (0%) in year 5.  
 
Figure 6. Total programme costs by year 
 
 
Component costs: The costliest vector control components were personnel and insecticide at 
US$2.9 million (85%) total. An increase in vector control costs in year 3 was associated with 
increased insecticide costs due to initiation of lambda-cyhalothrin for IRS in half of settlements 
sprayed. The costliest case management component was personnel at US$3.7 million (67%). 
Locally purchased antimalarials and imported primaquine, at US$272,283 (5%) and US$35,692 
(1%) respectively, were minor components. Provider transport increased as a share of costs 
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comparatively over time, from US$153,078 (12%) at baseline to US$83,374 (19%) in year 5. 
Service-users spent 22% more treating falciparum than vivax malaria (i.e. US$16,899 versus 
US$10,962 respectively), though these were minor components (0%) of overall societal costs.  
 
Per capita costs: The mean annual cost per capita for the full programme was US$0.56, ranging 
US$0.36-0.76 over five years. Mean annual costs per capita for vector control and case 
management separately were US$0.23 and US$0.33 respectively. For vector control, this ranged 
from US$0.0-0.34, highest in year 3. For case management, this ranged from US$0.23-0.40 and 
was highest in year 0 (US$0.36) and year 3 (US$0.40). 
 
Per-case costs: Provider costs per case diagnosed and treated averaged US$14.98 for vivax and 
US$14.93 for falciparum, with the largest component cost being US$10 for staff. Household 
costs per case were estimated from survey data as US$10.83 for vivax and US$18.91 for 
falciparum. Given low mortality rates, the largest household component cost per case was 
productive time lost to illness at US$8.22 for vivax and US$12.63 for falciparum. A malaria death 
caused an estimated US$16,038 lost productivity, using the assumption that individuals would 
continue with similar work and wage rates, given the protracted nature of the refugee setting 
and that at death an individual loses all future life-years and future productivity anyway.   
 
Cost-effectiveness analysis 
Table 4c shows changes in programme cost-effectiveness indicators over the course of year 1 to 
year 5. Table 5 compares cost-effectiveness of the integrated programme versus case 
management alone for a population of 100,000. It includes costs and ICERs of events averted 
averaged over the full five-year analysis period (years 1-5), and separately for years 1-3 and 4-5, 
to compare epidemic peak and ending. In a model population of 100,000, the cost per case 
prevented averaged US$88 (US$77 in years 1-3 and US$143 in years 4-5). For vivax, cases 
prevented averaged US$111 (US$103 in years 1-3 and US$160 in years 4-5). For falciparum, 
cases prevented averaged US$442 (US$331 in years 1-3 and US$1,361 in years 4-5). Cost per 
death prevented averaged US$316,734 (US$45,635 in years 1-3 and US$191,715 in years 4-5). 
Cost per YHLG averaged US$1,011 (US$806 in years 1-3 and US$2,323 in years 4-5). Cost per 
DALY averted averaged US$601 (US$524 in years 1-3 and US$972 in years 4-5). 
 
Table 5. Effects, costs, and incremental cost-effectiveness ratios of adding vector control to 
case management in refugee settlements in Pakistan over five years, and disaggregating years 
1-3 and 4-5, in US$2015 
Effects per 100,000 population 
Integrated 
programme 
Case 
management 
Comparison 
 n=100,000 n=100,000 n=100,000 
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Vivax cases prevented 835 .. 835 
Falciparum/mixed cases prevented 209 .. 209 
All cases prevented 1,044 .. 1,044 
Deaths prevented 0.29 .. 0.29 
YHLG 91 .. 91 
DALYs averted 153 .. 153 
        
Costs per 100,000 population Average cost-effectiveness ratio Comparison 
Costs of events averted over 5 years US$ US$ ICER US$ 
Programme costs per 100,000 92,250 51,406  
Cost per vivax case prevented 111 .. 50 
Cost per falciparum/mixed case prevented 442 .. 182 
Cost per case prevented 88 .. 39 
Cost per death prevented  316,733 .. 140,234 
Cost per YHLG 1,011 .. 448 
Cost per DALYs averted  *601 .. **266 
    
Costs of events averted in years 1-3 US$ US$ ICER US$ 
Programme costs per 100,000                      95,643                    55,420   
Cost per vivax case prevented 103 .. 43 
Cost per falciparum/mixed case prevented 331 .. 139 
Cost per case prevented 77 .. 32 
Cost per death prevented  45,635 .. 19,192 
Cost per YHLG 806 .. 339 
Cost per DALYs averted  *524 .. **220 
    
Costs of events averted in years 4-5 US$ US$ ICER US$ 
Programme costs per 100,000               84,539             42,284   
Cost per vivax case prevented 160 .. 80 
Cost per falciparum/mixed case prevented 1,361 .. 680 
Cost per case prevented 143 .. 71 
Cost per death prevented  191,715 .. 95,825 
Cost per YHLG 2,323 .. 1,161 
Cost per DALY averted  *972 .. *486 
NB: *Below WHO cost-effectiveness threshold of US$1,435.86 (3*US$478.62 or Y0 Pakistan GDP per capita) per DALY 
averted. **Highly cost-effective at <US$478.62 (Y0 Pakistan GDP per capita) per DALY averted. GDP=gross domestic 
product; <GDP per capita is ‘very cost-effective’, 1-3*GDP per capita is ‘cost-effective’, >3*GDP per capita is ‘not cost-
effective.’ 
 
The additional cost of including IRS in a model population of 100,000 averaged over five years 
per case prevented was US$39 (US$33 in years 1-3 and US$69 in years 4-5). For vivax cases 
prevented this was US$50 (US$43 in years 1-3 and US$80 in years 4-5). For falciparum cases 
prevented this was US$182 (US$139 in years 1-3 and US$680 in years 4-5). The additional cost 
averaged over five years per death prevented was US$140,234 (US$19,192 in years 1-3 and 
US$95,825 in years 4-5). The additional cost averaged over five years per YHLG was US$448 
(US$339 in years 1-3 and US$1,161 in years 4-5). The additional cost averaged over five years 
per DALY averted was US$266 (US$220 in years 1-3 and US$486 in years 4-5). Adding IRS to 
routine case management was thus ‘highly cost-effective’ using the WHO threshold of US$479 
per DALY averted (i.e. Y0 Pakistan GDP per capita) when averaged over five years and in years 
1-3. This reduced in years 4-5, as the epidemic ended, but remained below the WHO ‘cost-
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effective’ threshold of US$1,436 per DALY averted (i.e. 3 times Y0 Pakistan GDP per capita). The 
additional costs of adding IRS to case management per DALY averted were cost-effective over 
all time-periods using Woods et al’s threshold of US$87-669.  
 
Sensitivity analysis  
Table 6 shows results of varying treatment costs, population, cases prevented, days of 
productivity lost, time valuation, and DALY assumptions. Increasing falciparum treatment costs 
to account for ACT, reducing days of productivity lost, and reducing valuation of women’s time 
had no notable effect on the ICER for cases prevented. Reducing the population by one-half 
increased the ICER from US$39 to US$78. Increasing cases prevented by vector control by 50% 
reduced the ICER to US$26, while reducing cases prevented by vector control by 50% increased 
the ICER to US$79. Increasing cases prevented by case management increased the ICER to US$56 
for a 30% increase and US$78 for a 50% increase. For DALY assumptions, increasing the discount 
rate increased the ICER for DALYs averted from US$266 to US$399. Changing to non-uniform 
age weighting increased the ICER to US$477. Varying disability weighting had little effect, while 
varying life expectancy had no effect on the ICER. Lowering the CFR to a non-epidemic average 
increased the ICER to US$3,914. Doubling the CFR lowered the ICER to US$133. Thus, 
assumptions with the largest effects on the ICER for cases prevented were population size, cases 
prevented by vector control, and cases prevented by case management. Assumptions with the 
largest effects on the ICER for DALYs averted were the discount rate, age weighting, and CFR. 
Life expectancy differences had no effect on the ICER for DALYs averted. 
 
Table 6. Sensitivity to selected parameters of the societal incremental cost-effectiveness ratio 
(ICER) in US$2015 of cases prevented or DALYs averted 
Parameter: Cases prevented& ICER   Parameter: DALYs averted& ICER 
Study ICER for cases prevented 39  Study ICER for DALYs averted 266 
Cost of Pf treatment (US$0.83)     
Increased by 150%  39  DALY assumptions:  
Increased by 300% 39    
Population size (2,402,726)   Discount rate (3%)  
Reduced by 50%  78  5%   399 
Cases prevented by vector control (63%)   10%   611 
Increased by 50% 26  Age weighting (uniform K=0)   
Reduced by 50% 79  Non-uniform 477 
Cases prevented by case management (0%)   Disability weighting (0.053)   
30% of total cases prevented 56  0.005   323 
50% of total cases prevented 78  0.254   320 
Time valuation for women (US$1.65/day)   Life expectancy (2000)   
US$1.00/day 39  2014 table   266 
US$0.00/day 39  Case fatality rate (0.71%)  
Days productivity lost to illness (12.0; 18.4)   Lower non-epidemic (0.05%) 3,914 
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Pv 7.9 days 39  Higher epidemic (1.42%) 133 
Pf 10.9 days 39    
NB: &Actual parameter values used for the study are in parentheses. 
 
Discussion  
Primary findings 
This study is the first to model the cost-effectiveness of adding vector control to case 
management during an epidemic in a co-endemic vivax-predominant setting. It is one of the first 
to estimate costs per case averted and first to estimate costs per DALY averted by IRS in South 
Asia, where IRS has traditionally dominated as a means of malaria prevention54, 303.  
 
Annual indicators showed increasing then decreasing programme efficiency over six years as 
population and malaria incidence increased then declined. Similarly, the rise and sustained fall 
in household costs reflected fewer service-users due to population decline, reduced numbers of 
BHUs, and falling incidence. IRS prevented approximately 266% more vivax than falciparum 
cases (i.e. 67,988 vivax versus 18,578 falciparum), due to the dominance of P. vivax in the area. 
Conversely, IRS enabled approximately 154% more YHLG from falciparum than vivax prevention 
(i.e. 5,678 falciparum YHLG versus 2,235 vivax YHLG), because falciparum prevention was worth 
more YHLG (i.e. 0.30 years for falciparum versus 0.03 for vivax). DALYs averted, which included 
both vivax and falciparum, were relatively low due to the low estimated falciparum CFR.  
 
IRS appeared to improve horizontal equity (providing equal access to all those with equal needs) 
because it cost less than case management for households. Household case management costs, 
though insignificant within overall programme terms, were likely difficult for low-income 
service-users. Direct household costs were low because IRS was provided free to service-users 
and most attended BHUs, thus receiving free treatment to which they were able to walk. 
However, indirect case management costs such as income lost due to illness were a concern for 
low-income households. Additionally, those who attended private providers could pay 
significant amounts for less reliable diagnosis and treatment.  
 
Adding IRS appeared highly cost-effective in epidemic conditions and less so as cases and CFR 
reduced. This intervention supported refugees during prolonged epidemic conditions in refugee 
settlements, but cost-effectiveness can be compared with other programmes using costs to the 
health system (per capita), per case diagnosed and treated, and per case or DALY averted86. For 
example, health system costs per capita for five years (calculated by dividing total programme 
costs by total population in the study area), were US$0.73 for the full programme, US$0.62 for 
case management, and US$0.84 for vector control. These compared favourably to health system 
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costs for malaria control found by Shretta et al globally (US$2013 2.50), for sub-Saharan Africa 
(US$2013 1.21-3.47), and for South Asia (Afghanistan US$2013 1.34; India US$2013 0.30-9.39; 
Nepal US$2013 0.45-1.36)86. Average cost per patient diagnosed and treated (US$14.95) was 
similar to findings by Hansen et al for microscopy diagnosis and treatment in moderate 
(US$2013 10.64) and low (US$2013 22.38) transmission settings in Afghanistan and by 
Bualombai et al (US$2013 13.23) in Thailand, though higher than by Davis et al (US$2013 4.36) 
in Papua New Guinea per child vivax case diagnosed and treated26.  
 
Due to low morbidity and mortality compared with high-endemicity predominantly falciparum 
malaria settings, costs per event averted were relatively high, making cost-effectiveness results 
for IRS higher than in many endemic settings47, 303, 304. For example, average cost per case averted 
(US$88) was higher than findings by Smithuis et al (US$2013 16.54) or Kamolratanakul et al 
(US$2009 2.7) for IRS with DDT in Myanmar and the Thai-Myanmar border respectively, but 
lower than findings by Bhatia et al (US$2013 126.39) for IRS with deltamethrin in Gujarat26, 303. 
Given DDT was considerably cheaper than other IRS insecticides, this is perhaps unsurprising. 
Average cost per DALY averted (US$601) was considerably higher than findings by Yukich et al 
(US$2008 119-132) for IRS in Mozambique and KwaZulu-Natal47. The programme was more 
effectively compared with South Asian programmes, as malaria transmission patterns were 
similar. However, while Bhatia et al reported costs per case averted, no other South Asian 
studies were found reporting costs of cases or DALYs averted through IRS26, 39. It is possible that 
researchers in South Asia have tended to avoid calculating DALYs for malaria prevention 
interventions as relatively low incidence and proportionally high vivax transmission means fewer 
cases, lower mortality, and thus elevated costs per DALY averted. However, study results 
indicate that cost-effective results per DALY averted are still feasible in the region. Additionally, 
while it would have been useful to compare cost-effectiveness with interventions in epidemic 
situations, such evidence remains minimal as already noted by Worrell et al in 200453.  
 
As incidence continued to fall in the refugee settlements, the malaria control strategy evolved 
away from targeted IRS to insecticide-treated net (ITN) social marketing and then targeted free 
distribution of ITNs to communities at highest malaria risk115, 152. ITNs have generally been found 
to be more cost-effective than IRS, with a review by White et al finding the median ICER per 
DALY averted from a provider perspective was US$2009 27 for ITNs (range US$2009 8-110 from 
15 African studies) versus US$2009 143 for IRS (range US$2009 135-150 from two southern 
African studies)303. It is possible that the incremental cost of adding prevention using ITNs would 
be lower than for IRS. However, this cannot be assumed as IRS is generally more effective for 
transmission control in South Asia than it is in Africa and should be compared in the same 
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setting281. The policy of CQ treatment for P. vivax infection has not changed in Pakistan and vivax 
remains the predominant malaria species223.  
 
Implications   
Despite malaria incidence being relatively lower than in sub-Saharan Africa and vivax 
predominating, ICER results showed that adding malaria prevention with targeted IRS to routine 
case management was cost-effective using both WHO’s aspirational and potentially overly-
generous threshold of three times GDP and Woods et al’s more conservative range for Pakistan 
of US$87-669296, 299. Results can potentially provide lessons outside South Asia as malaria control 
progresses toward elimination. Considerations additional to cost will become increasingly 
important as countries transition to elimination and costs per event averted likely increase270, 
271, 305. Additionally, in mixed Plasmodium species settings, P. falciparum is more easily reduced 
by vector control, leaving P. vivax as the majority species85. Therefore, cost-effectiveness 
analyses of malaria control interventions in low-endemicity, unstable, and epidemic settings 
could become increasingly important.  
 
Sensitivity analyses indicated that the key assumptions for the ICER for cases prevented were 
population size, cases prevented by vector control, and cases prevented by case management, 
while those for DALYs averted were the discount rate, age weighting, and CFR. Changes in any 
of these assumptions could significantly change the ICER. This appeared to be a greater issue for 
ICER for cases prevented than for DALYs averted, as two of the three latter assumptions 
depended on societal values (e.g. perceived value of future versus present day, perceived value 
of the young). However, assumptions related to population size, cases prevented, and CFR relied 
primarily on data accuracy and would therefore require more attention from decision-makers 
when choosing interventions.  
 
Methodologically, accurate cost-effectiveness analysis for P. falciparum depends primarily on 
the accuracy of CFR calculations. The CFR estimate used was taken from a camp survey and BHS 
data282. Because no formal system for death notification existed for refugees, who had no 
incentive to report deaths, reported causes of death were not confirmed and CFR estimates 
were subject to unverifiable assumptions. Estimates for vivax and falciparum cases prevented 
were more reliable than deaths prevented because they were based on quality-assured 
microscopy of actual cases and on differences in clinical incidence between matched sprayed 
and unsprayed camps during the study period85, 150. Vivax malaria was three times more common 
than falciparum malaria and CFR was zero for vivax. Thus, cost-effectiveness analysis for vivax 
made fewer assumptions than for falciparum and can be assumed to be more accurate. 
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However, given this is an assumption it was still worthwhile to report falciparum and mixed 
infection results.   
 
Programmatically, changes to organisational structure could increase sustainability. Cost 
distributions for both case management and vector control indicated personnel as the major 
cost component. As HNTPO provided technical support in maintaining low malaria endemicity 
levels, its average costs increased as incidence fell. Thus, staff rationalisation appeared feasible 
over the long term by strengthening managerial skills and widening the responsibilities of local 
personnel and broadening the skill base of technical personnel (e.g. training malaria specific 
diagnosticians and health-workers to take a wider role in public health programmes, such as 
diagnosis and treatment of other diseases). Excepting insecticide and antimalarials, remaining 
cost components were minimal and their reduction would have minimal impact on total costs.  
 
Limitations 
Calculations were subject to several dataset limitations and assumptions. First, calculation of 
effectiveness indicators was subject to methodological assumptions. The use of matched 
unsprayed settlements was the best control group available retrospectively and the limited 
regional data did not allow for epidemic or other modelling to improve estimates further. Data 
testing indicated this comparison was valid. However, as data variability is an increasing concern 
as numbers decrease, cost-effectiveness results for Years 4-5 may be less accurate than those 
for Years 0-3. Second, use of private providers by refugees could have underestimated case 
numbers while vivax recrudescence could have caused overestimation of numbers yet 
underestimation of intervention effectiveness. Sensitivity analysis results demonstrated how 
increased or reduced estimates of cases prevented would affect cost-effectiveness estimates, 
improving or worsening them respectively. While programme managers would need to decide 
whether an ICER of US$79 was still worthwhile, it seems likely that this would be the case unless 
another prevention option such as ITNs could be shown to be more cost-effective. Third, low 
numbers of falciparum cases could have reduced accuracy of resulting service-user costs. 
Fourth, recall bias and reliance on settlement as a proxy indication of household wealth could 
have affected the accuracy of some cost data, though the proportions of estimated costs that 
relied on participant recall (e.g. household costs) were relatively minimal overall. Fifth, Woods 
et al’s cost-effectiveness threshold calculations used QALYs rather than DALYs and compared 
results directly with WHO thresholds, which seems justified for decision-making given the large 
margins of error likely in both approaches. Woods et al themselves call for further research on 
realistic cost-effectiveness thresholds for low and middle-income countries299. Finally, cost per 
death prevented was most sensitive to CFR, and respective indicators should be interpreted 
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cautiously. 
 
Conclusions 
While the cost-effectiveness of IRS varied depending on indicators used, the fact remains that 
many cases and deaths were prevented and the prolonged epidemic was controlled over the 
study period. Though case management remains a key component of malaria control, this study 
shows how prevention using IRS can be an important and cost-effective component of malaria 
transmission control even in a moderate endemicity, low mortality setting.  
 
Howard N: Malaria control for Afghans (1990-2005) 67 Chapter 4 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 CLINICAL TRIAL OF EXTENDED-DOSE CHLOROQUINE FOR RESISTANT FALCIPARUM MALARIA 
AMONG AFGHAN REFUGEES IN PAKISTAN (1995) 
 
 
 
 
Published as: 
Howard N, Durrani N, Sanda S, Beshir K, Hallett R, Rowland M (2011): Clinical trial of 
extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan 
refugees in Pakistan. Malar J;10:171. doi: 10.1186/1475-2875-10-171.   
 
Author contributions: 
NH registered the study, analysed and interpreted data, and wrote the manuscript. 
 
 
  
Howard N: Malaria control for Afghans (1990-2005) 68 Chapter 4 
 
Abstract  
Background 
Falciparum malaria is a significant problem for Afghan refugees in Pakistan. At the time of this 
study, refugee treatment guidelines recommended standard three-day chloroquine treatment 
(25mg/kg) for first episodes and extended five-day treatment (40mg/kg) for recrudescent 
infections, based on the assumption that a five-day course would more likely achieve a cure. An 
in-vivo randomized controlled trial was conducted among refugees with uncomplicated 
falciparum malaria to determine whether five-day treatment (CQ40) was more effective than 
standard treatment (CQ25). 
 
Methods 
142 falciparum patients were recruited into CQ25 or CQ40 treatment arms and followed up to 
60 days with regular blood smears. The primary outcome was parasitological cure without 
recrudescence. Treatment failures were retreated with CQ40. PCR genotyping of 270 samples, 
from the same and nearby sites, was used to support interpretation of outcomes.  
 
Results 
84% of CQ25 versus 51% of CQ40 patients experienced parasite recrudescence during follow-up 
(adjusted odds ratio 0.17, 95%CI 0.08-0.38). Cure rates were significantly improved with CQ40, 
particularly among adults. Fever clearance time, parasite clearance time, and proportions 
gametocytaemic post-treatment were similar between treatment groups. Second-line CQ40 
treatment resulted in higher failure rates than first-line CQ40 treatment. CQ-resistance marker 
pfcrt 76T was found in all isolates analysed, while pfmdr1 86Y and 184Y were found in 18% and 
37% of isolates respectively. 
 
Conclusions 
CQ was not suitable for first-line falciparum treatment in Afghan refugee communities. The 
extended-dose CQ regimen could overcome 39% of resistant infections that would recrudesce 
under the standard regimen, but the high failure rate after directly observed treatment 
demonstrated that its use was inappropriate. 
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Background 
During the extended Afghan conflict, waves of refugees totalling almost three million entered 
northwest Pakistan with more than one million remaining in 2017, despite efforts by the 
government of Pakistan to repatriate them157, 275, 276. Malaria became a major problem in Afghan 
refugee camps, due to overstretched health infrastructure and some camps being located on 
marginal land prone to anopheline mosquito breeding275. By the 1990s, malaria among refugees 
increased ten-fold to over 100,000 cases per annum275. Approximately 30% of confirmed cases 
were due to P. falciparum and the remainder to P. vivax306. CQ was Pakistan’s first-line treatment 
for uncomplicated falciparum malaria from 1950 to 2007306. It remains first-line treatment for 
vivax malaria, so is still used for treating unconfirmed malaria and falciparum infections 
undetected by microscopy or misdiagnosed as vivax93, 307.  
 
UNHCR, following national guidelines, adopted a three-day CQ treatment course (total 25mg/kg 
as 10mg/kg on Day 0 and Day 1 and 5mg/kg on Day 2) in refugee settlements. However, it 
became apparent during the 1990s that CQ was failing243, 308. BHU doctors claimed that many 
refugees stopped taking CQ tablets once clinical symptoms reduced or only took them 
intermittently. Health policy-makers assumed that refugee patients were more likely to take 
sufficient CQ to cure infections if given a five-day course. Consequently, MoH Pakistan adopted 
as policy a five-day extended CQ course (CQ 40mg/kg as 10mg/kg/day on Days 0-2 and 5 
mg/kg/day on Days 3-4) for any refugee patient returning to a BHU with parasitaemia within a 
few weeks of their first episode. When this policy was introduced, no in vivo resistance survey 
had been undertaken in refugee camps, despite CQ-resistant falciparum parasites spreading 
widely in Pakistan in the 1990s243, 308, 309.  
 
As there was no evidence to support claims of poor adherence or the efficacy of extended-dose 
CQ, an open-label randomized clinical trial was conducted to determine whether supervised CQ 
treatment administered at 40mg/kg over five days (CQ40) was more effective than 25mg/kg 
over three days (CQ25) for curing infections completely without recrudescence310. The trial aim 
was to provide stronger evidence for the extended-dose CQ (ECQ) treatment or justification for 
discontinuing the policy. 
 
Methods 
Study design 
The primary trial outcome was the proportion of individuals in each treatment arm that showed 
clinical and parasitological cure with no recrudescence. Sample size was calculated to detect a 
difference of 15% in cure rate between CQ25 and CQ40 treatment arms with 95% confidence 
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and 90% precision, assuming a 20% loss to follow-up. The surveys were conducted during winter 
months to select only recrudescent episodes. Mosquito densities and malaria transmission drop 
during December and January, providing little opportunity for trial participants to receive further 
infective bites within the 60-day follow-up period 85, 311. Thus, subsequent falciparum episodes 
were regarded as recrudescence.  
 
Two trials, completed in 1998, were conducted in Baghicha, Kagan and Adizai refugee camps 
(Figure 7). In Baghicha and Kagan, 121 patients were recruited into two treatment groups and 
followed for 60 days. The 60-day duration was deliberate to allow sufficient time for back-to-
back 30-day in vivo studies (i.e. sufficient time for cases to recrudesce following initial CQ 
treatment and recrudesce again following second-line CQ treatment). In Adizai camp, 21 
patients were recruited per treatment group and followed for only 28 days. CQ25 patients 
received standard three-day treatment (CQ 25mg/kg as 10mg/kg on Day 0 and 1, and 5mg/kg 
on Day 2). CQ40 patients received extended 5-day treatment (CQ 40mg/kg as 10mg/kg/day on 
Days 0-2 and 5 mg/kg/day on Days 3-4). Dosages were measured in ¼ CQ tablets of 37.5mg each 
to give an average dosage (range) of 26.2 (25.0, 27.8) mg/kg for the CQ25 arm and 42.1 (40.0, 
45.3) mg/kg for the CQ40 arm. All treatment was directly observed for 30 minutes post-
treatment.  
 
If parasites reappeared during the follow-up period, patients received CQ40 second-line rescue 
treatment as per MoH and UNHCR guidelines. However, while investigators were required to 
follow national guidelines for second-line treatment it was anticipated that many would fail312. 
Thus, if parasites reappeared a further time, patients received single-dose sulphadoxine-
pyrimethamine (S: 25mg/kg, P: 1.25mg/kg) or mefloquine (25mg base/kg) treatment, which was 
known to be more effective. CQ was manufactured by Aventis and supplied by the WHO-Special 
Programme for Research and Training in Tropical Diseases (TDR). SP and mefloquine tablets 
were manufactured by Roche. Samples of P. falciparum for genotyping analysis were taken at 
baseline from a clinical trial of CQ and SP conducted by the authors in Adizai camp and Jalalabad 
eastern Afghanistan in 2002 and 2003 (Rowland unpublished). 
 
Patient recruitment and follow-up 
Participants were recruited through passive case detection at BHUs and active case detection in 
communities. Individuals with symptomatic falciparum malaria who met WHO in vivo selection 
criteria for low to moderate transmission settings were randomized to either CQ25 or CQ40 
groups using randomized lists 313. Exclusion criteria were infants under six months, pregnant 
women, vivax malaria co-infections, cases with other febrile illness, parasitaemia outside the 
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range of 1,000-100,000 asexual parasites/µl, or severe malaria. All patients gave informed 
consent. Ethical approval was provided by both UNHCR Health Committee and the LSHTM Ethics 
Committee. The trial was registered at the Clinical Trials website, reference number 
NCT01019408314.  
 
Local health supervisors collected demographic and clinical information at enrolment, including 
weight, temperature, and symptoms. Supervisors directly observed treatment according to 
dosing schedules, prepared blood smears, and recorded temperature and clinical symptoms 
daily for the first five days, then every third day until day 28. Patients in Kagan and Baghicha 
were additionally observed every four days until day 60.  
 
Thick and thin blood smears were stained with 3.5% Giemsa solution and all slides read on day 
of collection by a BHU-based microscopist. Trophozoites and gametocytes were counted against 
200 white blood cells (WBC) from thick blood smears, assuming a WBC count of 8,000/µl. A 
smear was declared negative if no parasites were seen after examining 100 fields. Slides were 
re-examined for accuracy of diagnosis and recounted by an independent senior microscopist, 
blinded to patient, follow-up day, original result, and outcome. Differences in count were on 
average no greater than 5%. Finger-prick blood samples (~200 μL) were dried on Whatman filter 
paper prior to treatment (Day 0) and sent to LSHTM for genetic analysis. 
 
Trial outcomes were treatment failure rates, fever clearance times (FCT), parasite clearance 
times (PCT), and number of recrudescences. Therapeutic responses were early treatment failure 
(ETF), late treatment failure (LTF) and adequate clinical and parasitological response (ACPR) 
using standard WHO in vivo criteria313. Parasitological responses were classified using the WHO 
S-RIII scale for comparison with earlier literature from low transmission settings313, 315. Trial staff 
were trained to ask about and record adverse and severe adverse events. However, adverse 
event data were not available at the time of analysis.   
 
Statistical analysis 
Data were double-entered in Microsoft®Excel, with range and consistency checks to reduce 
transposition error, and analysed using Stata®11.0. Analysis was conducted on an intention-to-
treat basis. Data from the three study sites were combined for the first 28 days to calculate 
therapeutic outcomes and analyse subsequent malaria episodes and Kaplan-Meier survival 
estimates313. Data recorded over 60 days from Baghicha and Kaghan were used to estimate 
second-line therapeutic outcomes. A p-value of <0.05 was considered significant. Univariate 
analysis used Pearson’s chi-square (2) tests for proportions and Mann-Whitney U tests for 
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continuous data. Logistic regression was used to calculate odds ratios (OR) of treatment success 
at weekly intervals and differences between treatment outcomes. A priori confounders (i.e. 
camp, gender, weight, age) were adjusted for in multivariate analysis. 
 
Genetic characterisation 
PCR genotyping could not be conducted on patient data to determine recrudescences as 
samples were lost in transit. However, the authors were able to analyse 90 blood samples from 
falciparum cases in Adizai (the same camp) and 180 from Jalalabad, Afghanistan, collected 
shortly afterwards for a clinical trial to characterize resistance genotypes (Rowland 
unpublished). Parasite DNA was extracted from 270 blood spots collected on filter paper pre-
treatment (Day 0)316. PCR-sequence specific oligonucleotide probe assays were used to analyse 
genetic polymorphism of P. falciparum chloroquine-resistance transporter gene (pfcrt) at 
codons 72-76 and P. falciparum multidrug resistance protein-1 (pfmdr1) at codons 86 and 184317. 
CQ resistance is associated primarily with point mutations in pfcrt leading to a lysine to 
threonine change at codon 76 (K76T) while pfmdr1 N86Y and Y184F were thought to have a 
modulatory effect318-320. The pfcrt 76T and pfmdr1 86Y alleles may serve as predictive markers 
for CQ resistance in non-immune individuals living in low-transmission areas, while combined 
pfcrt 76T and pfmdr1 86Y may be useful molecular markers for resistance to additional drugs, 
such as amodiaquine (AQ)320-324. 
 
Figure 7. Trial profile 
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Results  
Enrolment characteristics 
Figure 7 shows the trial profile. Of 163 patients recruited, 83 were randomized to CQ25 and 80 
to CQ40 treatment groups. Table 7 shows no significant differences in enrolment characteristics 
between treatment groups on Day 0.  
 
Table 7. Enrolment characteristics on Day 0, by treatment group 
Demographic characteristics CQ 25 mg/kg CQ 40 mg/kg 
Number enrolled 83 80 
Camp    
 Adizai 21 21 
 Baghicha 44 47 
 Kaghan 18 12 
Mean age in years (SD) 12.9 (11.3) 12.9 (11.3) 
Age group   
 0-5 19 18 
 6-14 44 44 
 15+ 20 18 
Total female  40 48 
Mean weight in kg (SD) 30.1 (16.1) 32.2 (18.5) 
   
Clinical characteristics CQ 25 mg/kg CQ 40 mg/kg 
Number (%) with temperature >37.5oC 37 (45) 42 (53) 
Trophozoite density* (range) 5702 (4297-7566) 6320 (4816-8295) 
Number (%) with gametocytes 38 (46) 28 (35) 
Gametocyte density* (range) 140 (82-238) 148 (84-260) 
   
NB: *refers to geometric mean. SD is standard deviation.  
 
First-line therapeutic outcomes 
No participants were lost to follow up by day 28. Table 8 shows therapeutic and parasitological 
outcomes using: (i) the WHO in vivo system of early and late treatment failure or adequate 
clinical and parasitological response, and (ii) the parasitological response system of S, RI, RII, RIII 
313, 325. Fever clearance and parasite clearance times were similar in CQ25 and CQ40 arms (Table 
8). CQ25 provided adequate clinical and parasitological response in only 13/83 (16%) of patients 
by day 28, while CQ40 provided 40/80 (50%) ACPR (adjusted OR 0.17; 95%CI 0.08, 0.38). There 
were few (7%) early treatment failures in either treatment group.  
 
CQ40 patients had fewer recrudescences than did CQ25 patients during the first 28 days. Among 
CQ40 patients, only one recrudescent episode occurred before Day 7. Among CQ25 patients, 
86% of recrudescence occurred between days 7 and 28 post-treatment. The parasitological 
failure rate was negatively associated with age, with failure highest among under-fives and 
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lowest among over-fifteens (Table 8). Within each age band, failure rates were consistently 
lower in the CQ40 group than in the CQ25 group, irrespective of gender or camp.   
 
Table 8. Outcomes on day 28 by treatment group, odds ratios adjusted for age, weight, gender, 
and camp using logistic regression 
Outcomes  CQ 25 mg/kg CQ 40 mg/kg OR1 (95%CI) 
Total enrolled 83 80  
Total lost, excluded, or withdrawn 0 0  
Mean days to fever clearance2 (95% CI)  2.6 (1.9, 3.3) 2.6 (1.9, 3.3)  
Mean days to parasite clearance (95% CI) 2.9 (2.6, 3.1) 3.1 (2.8, 3.3)  
    
Treatment outcomes: n=163 (%)    
Adequate clinical and parasitological response 13 (16) 40 (50) 1 
Early treatment failure  6 (7) 6 (7) 0.28 (0.07, 1.09) 
Late treatment failure***  64 (77) 34 (43) 0.16 (0.07, 0.35) 
    
Parasitological outcomes: n=163 (%)    
S 13 (16) 39 (49)  
RI 60 (72) 40 (50)  
RII 10 (12) 1 (1)  
    
First-line treatment success: n=52 (%)    
Complete parasitological cure without 
recrudescence*** 
13 (16) 39 (49) 0.17 (0.08, 0.38) 
    
First-line treatment failures: n=111 (%)     
Age group    
      0-5 17 (89) 11 (61) 0.18 (0.03, 1.05) 
      6-14** 38 (86) 24 (55) 0.17 (0.06, 0.50) 
      15+* 15 (75) 6 (33) 0.17 (0.04, 0.70) 
Gender    
      Male** 35 (81) 15 (47) 0.17 (0.06, 0.51) 
      Female** 35 (88) 26 (54) 0.19 (0.07, 0.56) 
Camp    
      Adizai 17 (81) 11 (52) 0.26 (0.06, 1.12) 
      Baghicha** 37 (84) 24 (51) 0.16 (0.06, 0.46) 
      Kagan 16 (89) 6 (50) 0.23 (0.03, 1.63) 
NB: 1OR is odds ratio, comparing CQ40 to CQ25 adjusted for age, weight, gender, and refugee camp using logistic 
regression. 2FCT (<37.5C) excludes those without fever on admission. *<0.05,**p<0.01,***p<0.001 
 
Figure 8 shows the proportion of patients found positive during the first seven days of treatment 
and the probability of failure among those still positive on subsequent days. The longer a patient 
took to clear parasites the greater the probability of eventual recrudescence. All cases treated 
with CQ25 who were still positive on Day 3 ultimately recrudesced, while all cases treated with 
CQ40 still positive on Day 4 ultimately recrudesced.  
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Figure 8. Parasite clearance rates and probability of treatment failure among cases still 
positive on daily intervals after treatment start 
 
 
Figure 9 shows cumulative incidence of failure during each week of follow up.  
 
Figure 9. Cumulative incidence of treatment failure for each treatment group 
 
 
Table 9 shows that adjusted odds of treatment failure remained consistent between CQ40 and 
CQ25 groups at each 7-day interval. After Day 30 there was no further recrudescence in either 
group (Figure 9).  
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Table 9. Odds ratios of treatment success at weekly intervals post-treatment, comparing CQ 
40 mg/kg with CQ 25 mg/kg, adjusted for age, weight, gender, and camp using logistic 
regression 
Days after treatment start Odds ratio (95% CI) p-value 
7 0.20 (0.05, 0.73) 0.02 
14 0.18 (0.08, 0.40) <0.0001 
21 0.15 (0.07, 0.31) <0.0001 
28 0.18 (0.09-0.38) <0.0001 
35 0.18 (0.08, 0.39) <0.0001 
NB: OR compares CQ40 to CQ25, adjusted for age, weight, refugee camp, and gender using logistic regression.  
 
Figure 10 shows the proportion of cases gametocytaemic and average gametocyte densities at 
weekly intervals. There were no significant differences in the proportion gametocytaemic or 
geometric mean gametocyte densities between the two treatment groups at any stage after 
treatment.  
 
Figure 10. Percentage of cases gametocytaemic and geometric mean gametocyte density 
(95%CI) at weekly intervals post-treatment 
 
 
Second and third-line therapeutic outcomes 
Table 10 provides therapeutic results for second-line treatment. CQ 40mg/kg administered as 
second-line was less effective than as first-line treatment, regardless of whether first-line 
treatment was CQ25 or CQ40. Second-line CQ40 cured a higher proportion in the former CQ40 
group than in the former CQ25 group, but this difference was not significant (adjusted OR 0.41; 
95%CI 0.14, 1.19; p=0.10). SP administered as third-line provided 88% (44/50) parasitological 
cure before the trial ended at 60 days.  
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Table 10. Parasitological outcomes among 81 treatment failures receiving second-line 
CQ40mg/kg categorized by initial treatment group 
Outcomes  CQ 25mg/kg CQ 40mg/kg Odds Ratio (95%CI) 
Total receiving CQ40 second-line treatment 52 29  
Lost , excluded 0 0  
    
Treatment outcomes: n=81 (%)    
Adequate response 9 (17) 10 (34) 1 
Early failure (0-3 days) 6 (12) 3 (10) 0.46 (0.09, 2.40) 
Late failure  (4-28 days) 37 (71) 16 (55) 0.41 (0.13, 1.20) 
    
Second-line treatment success: n=19 (%)    
Complete parasitological cure (0-28 days) 9 (17) 10 (34) 0.41 (0.14, 1.19) 
    
Second-line treatment failures: n=62 (%)    
Age group    
      0-5 14 (93) 5 (62) 0.12 (0.01, 1.50) 
      6-14 21 (84) 12 (75) 0.77 (0.14, 4.21) 
      15+ 8 (67) 2 (33) 0.27 (0.03, 2.45) 
Gender    
      Male 18 (82) 8 (67) 0.44 (0.09, 2.24) 
      Female 25 (83) 11 (64) 0.37 (0.09, 1.46) 
Camp    
      Baghicha 29 (78) 15 (65) 0.52 (0.16, 1.66) 
      Kagan 14 (93) 4 (67) 0.14 (0.01 2.05) 
    
NB: Odds ratios adjusted for age, weight, gender, and camp using logistic regression and 29 first-line failures from 
Adizai excluded from analysis as these were treated with SP. 
 
PCR analysis of genetic markers 
Table 11 shows the frequency of pfcrt and pfmdr1 point mutations among isolates from Adizai 
and Jalalabad. The CQ resistance-associated pfcrt codon 72-76 haplotype SVMNT (Ser-Val-Met-
Asn-Thr) was present in 100% of samples successfully analysed from Adizai (63) and Jalabad 
(179). Pfmdr1 86Y was found in 14% (12/88) of Adizai and 22% (33/151) of Jalalabad samples. 
The pfmdr1 184Y allele was found in 27% (22/82) of Adizai samples and 46% (69/151) of 
Jalalabad samples. 
 
Table 11. PCR results for refugee isolates collected at baseline in Adizai and Jalalabad sites 
Gene  Allele Adizai isolates Jalalabad isolates 
  n= 90 (%) n=180 (%) 
Pfcrt 76 K 0 (0) 0 (0) 
  76 T 63/63 (100) 179/179 (100) 
      
Pfmdr1  86 N 76/88 (86.4) 118/151 (78.1) 
 86 Y 12/88 (13.6) 33/151 (21.9) 
      
 184 Y 22/82 (26.8) 69/151 (45.7) 
 184 F 60/82 (73.2)   
NB: Denominators are all readable isolates. The Jalalabad isolates of 184F could not be read. 
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Discussion 
CQ failure rates were higher than anticipated, and since administration was directly observed, 
failure was due to resistance rather than poor adherence. Analysis showed that with 51% failure 
in CQ40 and 84% failure in CQ25, CQ was no longer suitable for falciparum malaria treatment 
among Afghan refugees, either as first or second-line with short or extended regimens, and 
usage needed to stop. Second-line CQ40 achieved a higher failure rate than did first-line, 
demonstrating lack of suitability for this purpose as well312. Study investigators were expected, 
as part of UNHCR ethics approval, to follow national guidelines for second-line treatment as it 
was not the intervention. However, this trial demonstrated the ethical inadequacy of using a 
failing treatment drug for both intervention and second-line treatment for one of the trial arms. 
Fortunately, resistance was expected, so suitable third-line drugs were available and 
demonstrated resistance could then be used to advocate for policy change223. Clinical trials must 
adhere to clear ethical standards, including Good Clinical Practice (ICH-GCP) international ethical 
and scientific standard guidelines, the Helsinki Declaration, and International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (e.g. about involving potentially vulnerable 
subjects, including those under-age and low-income refugees)326-328. These have progressed 
significantly since this trial was implemented, and it is less likely that usage of the same first-line 
and second-line treatment would now be approved by an ethics committee, as patient need and 
welfare would need to be demonstrated.  
 
While the authors were unable to make use of PCR genotyping to distinguish recrudescent from 
new infections, other in vivo trials conducted in the area that did include genotyping indicated 
fewer than 5% would be new infections329. The most compelling evidence for subsequent 
infections being therapeutic failures is the very high failure rates by Day 28 and apparent 
absence of any new parasitaemias over 60 days of follow up.  
 
The finding of the pfcrt 76T mutation in 100% of isolates analysed was consistent with a low 
degree of heterogeneity in the parasite population, as also shown by Khatoon et al in isolates 
from nearby Bannu district318. The pfcrt 76T allele has been strongly associated with CQ and 
amodiaquine (AQ) resistance in falciparum isolates from Asia, Papua New Guinea, Africa, and 
South America311, 318, 330, 331. Pfmdr1 86Y and 184Y alleles, which were also associated with CQ 
and AQ resistance, were present in only a minority of isolates from Adizai camp or from Bannu 
district318. In a clinical trial of AQ in nearby Afghanistan, which also resulted in high rates of 
recrudescence, pfmdr1 alleles were not strongly selected among treatment failures161. These 
findings indicated that the pfcrt codon 72-76 haplotype SVMNT present in Pakistan was 
sufficient by itself (i.e. without pfmdr1 86Y and 184Y) to cause high-level CQ and AQ 
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resistance161, 311, 330. By contrast, in Africa where the CQ-resistant variant pfcrt codon 72-76 CVIET 
appeared to be the predominant haplotype, AQ remained relatively effective311. In a clinical trial 
in East Africa in which AQ did demonstrate high levels of in vivo resistance, the CQ-resistant 
variant CVIET haplotype was present with pfmdr1 86Y and 184Y alleles, which presumably added 
to the resistance there311, 324, 332-335.  
 
The rate of parasitological failure was higher after second-line than after first-line CQ40 
treatment. Recrudescent infections presumably started with higher proportions of resistant 
parasites than did initial infections. However, this could not explain why the initial CQ40 course 
seemed to eliminate around 39% of resistant infections, as indicated by the improved cure rates 
over 60 days following initial five-day (51% recrudescence) as compared to three-day treatment 
(84% recrudescence). Among this 39%, any resistant parasites must have been removed by the 
additional two days of treatment and did not reappear over the subsequent 60 days. Ursing et 
al had, in parallel, undertaken clinical studies with high-dose CQ in Guinea-Bissau336, 337. They 
found that high-dose CQ (75mg/kg as split-dose over five days) was well-tolerated (as was the 
40mg/kg administered in this trial) and 78% of infections carrying pfcrt 76T were successfully 
treated compared to only 34% with 25mg/kg336. This was a higher treatment success rate than 
in Pakistan.  
 
While pfcrt 76T was highly prevalent in the Pakistan samples, pfcrt 76T prevalence in the Guinea-
Bissau population, discussed above, remained stable at a much lower 25% between 1990 and 
2005336, 338. These contrasts in pfcrt 76T between continents were likely due to differences in the 
fitness of resistance alleles, as the pfcrt 72-76 SVMNT resistance haplotype dominant in India, 
Iran, Pakistan and Afghanistan was not associated with re-emergence of CQ sensitivity or 
fluctuations in seasonal prevalence shown by the CVIET haplotype in some parts of Africa332, 336, 
337, 339-341. Drug pressure may also have affected stability. If most infections were treated with a 
quinoline, pfcrt 76T frequency would remain high. In the African settings, sensitive parasites may 
have found a niche in the many untreated infections, where their greater fitness would allow 
them to compete better than any co-infecting resistant parasites. It was more difficult for CVIET-
carrying parasites to gain the same high prevalence in Africa as SVMNT-carrying parasites have 
achieved in parts of Asia.  
 
This trial did not measure adherence, as it was designed to assess efficacy rather than 
effectiveness. Consequently, it could not challenge the initial assumption that refugees failed to 
adhere to either three-day or five-day courses. However, later research demonstrated that with 
appropriate instructions - as in a trial of unsupervised 14-day primaquine treatment - Afghan 
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refugees did adhere to much longer treatment regimens than the five-day course described 
here161, 342. What was clear from directly-observed treatment was that neither CQ25 nor CQ40 
regimens could continue to be justified, as neither could provide acceptable cure rates given the 
high prevalence of CQ-resistant falciparum malaria in Pakistan93, 243, 308.  
 
In Afghanistan, where many refugees have returned, numerous malaria cases are still treated 
with CQ, without parasitological diagnosis by either microscopy or RDT92, 343, 344. This makes this 
study, though conducted more than fifteen years ago, still highly relevant. About 80-95% of 
cases in Afghanistan are due to vivax and will respond to CQ273. However, most of the falciparum 
cases treated with CQ - whether for three days or longer - are likely to fail91, 92, 342. While the total 
number of falciparum cases will be small, without effective treatment these risk developing into 
severe malaria. As up to one-fifth of suspected malaria cases arrive at government clinics with 
detectable CQ present in their urine, irregular or intermittent treatment with CQ might be 
common91, 344, 345. The need for routine parasitological diagnosis by microscopy or RDT to allow 
differential and, most importantly, effective treatment for both falciparum and vivax malaria 
remains paramount in Pakistan and Afghanistan.  
 
Although combination therapy using artesunate-SP was adopted as policy for treatment of 
confirmed falciparum malaria in both Pakistan and Afghanistan, implementation remains 
patchy273, 329, 344, 346. While follow-up and numbers of SP patients were too few in this trial to 
determine significance, the 12% SP failure rate raised questions about SP’s long-term efficacy. 
While SP has a role as combination partner in Pakistan and Afghanistan, if administered without 
artesunate, resistance to SP may select rapidly94, 347.  
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Abstract  
Background 
Scaling up ITN coverage is a key malaria control strategy even in conflict-affected countries. 
Socioeconomic factors influence access to ITNs whether subsidized or provided free to users. 
This study examines reported ITN purchasing, coverage, and usage in eastern Afghanistan and 
explores women’s access to health information during the Taliban regime (1996-2001). This 
strengthens the knowledge base on household-level health choices in complex-emergency 
settings. 
 
Methods  
Fifteen focus group discussions (FGDs) and thirty in-depth interviews (IDIs) were conducted with 
men and women from ITN-owning and non-owning households. FGDs included rank ordering, 
pile sorting and focused discussion of malaria knowledge and ITN purchasing. Interviews 
explored general health issues, prevention and treatment practices, and women’s malaria 
knowledge and concerns. Seven key informant interviews with health-related workers and a 
concurrent survey of 200 ITN-owning and 214 non-owning households were used to clarify or 
quantify findings. 
 
Results  
Malaria knowledge was similar among men and women and ITN owners and non-owners. 
Women reported obtaining health information through a variety of sources including clinic staff, 
their husbands who had easier access to information, and particularly female peers. Most 
participants considered ITNs very desirable, though not usually household necessities. ITN 
owners reported more household assets than non-owners. Male ITN owners and non-owners 
ranked rugs and ITNs as most desired, while women ranked personal assets such as jewellery 
highest. While men were primarily responsible for household decision-making and purchasing, 
older women exerted considerable influence. Widow-led and landless households reported 
most difficulties purchasing ITNs. Most participants wanted to buy ITNs only if they could cover 
all household members. When not possible, preferential usage was given to women and 
children.  
 
Conclusions  
Despite restricted access to health facilities and formal education, Afghan women were 
surprisingly knowledgeable about the causes of malaria and the value of ITNs in prevention. 
Inequities in ITN usage were noted between rather than within households, with some unable 
to afford even one ITN and others not wanting ITNs unless all household members could be 
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protected. Malaria knowledge thus appears a lesser barrier to ITN purchasing and coverage in 
eastern Afghanistan than are pricing and distribution strategies. 
 
Background 
Scaling up coverage of ITNs has become a global malaria-control strategy10, 13, 30. Many countries, 
striving to reach malaria-related SDG and RBM targets, rely on ITN implementation51, 268, 348, 349. 
However, socioeconomic factors can heavily influence success, even with free ITN or LLIN 
distribution350-353. ITN purchasing can depend on cost and availability, perceived value and 
safety, ideas of disease causation, risk conceptions, and peer acceptance115, 353-355. Regular usage 
can depend on amount of insect nuisance biting, perceived malaria danger, sleeping patterns, 
comfort, and convenience considerations38, 352, 355, 356. This study examines aspects of reported 
ITN purchasing, coverage and usage in eastern Afghanistan during Taliban control. By 
disaggregating women’s malaria knowledge and reported behaviour from that of men, it builds 
on limited knowledge of household-level health choices in socially conservative complex-
emergency settings186, 350-352, 357-360.  
 
Before Afghanistan’s extended conflict, malaria was almost eliminated as a public health issue 
through vertical governmental IRS and CQ treatment 52, 152, 246. As control infrastructure 
deteriorated malaria rates increased, peaking during the mid-1990s 152, 246. From 1992, eastern 
Afghanistan became stable enough to establish a network of NGO-supported clinics, standardize 
training and monitoring of microscopists and clinical staff, and distribute ITNs and insecticide 
retreatment. Malaria control was coordinated by technical agency HNTPO152. During the 
mujahedeen and Taliban eras (1992-96 and 1996-2001), HNTPO developed a package of 
interventions shown through operational research to be effective, popular and not requiring 
significant government input52, 151, 153, 188, 246, 251, 361. Government infrastructure and support 
remained minimal 248.  
 
HNTPO coordinated wide promotion and subsidized sales of ITNs in eastern Afghanistan and 
refugee communities in Pakistan since 1992 152. Endemicity was seasonal and health 
infrastructure weak, making household-level interventions more practicable and cheaper for 
implementing agencies246. Using several distribution strategies, HNTPO disseminated sufficient 
family-size ITNs to cover approximately one million Afghans by the time the Taliban first gained 
power. ITNs were available both in BHCs and through mobile teams. Strategies included mobile 
teams of ITN salesmen, health educators and logisticians for remote areas, community-based 
ITN implementers, and BHC-based health education, sales and insecticide treatment provided 
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by trained BHC staff. By 2000, HNTPO was attempting cost recovery to create a revolving fund 
that could extend the limited resources then available for malaria control51, 152, 362, 363.  
 
Investigators were not convinced that coverage achieved by these strategies could provide 
sufficient community-wide protection, and wanted to find ways to increase ITN purchasing. As 
part of this, social research was undertaken in 2000 among men and women from ITN-owning 
and non-owning households in Nangarhar Province, Eastern Afghanistan. A concurrent 
socioeconomic analysis showed that the wealthiest 25% of households surveyed were 4.5 times 
more likely to own ITNs than the poorest 25%115. Objectives of qualitative data collection were 
to deepen understanding of factors affecting ITN purchasing, coverage, and usage patterns in 
the area.  
 
Figure 11.  Nangarhar Province and districts, showing percentage ITN coverage 
 
 
Source: HNTPO, Jalalabad office 2000 
 
Methods 
Study design and target population 
A mixed-methods study design was chosen, incorporating FGDs, IDIs, and a quantitative 
household survey, which allowed for collection of measurable data and more in-depth personal 
data on socioeconomic and cultural contexts of reported behaviour. The target population was 
men and women in ITN-owning and non-owning households from an estimated population of 
500,000 in Nangarhar Province exposed to HNTPO’s ITN programme (Figure 11). The population 
around Jalalabad had been exposed to almost a decade of HNTPO health education and ITN 
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social-marketing, through static BHCs and mobile sales teams, and differences in geographical 
access were expected to be minimal. Study components were conducted during February-April 
2000, as the low transmission season was intended to help reduce overestimation of malaria 
risk and ITN usage. ‘Household’ was defined as a family group sharing a compound and cooking 
facilities. ‘ITN ownership’ was defined as having one or more ITNs. ‘ITN usage’ was defined as 
‘sleeping under an ITN,’ rather than the narrower ‘sleeping under an ITN the previous night’ 
sometimes used in the literature, as ITN usage reflected mosquito and malaria seasonality and 
research indicated owners actually used their ITNs52, 151. Interviews and household survey were 
conducted following initial analysis of FGDs. 
 
Sampling and recruitment 
FGD sampling and recruitment were purposive, with the main aim to determine the feasibility 
of conducting community-level social research in this setting. Three districts (i.e. Achin, 
Muhmand-Dara, Shinwar) were selected purposively for accessibility, security, and ITN 
ownership of less than 40%. FGD participants were recruited purposively, by either HNTPO or 
BHC staff, to provide a sufficient range of men and women from ITN-owning and non-owning 
households.  
 
Survey sampling was multi-stage. Survey sample size was calculated to detect a difference of 
10% versus 20% between strata of equal size with 80% power and 95% confidence interval. First, 
eight districts were purposefully selected to include those regularly targeted by ITN sales 
campaigns and those further from Jalalabad, the provincial capital, that had been targeted less 
frequently. Second, approximately twenty villages were randomly selected from those 
previously exposed to HNTPO’s ITN campaigns. Third, households in these villages were 
randomly selected using a directional numbering system in which the interviewers, on leaving 
the house of the village head, asked any child to choose a number between 1 and 4 and 
proceeded to the second house in the direction thus selected and conducted an interview if the 
household was eligible. To be eligible a household had to consist minimally of husband, wife and 
a child under 12 years of age. Interviewers were given a daily target of eight to 24 households 
depending on village size, and instructed to select approximately equal numbers of net-owning 
and non-owning households. Once half his daily target had been interviewed (e.g. if six ITN 
owner questionnaires had been filled), he continued the four directional selection method until 
the other half of the day’s target had been completed (e.g. six non-owners interviewed).  Thus, 
approximately even numbers of owners and non-owners where randomly selected and 
interviewed each day. This method was chosen because it was relatively simple, required no 
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equipment, allowed community participation, and no village census data or maps were 
available.  
 
Interviews were conducted concurrently with the household survey. Interview sampling was a 
mix of theoretical and convenience, as described by Green and Thorogood. Participants were 
recruited purposively, so as to interview two man and two woman from different ITN-owning 
and non-owning households (i.e. approximately four interviews) per district364, 365. Additional key 
informant interviews were completed with clinic staff, informal health providers, and ITN 
implementers on a convenience basis to clarify findings.  
 
Data collection  
FGDs were conducted during February, separately with men and women from ITN-owning and 
non-owning households. See Annex 1.1-1.2 for FGD topic guides. Each group was moderated in 
Pashtu or Dari by a trained local researcher of the same gender as participants and supervised 
by an experienced LSHTM-based qualitative researcher. FGDs took place in locations selected by 
participants and were tape-recorded, with participants’ verbal consent, for later transcription 
and translation. FGDs included formal pile-sorting and rank-ordering exercises and targeted 
discussion of malaria knowledge and perceptions, ITNs and retreatment, and gender and 
cultural attitudes.  
 
Interviews were conducted in March-April in Achin, Bati Kote, Bihsood, Lalpur, Muhmand-Dara, 
Nazyan, Shinwar, and Surkhrod districts, by an Afghan male and foreign female researcher using 
a sub-headed topic guide (Annex 2.1). Interviews investigated FGD topics plus perceptions of 
malaria’s relative importance, prevention and treatment practices, and women’s malaria-
related health information and access. All, except three with doctors in English, were interpreted 
directly between English and Pashtu or Dari. Researchers were constrained by the lack of an 
experienced female interpreter, but recruited a male researcher who appeared youthful enough 
to be considered culturally acceptable. Researchers chose not to tape interviews because 
several male family members refused consent for women to be recorded and researchers 
wanted to interview as many women as possible and remain methodologically consistent366, 367. 
To minimize data loss, both researchers took notes under simple topic codes in English or 
Dari/Pashtu. Notes and observations were discussed by researchers after each interview and 
written up each evening367. Interviews were conducted by the DrPH candidate and AS, the lead 
translator and an experienced local researcher.  Most lasted 35 minutes to an hour.   
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The household survey was conducted in March-April, with structured questionnaire interviews 
conducted in Pashtu or Dari by five trained male data-collectors. Five Pashto-speaking 
interviewers were hired in Jalalabad and trained for three days on survey techniques, malaria 
control issues, and health education. Continuous field monitoring and feedback sessions were 
conducted throughout the study. The questionnaire was developed from similar instruments 
and FGD results, and piloted in three villages not included in the study. The questionnaire 
included demographics, socioeconomics, health knowledge, malaria, mosquitoes, and ITNs 
(Annex 2.2). Household assets and socioeconomic indicators, identified in a preliminary survey 
and from published literature368-370, formed the basis for a structured questionnaire that was 
developed in English, translated into Pashtu, checked by two translators, and back-translated 
into English by a third to validate accuracy. The questionnaire was field tested over a 3-day 
period, and some questions changed or removed (e.g. “How many wives in the household?” was 
removed as sensitive and not culturally useful, while questions on direct monetary amounts such 
as “salary level”, were changed to a binary “is part of your income from salaries” format to 
encourage accurate reporting). Gold jewellery ownership, though a potential indicator, was 
removed due to sensitivity and inaccurate reporting. As houses were almost universally 
unscreened mud-brick, questions on housing materials were excluded.  Some categorical 
responses, such as “what causes malaria?” were partially precoded, while others, such as “job 
of household head” were coded at data entry.  
 
Analysis 
Data were transcribed and translated in Peshawar and analysed in London. Qualitative data 
were analysed descriptively and thematically. The full range of responses and views expressed 
by FGD and interview participants was assessed and shared responses grouped using thematic 
coding365. Survey data were analysed in Stata® and outcomes assessed for associations with ITN 
ownership using logistic regression. 
 
Ethics 
The LSHTM Research Ethics Committee provided ethics approval. Local ethics approval for 
operational research was not required, nor was any research ethics body available within the 
Taliban government, during the time of the study. Informed consent was obtained from all 
participants and data were anonymized. 
 
Results 
Fifteen FGDs were conducted in six villages: five with male ITN owners, one with female ITN-
owners, five with male non-owners, and four with female non-owners. Eighty-two men and 40 
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women participated. Rank-ordering and pile-sorting exercises were successfully completed in 
men’s but not women’s FGDs owing to moderator inexperience. Thus, pile-sorting and ranking 
analysis is restricted to data from men’s FGDs. 
 
Thirty IDIs were conducted in eight districts: eight with men and six with women from ITN-
owning households, and seven with men and eight with women from non-owning households. 
Most women chose to be interviewed with female relatives or friends present, due to the 
absence of a female interpreter. Seven key informant interviews, completed with health-related 
workers (i.e. three doctors, one laboratory technician, one traditional healer, and two ITN 
implementers), were analysed separately. 
 
Two-hundred ITN-owning and 214 non-owning households completed survey interviews. The 
response rate was 95%, with non-participation reported as due to ongoing poppy harvesting. All 
but five household heads were male, and only 48 (11.6%) respondents were female.  Most self-
identified as Pashtun, while 36% in Bihsood district were of Tajik ethnicity.  Half of households 
(58%) relied on agriculture. Main crops were wheat, opium poppy, corn, and cotton.  Most (83%) 
came to the area in 1993, when security improved in eastern Afghanistan.  
 
Table 12. Percentage reported malaria knowledge and practices, comparing ITN-owning to 
non-owning households 
 % ITN Non-owners 
(n=214) 
% ITN Owners 
(n=200) 
What causes malaria?   
   Mosquitoes 77 73 
   Water 18 20 
   Other/Don’t know 6 8 
Where do mosquitoes breed?   
   Water 58 69 
   Grass 23 20 
   Other/Don’t know 19 12 
Malaria season   
    Summer 46 40 
    Spring/Summer 33 39 
    Autumn 11 11 
    Other/All 10 10 
Who is at most risk from malaria?   
    Children 50 48 
    Women and children 25 19 
    Everyone 21 17 
    Pregnant women and under-fives* 1 10 
    Women 3 4 
    Aged 1 2 
What is the best malaria protection?*   
   ITNs 74 86 
   IRS 12 7 
   Other (e.g. electric fans) 7 5 
Howard N: Malaria control for Afghans (1990-2005) 89 Chapter 5 
   Traditional 3 1 
   Don’t know 4 1 
What current malaria protection do you use?*1   
   ITNs 4 95 
   Other (e.g. smoke, chadors) 92 1 
   Insecticide spray 4 3 
   Traditional 0 1 
Who in your household was seriously ill this year?   
   All 57 54 
   Children 35 32 
   None 4 8 
   Aged 3 3 
   Women 1 3 
What is the best treatment for malaria?*   
   Chloroquine 68 79 
   Don’t know 21 11 
   Traditional/Other 7 7 
   Paracetamol 4 3 
Who makes treatment-seeking decisions?   
   Household head 92 90 
   Other 8 10 
Where do you go for malaria treatment?   
   Get treatment at NGO clinic 42 48 
   Private doctor (unregulated) 35 24 
   Other/Combination 22 28 
   Private drug seller (unregulated) 2 1 
Average reported costs for malaria treatment2 (US$15) (US$15) 
   Adult visit 0.64 0.48 
   Adult drugs 9.02 6.58 
   Child visit 0.62 0.46 
   Child drugs 5.78 4.28 
Average costs per ITN2 (US$15) (US$15) 
ITN (insecticide added at point-of-purchase) 7.16 7.16 
ITN retreatment (annual) 0.08 0.08 
NB: Sample size is 414. Logistic regression *p-value<0.05 or 1p<0.001. 2Costs were not disaggregated by provider. 
Pakistani rupee 2000 prices have been converted to US dollar 2015 constant equivalents (US$15). 
 
Pile sorting and ranking exercises 
Information generated by pile sorting indicated differences in household asset ownership 
between participating ITN owners and non-owners. Non-owners generally reported fewer 
possessions than ITN owners. This was particularly noticeable for rugs (59% versus 27%), radios 
(54% versus 29%), jewellery (54% versus 29%) and pressure cookers (54% versus 29%). Some 
non-owners reported very few household possessions. For example, 16% reported no kettle and 
12% no lamps, whereas all ITN owners had these items. Approximately 15% of non-owners 
reported similar quantities of household assets as ITN owners (i.e. radio plus at least two - rug, 
pressure cooker, or jewellery).  This reinforced quantitative survey findings, that households 
with at least one ITN were likely to have more assets than those without  ITNs115.     
 
FGD participants were asked to rank household assets in the order in which they would most 
likely procure them if they had extra cash or goods for bartering. Rugs and ITNs ranked highest 
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among both ITN owners and non-owners. Items deemed essential, such as clothes and a lamp, 
ranked in the top three for non-owners. Bicycles and pressure cookers, reported as luxury items, 
were ranked in the top three by ITN owners.  In discussing ranking, non-owners explained that 
they ranked clothing highly because it was essential for wives to keep covered when going 
outside due to Taliban restrictions. They also revealed that rugs, topping the list for both groups, 
were seen as status items. Even men who already owned rugs said they would, as a first choice, 
purchase more. ITN ownership was also described as reflecting status, though data needs 
caution as FGD participants were aware that researchers were associated with HNTPO’s malaria 
control programme. However, both ITN owners and non-owners ranked IRS highly, suggesting 
that mosquitoes and other insects were problematic.  
 
Women were eager to participate in FGD discussions, but appeared so determined to talk that 
they generally did not complete formal exercises. Discussions clarified that women ranked 
clothing and jewellery, assets Afghan women own personally, as the two most important 
household assets.  
 
Knowledge and reported behaviour 
Interview, survey, and remaining FGD results are reported under key themes: malaria 
knowledge and perceptions; malaria prevention and treatment; ITN knowledge and 
perceptions; reported ITN purchasing; reported ITN coverage and usage; and health-related 
workers’ perceptions.  
 
Malaria knowledge and perceptions. There appeared to be little difference in knowledge of 
malaria transmission between genders or between ITN owners and non-owners.  Table 12 shows 
approximately 75% of survey respondents said mosquitoes caused malaria, though 19% said it 
was caused by water. Unsurprisingly, participants could not distinguish between vector and 
nuisance mosquitoes. 
“When mosquitoes bite healthy people they catch malaria.” (Female non-owner, Ghazgay, 
Muhmand-Dara) 
 
Approximately one-third of interviewees suggested mosquito bites were only one way of 
catching malaria with the main contributor reported as drinking dirty water. Most survey 
respondents (64%) knew that mosquitoes breed in water, but most participants did not know 
how mosquitoes transmit malaria, often describing faecal-oral routes (e.g. mosquitoes breed in 
dirty water and garbage, and this dirt infects people when they are bitten).   
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“Malaria is caused by mosquitoes who get parasites from dirty water” (Male ITN owner, 
Muhmand-Dara) 
 
Another belief reported in each district was that malaria, if it continues or increases in severity, 
becomes moriqa (typhoid).    
“Malaria comes from mosquitoes and dirty water.  Mosquitoes breed in dirty ponds, cow 
dung and refuse... malaria becomes typhoid if it is not cured” (Male non-owner, Bati Kote) 
 
 “The clinic doctors told us typhoid is from malaria.” (Female ITN owner, Ghani Khel, 
Shinwar) 
 
Participants reported that malaria was a serious illness. In interviews, researchers attempted to 
estimate its perceived importance by asking participants the three greatest health concerns in 
their community. The top three concerns reported were diarrhoea, ‘maternal problems,’ and 
tuberculosis.  
 
While not directly related to this research, it is interesting that as early as 2000, maternal ill 
health was reported as a major concern by both genders in all districts. It was described as a 
particular concern due to female travel restrictions, and lack of female health staff or culturally 
acceptable facilities. Several women mentioned the lack of confidential contraception as their 
main health concern.  
“It’s not appropriate for our women to give birth publicly in the clinic.  Many women have 
serious problems during childbirth... We can’t afford when the lady doctor comes to the 
house and anyway she usually doesn’t because she can’t come alone.  There is no one 
around who knows how to birth the baby properly and so many die.” (Male non-owner, 
Bati Kote) 
 
Health messages, aimed at men for cultural reasons, did appear to reach women. Women 
interviewees reported getting most of their health and ITN information from clinics, their 
husbands, or most commonly from each other.  
 “When one of us learns something, then she tells it to the others.” (Female non-owner, 
Shinwar) 
 
“Our husbands don’t let us listen to radio because it uses up the batteries.  We are 
encouraged to listen to religious programmes.  I learned about ITNs from my husband and 
the clinic doctors.” (Female ITN owner, Nazyan) 
Howard N: Malaria control for Afghans (1990-2005) 92 Chapter 5 
 
Malaria prevention and treatment.  Eighty percent of survey respondents said ITNs were the 
best means of malaria prevention. Interviewees reported that other common forms of 
protection against mosquitoes were burning grass, rubbing lamp or motor oil on the skin, and 
sleeping wrapped in wet chadors (traditional outer garments).  
“Preventive measures are good against malaria, but there are no effective ones; sprays 
wash off, ITNs only protect part of the time.  Burning straw is very effective against 
mosquitoes, but there is some problem with coughing and TB.  Electricity is better because 
we can use fans.” (Female non-owner, Shinwar) 
 
Many participants said previous government IRS campaigns had been very effective against 
mosquitoes, though only 9% of survey respondents considered IRS to be the best means of 
malaria prevention. These IRS campaigns were generally described as intrusive, but most said 
they favoured a return to spraying. IRS provision had been free and sprayers reportedly paid for 
information on households with malaria cases. Now households needed to spend their own 
money on ITNs. 
“We are talking about 20 years ago when the government authorities were spraying 
houses by force.  We didn’t know the benefits of spraying and now we know how effective 
it was!” (Male ITN owner, Pakhail, Achin) 
 
“Spraying should be done by the government, because if we spray individually or have 
ITNs, mosquitoes will keep coming from our neighbours’ houses.” (Female non-owner, 
Bihsood) 
 
Most participants, including 73% of survey respondents, named CQ as the best treatment for 
malaria. Some interviewees, though only 7% of survey respondents, favoured traditional 
treatments The main reason reported was cost, though a minor percentage were concerned 
about safety (e.g. for pregnant women). Traditional treatments included cooling drinks, such as 
dogh or lassie (from yoghurt), or various plants, the most common of which was a tea from 
shamaki roots. Shamaki is a Pashtu term for a plant used locally in traditional medicine, said by 
some respondents to contain quinine.  
“We usually resort to traditional treatment rather than clinical treatment unless the 
traditional treatment doesn’t work.  It is due to poverty and people can’t afford to cover 
doctor’s and transportation costs.”  (Male ITN owner, Gharzay, Muhmand-Dara) 
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Some interviewees said they would only buy half the recommended tablets to reduce treatment 
costs, while others reported they could be treated on credit. 
“…sometimes we borrow from doctors for treating our patient.  For instance, doctors in 
the clinic treat our patient and we will pay them later in the harvest time or as soon as we 
get cash.  The other way is to pay them with wheat or corn.”  (Male non-owner, Gharzay, 
Muhmand-Dara) 
 
While participants agreed it was less costly to prevent than to treat malaria, emergency funds 
for treatment could be borrowed from relatives or neighbours, while funds for protective goods, 
such as ITNs, could not be readily mobilised.  
“I saved money for four years to buy ITNs. I can borrow money from my neighbours and 
relatives to pay for treatment, but they’re not willing to lend for something like a bednet.” 
(Widow, ITN owner, Bihsood) 
 
ITN knowledge and perceptions. All participants could accurately describe ITNs and how they 
should be used. Authors found no differences between genders or ITN-owners and non-owners 
in recall of health messages about the benefits of sleeping under ITNs.  
“Using ITNs has two benefits.  One is that it protects you from malaria and the second is 
that you sleep well.”  (Male non-owner, Achin) 
 
“We need ITNs for protection against malaria, not for having fun!” (Male non-owner, 
Achin) 
 
While ITNs were frequently mentioned as playing an important role in the prevention of both 
nuisance biting and malaria, some participants said they did not want to make the initial 
investment.    
“Malaria is not something that much can be done about, just to endure.  ITNs are out of 
reach and not useful enough to buy.” (Male non-owner, Shinwar) 
 
Participants in a women’s FGD, asked their views on possible inclusion of ITNs as part of a dowry, 
responded with laughter. As this differed from men’s pile-sorting and ranking results, it indicates 
that either women valued ITNs less than did men or that ITNs were affordable for many 
households and thus not of sufficient monetary value to feature in a dowry. 
 “That is totally absurd! How should we let this stupid boy get married with our daughters 
by providing us with nets rather than paying?” (Female non-owner, Meydanak, Achin) 
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“We work hard to bring up our daughter and then to give her for ITNs? It is an absolutely 
silly thing to do! We are not stupid.” (Female non-owner, Meydanak, Achin) 
 
Reported ITN purchasing. Table 13 shows 84% of survey respondents said they were planning to 
buy ITNs. While 57% wanted them to reduce mosquito nuisance, 38% wanted them for malaria 
protection. Of those not planning to buy ITNs, the primary reasons given were cost (39%) and 
already having enough (30%). Responsibility for purchasing decisions rested with the household 
head, almost invariably an adult male - husband, father, or grandfather.  
 
Table 13. Percentage reported purchasing intentions, comparing ITN-owning to non-owning 
households 
 % Non-owners 
(n=214) 
% ITN owners 
(n=200) 
Planning to buy ITNs* 89 78 
Not planning to buy ITNs 9 19 
Not sure about buying ITNs 2 3 
We’ll buy ITNs when they’re available 81 83 
We’ll buy ITNs this month 12 12 
We’ll buy this year/Unknown 7 5 
Want ITNs to prevent mosquito bites* 51 62 
Want ITNs to prevent malaria 42 35 
Other/Unsure  7 3 
Don’t want ITNs due to cost* 46 35 
Don’t want ITNs due to having enough already 0 47 
Other/Unknown* 54 19 
NB: Sample size is 414. *Logistic regression p-value <0.05 to <0.01. 
 
 “Head of the family - father or grandfather - is responsible for making the decision to buy 
something like nets and protection of the family.” (Male ITN owner, Hazar Naw, 
Muhmand-Dara) 
 
Heads of ITN-owning households were significantly better educated. Comparing ITN-owning to 
non-owning households, household heads with above secondary-school education were 1.85 
times more likely to own ITNs than were those with no education (95% confidence interval 1.2-
2.8).  
 
Women participants said they had little decision-making power or opportunity to make 
purchases, but some said their husbands could be persuaded to buy items that they requested. 
Young women, even if married, were not able to go outside without accompaniment by their 
husband or parent-in-law. 
“We don’t go ourselves.  Our husbands don’t allow us to go for shopping. They usually 
provide us with what we want them to buy.” (Female non-owner, Sunduq, Achin) 
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“No woman can go anywhere without asking the permission of her husband.” (Female ITN 
owner, Meydanak, Achin) 
 
A common perception of HNTPO among interviewees was as an ITN sales company rather than 
a humanitarian organization. This was despite several local clinics being sign-posted as run by 
HNTPO. However, it was not clear whether this perception was likely to help or hinder HNTPO’s 
activities.  
 
Four main purchasing constraints were reported. The first was cost. ITNs were sold for the 
average equivalent of US$7.16 in 2015 constant prices, with insecticide retreatment costing the 
US$15 equivalent of US$0.08. Poorest people said they had more urgent problems for daily 
survival than mosquitoes and fever.  
 
Cost was the most frequently mentioned ITN purchasing constraint among non-owners. Some 
participants appeared unable to afford an ITN at prevailing prices.  Poorest households appeared 
to be those headed by widows, women whose husbands were disabled or working in Pakistan, 
and those who did not own enough land to support their household.  Women whose husbands 
were in Pakistan could purchase some supplies from local shops on credit.  Credit limits were 
unclear, though several women said that making ITNs available on credit would increase their 
ability to buy them. 
“ITNs are the best way to protect against malaria, but we can’t afford to buy them because 
we barely have enough to get food every day, and if we have enough for food, we have to 
buy clothes to cover our bodies.  We can’t go around naked!” (Female non-owner, Bati 
Kote) 
 
 “We know everything about ITNs but don’t have the money to buy.” (Male non-owner, 
Muhmand-Dara) 
 
A second purchasing constraint reported was that participants did not have sufficient money for 
enough ITNs to cover everyone in their households. Some non-owners expressed reluctance to 
buy ITNs unless they could provide for the whole household. 
 “Fifteen people in my family and we have only one net! I don’t have any money in hand 
to buy more nets.” (Male ITN owner, Gerday-Ghous, Muhmand-Dara) 
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“The other problem is that there are 20-30 people in each household and to cover them all 
with ITNs we need at least 8-10 ITNs that we can’t afford to provide.” (Male non-owner, 
Ghazgay, Muhmand-Dara) 
 
A third purchasing constraint, mentioned by both non-owners and owners purchasing additional 
ITNs, was that seasonal income did not match ITN availability. Several participants complained 
that ITNs were made available at the beginning of malaria season when they did not have 
enough cash to purchase them, and when they did ITNs were no longer available.   
“ITNs are available in this village only for a couple of weeks and that’s usually the time 
which doesn’t match harvest time (March/April) or when we don’t have money” (Male ITN 
owner, lower Meydanak, Achin) 
 
This lack of consistent availability led some non-owners to speculate that ITN sellers were 
favouring certain families and health staff were selling ITNs in Pakistan or charging more than 
they should.  However, recent purchasers reported paying the price recommended by HNTPO. 
“We had money last year, but ITNs were not available.  Only relatives and friends of the 
sellers were able to buy them.” (Male, non-owner, Bati Kote) 
 
“Clinic staff sell the ITNs and drugs in the bazaar to make money.  If you don’t know 
someone in the clinic, you won’t get help.” (Female, non-owner, Bihsood) 
 
The final purchasing constraint reported was that perceptions of poor-quality ITN retreatment 
were discouraging ITN purchasing. Several non-owners reported as a strong purchasing 
disincentive ITN-owning neighbours telling them ITNs were not as useful as previously. HNTPO 
had recently switched from permethrin to deltamethrin, and complaints about retreatment with 
watered down or expired insecticide may have affected ITN sales and retreatment uptake. 
“Retreatment is good, but not like it was.  Salesmen add more water now, but they say 
they know what they are doing.”  (Female ITN owner, Bihsood) 
 
“There has been a gradual decrease in effectiveness since 1994.  Maybe the insecticide is 
not good quality or they’re mixing it with too much water. There have been many 
complaints and many surveys, but nothing ever changes” (Male ITN owner, Bihsood) 
 
 “Poor quality retreatment stops people buying ITNs.” (Male ITN owner, Pakhail, Shinwar) 
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Reported ITN coverage and usage  
Table 14 shows most owners (69%) paid for ITNs from savings. ITN-owning households had an 
average of three ITNs and four occupants per ITN. Where ITNs were limited, 70% of survey 
respondents said children and women were given preference.  Participants said available ITNs 
were used by children and women, because they were the weakest and most vulnerable 
household members and keeping children covered by blankets to protect them from mosquitoes 
was very difficult. These practices may result from effective health messages, which emphasize 
the need to cover the most vulnerable (i.e. young children and pregnant women), but also reflect 
beliefs that women and children are weak, uninformed and unable to protect themselves.  
 
Table 14. Percentage reported ITN usage among ITN-owning households 
 % ITN owners (n=200) 
No. of  ITNs per household Mean=2.9 (SD=2.4) 
Who sleeps under ITNs in your household?  
   Children 36 
   Women/Children 31 
   Everyone (sufficient ITNs for all) 29 
   Women 3 
   Aged/Other 1 
Are your mosquito nets insecticide treated?  
   Yes 61 
   No/Unknown 39 
How often are your ITNs retreated?  
   Yearly 78 
   Bi-annually 12 
   Don’t know/Never 10 
   After cleaning 1 
Where did you get funds to pay for your ITNs?  
   Savings 69 
   Loan 17 
   Gift 8 
   Crop sales 4 
   Other 4 
NB: Sample size is 200. 
 
 “They (women and children) are weak in nature and also we men keep covered the 
exposed parts of our body, though children don’t care about this.” (Male ITN owner, 
Meydanak, Achin) 
  
“If malaria mosquitoes bite children they will immediately get ill and can’t resist against 
fever either, and the same applies to women.  It is OK with men; they can go to the clinic 
on foot.” (Male ITN owner, Gerday Ghaus) 
 
The average number of children under five per ITN was 1.6 (±SD 1.4), though the number of 
children under five per household was not associated with ITN ownership (logistic regression 
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p=0.86).  Only one man reported using the household ITN for himself, since as the family bread-
winner he wanted to stay healthy.  However, a few respondents (1%) said they gave preferential 
ITN use to the weak old men.  
 
Interviewees reported that most ITN users did not sleep under them throughout the year. The 
primary reasons given for ITN use were to prevent both nuisance biting and malaria. Malaria 
was reported to be a more serious but less frequent problem, while nuisance biting was an 
everyday frustration.  Many owners said that they used ITNs only in summer when mosquito 
densities and nuisance biting were highest and perceptions of malaria risk increased. However, 
some participants were aware that malaria could be transmitted in other seasons.   
“We use ITNs only during the nights and particularly in the summer – only in summer.” 
(Female ITN owner, Ghazai) 
  
“There is (malaria) in winter but not as high as in the summer.”  (Male ITN owner, Ghazai) 
 
While there was still some risk of both nuisance biting and malaria in winter, several participants 
said that people slept under blankets in winter so the likelihood of mosquito bites was reduced. 
 
Health-related workers’ perceptions 
Interviews with health workers and ITN implementers supported general findings and 
sometimes provided additional insight.  
 
Those doctors interviewed considered malaria an important contributor to morbidity and lost 
productivity, though not the primary disease priority in communities. 
“The most dangerous (disease) is TB because it’s transmissible easily and also if a person 
is diseased by this microbe and doesn’t take care of himself he will die.  But in malaria 
death is not essential, and the treatment of TB requires more time, at least 6 months, and 
the drugs are very expensive.” (Doctor, Bati Kote) 
 
Almost half of participants reported first going to public/NGO clinics for treatment, because they 
were cheapest. However, if treatment results were unsatisfactory many also went to private 
doctors. Several health workers described this type of treatment seeking negatively.  
“If the clinic technician says it’s not malaria she will think he’s no good and go to a private 
lab where they will tell her it’s malaria.  There’s a lot of overprescribing of chloroquine to 
make people happy.”  (Laboratory technician, Bihsood) 
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While most participants favoured the idea of credit schemes, and said that purchasing ITNs 
through small weekly or monthly sums would be beneficial, ITN implementers were not so 
eager. 
“I’m only working seven months a year.  It would take at least nine months to collect 
money from credit.  We (ITN implementers) know who needs and deserves credit and could 
take responsibility for monitoring, but they would need to pay us all year round.” (ITN 
implementer, Bihsood) 
 
Discussion 
Many aspects of ITN purchasing are similar for countries during conflict or peace, under despotic 
or benign authority. The Taliban, espousing a strict anti-modern antifeminist ideology adapted 
from Sunni Muslim sharia and Pashtun tribal codes, governed Afghanistan from 1996 to late 
2001152, 371, 372. While the presence of the Taliban placed profound restrictions on mobility, access 
and acquisition of information, their influence was far from all-pervasive and householders – 
women in particular – adopted a number of coping strategies to access information and 
influence health-related family decision-making.  
 
ITN purchasing  
Two key issues influencing purchasing were availability and pricing, constraints also found in 
several African studies of the same period373-376. Afghan men and women were aware of the link 
between mosquitoes and disease and of the protective effects of ITNs. Knowledge did not 
appear to be the main factor influencing ITN purchase and usage, as there was little difference 
in knowledge between ITN owners and non-owners377, 378. This is attributable to successful 
transmission of health information from sources such as health facility staff, HNTPO 
implementers, and radio programmes (e.g. BBC Pashtu Service news and dramas). HNTPO’s ITN 
coverage reached 60% in some trial areas where no limits were placed on the numbers of ITNs 
individuals purchased. Overall coverage was around 30% (Figure 11). Among participants who 
did not have ITNs, most said they wanted but could not afford them. Despite successful 
transmission of health messages, ITNs were not yet seen as household necessities. Rather, they 
were one of the first ‘extras’ families with greater financial stability felt able to afford. Household 
decision-makers appeared to understand the reasons for having ITNs, but make purchasing 
decisions based on overall risk perceptions 379, 380. More research is needed to explore this. 
 
Lack of ITN availability when participants said they were ready to purchase suggests delivery 
strategies could have benefited from restructuring41, 381, 382. ITNs were usually available during 
summer when mosquito nuisance was severe, but spare cash from harvests was already spent. 
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Making ITNs available when people were likely to have cash (e.g. harvest or crop purchase times) 
could increase sales382. Making ITNs more visible throughout the year (e.g. through mobile 
salesmen or local shops) could improve awareness of ITNs as household rather than health 
products and increase availability when cash was available. Strong perceptions existed that 
clinics and salesmen were preferentially selling ITNs to relatives or for profit. Year-round 
availability of ITNs, clearer promotion and pricing, and improved staff monitoring could reduce 
complaints383, 384.  
 
Some high-risk households (e.g. widow-led) did not have sufficient funds to purchase ITNs at 
prevailing prices. While free mass distribution is more difficult to justify in this low-transmission 
area, maintenance of a targeted subsidy to make ITNs affordable for those who truly cannot pay, 
or free distribution to most-at-risk groups is probably necessary to improve coverage rates373, 
385, 386. Additional distribution through local shops, where poorer women could get credit, might 
also increase access381, 386.  
 
Table 12 shows the price of an ITN was only slightly more than the average cost of treating one 
malaria episode. However, participants noted that emergency funds were easier than 
prevention funds to mobilise. It is also worth noting that non-owners reported slightly higher 
average malaria treatment prices (Table 12). This might indicate either the operation of informal 
credit mechanisms or respondent bias. As reported ITN prices were the same for both groups, 
more research on informal financing mechanisms may be warranted. However, authors found 
that money was as sensitive an issue as gender in rural areas. Since this study was conducted, 
foreign funding for malaria control in Afghanistan has increased dramatically. Mass distribution 
of LLINs is coordinated by HNTPO through a greatly expanded BHC-based system235. ITNs 
continue to be subsidized rather than provided free to users and findings reported here are still 
applicable.  
 
ITN coverage and usage 
Three key issues raised by ITN owners were seasonality, sleeper prioritization, and poor quality 
re-treatment. Most participants used ITNs in summer. This corroborates an earlier clinic-based 
case-control study of ITN effectiveness against malaria in Nangarhar, showing that despite high 
summer and autumn temperatures this was when people used nets most52. Fortunately, this is 
the peak malaria transmission season246. Many who did not use ITNs reported sleeping wrapped 
in their water-soaked chadors to keep cool. In emergencies, chadors treated with the repellent 
insecticide permethrin have provided some malaria protection251. Soaking in water could limit 
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the effectiveness of insecticide-treated chadors unless rendered wash-resistant through newer 
formulations.  
 
Prioritisation of women and children under ITNs was a key health message emphasized by ITN 
implementers in Afghanistan152. Most families automatically prioritised children, and to a lesser 
extent women, so messages could focus on youngest children and pregnant women as those at 
greatest potential risk. With current donor focus on gender issues and women’s capacity-
building in Afghanistan, there is more scope for improvement in this area than when this study 
was conducted.  
 
A widely held perception that the quality of insecticides used to re-treat ITNs had deteriorated 
was attributed to implementers over-diluting insecticide. In reality, the type of insecticide used 
had changed. Initially HNTPO used permethrin, but as this became harder to obtain the agency 
switched to lambda-cyhalothrin and deltamethrin. These alphacyanopyrethroids are more toxic 
but less repellent than permethrin, possibly giving the impression implementers had tampered 
with insecticide387-389. If people continued to perceive that the retreatment insecticide did not 
work, they would be less likely to have ITNs retreated or recommend that others buy ITNs. 
Fortunately, with the transition to long-lasting technologies this is less of an issue, as only LLINs 
are now sold in Afghanistan. 
 
During the malaria eradication era of the 1950s and 1960s, IRS was widely and successfully 
applied in Afghanistan390, 391. IRS and effective treatment drugs, as parasites were not yet 
resistant to chloroquine, led to low malaria prevalence in most parts of the country176. Effective 
IRS campaigns require infrastructure and planning that was not feasible during the Soviet and 
civil wars248. Participants indicated they would favour reintroducing an IRS programme, as it 
protected all household members, reduced overall mosquito numbers, and was free-of-cost to 
households. However, additional technical and coordination requirements often make it more 
costly than ITNs for implementers10, 47, 392. As sentinel surveillance data indicates malaria in 
Afghanistan is declining, coinciding with the scale-up of LLINs and wider use of more effective 
anti-malarial drugs, a return to IRS appears unwarranted. 
 
Gender  
Three gender-related issues could be further addressed. First, the authors found it possible to 
conduct research among Afghan women, even in Taliban-controlled areas. Teaming a foreign 
female and Afghan male researcher was a relatively novel approach in these isolated areas. 
Women wanted to meet ‘the foreign lady,’ and allowing curiosity to overcome suspicion enabled 
access to women in their home environment that might not otherwise have been allowed. Such 
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direct engagement could increase bias if not handled sensitively, but worked effectively when 
combined with findings from other data sources. More could be done to adapt social research 
methods for conservative, conflict-affected, and insecure environments.  
 
Second, while men had the primary role in household decision-making, information access and 
purchasing, older women particularly mothers-in-law exerted considerable influence. Efforts 
could be made to mobilize these women more effectively in health promotion campaigns.  
 
Third, male-focused health education did appear to filter through to women, making this a 
potential approach for socially-segregated environments. Interviews and FGD results with 
women corresponded well with quantitative survey findings, even though most survey 
participants were men. 
 
Implications and further research 
Issues for further investigation include equality of access to ITNs and the status of widow-led 
families in post-war Afghanistan, women whose husbands are economic migrants, and landless 
households. Work has been done on this in Africa, but more research is required to identify how 
best to target and support these high-risk households in Afghanistan41, 375, 383, 393, 394. Additional 
research could explore delivery strategies and cost-effectiveness of ITNs in areas of relatively 
low malaria endemicity or whether ITNs should form the basis of a malaria elimination strategy 
– important issues that were not addressed in this study394.   
 
Limitations 
Several potential limitations should be considered. First, due to security and access concerns for 
foreign researchers, sampling and recruitment of FGD and IDI participants was a combination of 
purposive and convenience. This may have affected responses received. Second, social 
acceptability bias may have been worsened by the relative inexperience of field interviewers. 
However, IDIs gave the opportunity to probe more carefully into both predictable and more 
unusual issues. Third, variations in ITN ownership by socioeconomic status may have been due 
to barriers other than cost that were not identified in principal components analysis, for example 
undisclosed socio-cultural influences or hierarchies, tribal issues, or unidentified geographical 
constraints.   
 
Conclusion 
Conditions in parts of rural Afghanistan have not changed greatly since this research was 
conducted. The south and east of the country have become, if anything, more insecure since 
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allied occupation and as a result, INGOs have less freedom to operate than did the researchers 
in 2000. Health funding and infrastructure have greatly improved over the decade since the 
Taliban last held power. However, availability of health services in remote communities remains 
variable. While women have greater freedom of movement and better access to health care and 
information than under the Taliban, they still face many financial and social barriers. This paper 
provides an indication of health-related constraints and potential approaches should support 
for the Afghan government deteriorate or a group such as the Taliban once again gain control in 
Afghanistan. 
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Abstract  
Background 
Afghanistan has some of the worst maternal and infant mortality indicators in the world and 
malaria is a significant public health concern. Study objectives were to assess prevalence of 
malaria and anaemia, related knowledge and practices, and malaria prevention barriers among 
pregnant women in eastern Afghanistan.  
 
Methods 
Three studies were conducted: (i) a clinical survey of maternal malaria, maternal anaemia, and 
neonatal birthweight in a rural district hospital delivery-ward; (ii) a case-control study of malaria 
risk among reproductive-age women attending primary-level clinics; and (iii) community surveys 
of malaria and anaemia prevalence, socioeconomic status, malaria knowledge and reported 
behaviour among pregnant women.  
 
Findings 
Among 517 delivery-ward participants (i), one malaria case (prevalence 1.9/1,000), 179 anaemia 
cases (prevalence 346/1,000), and 59 low-birthweight deliveries (prevalence 107/1,000) were 
detected. Anaemia was not associated with age, gravidity, intestinal parasite prevalence, or low-
birthweight at delivery. Among 141 malaria cases and 1,010 controls (ii), no association was 
found between malaria infection and pregnancy (AOR 0.89; 95%CI 0.57-1.39), parity (AOR 0.95; 
95%CI 0.85-1.05), age (AOR 1.02; 95%CI 1.00-1.04), or anaemia (AOR 1.00; 95%CI 0.65-1.54). 
Those reporting ITN usage had 40% reduced odds of malaria infection (AOR 0.60; 95%CI 0.40-
0.91). Among 530 community survey participants (iii), malaria and anaemia prevalence were 
3.9/1,000 and 277/1,000 respectively, with 34/1,000 experiencing severe anaemia. Despite 
most women having no formal education, malaria knowledge was high. Most expressed 
reluctance to take malaria preventive medication during pregnancy, deeming it potentially 
unsafe.  
 
Conclusions 
Given the low malaria risk and reported avoidance of medication during pregnancy, IPT in 
pregnancy is hard to justify or implement. Preventive strategy should instead focus on LLINs for 
all pregnant women. 
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Background 
Infection with P. falciparum or P. vivax can be dangerous in pregnancy, increasing risks of severe 
anaemia, premature delivery, low-birthweight (LBW), and foetal, neonatal and maternal 
death395-397. Falciparum infection in pregnancy causes up to approximately 10,000 maternal 
deaths, 3-8% infant deaths, and 8-14% LBW deliveries annually, and pregnant women are often 
prioritised for preventive interventions including LLINs and IPT397-399. In unstable transmission 
settings, such as much of South Asia, pregnant women experience 2-3 times higher risk than 
non-pregnant women of developing severe malaria or malaria-related severe anaemia396, 399-401.  
 
Malaria in pregnancy is most studied for falciparum infection in sub-Saharan Africa and 
Southeast Asia397, 398, 402, 403. Though less documented, growing literature on vivax infection in 
pregnancy indicates considerable risk and approximately 71 million pregnancies in vivax-
endemic areas globally395, 399, 401, 404-411. P. vivax is the most geographically widespread human 
malaria parasite - endemic in much of Asia, including Afghanistan, with approximately 2.9 billion 
people at risk globally410-415. It has been associated with severe clinical manifestations in 
pregnancy, including severe anaemia, thrombocytopenia, miscarriage, low-birthweight, and 
preterm delivery395, 399, 415, 416. Though in vivo P. vivax placental sequestration has not been 
identified, in vitro evidence exists of cytoadherence to placental glycosaminoglycans417. 
Relapsing infections from hypnozoite reservoirs cannot be treated effectively, as primaquine is 
contraindicated in pregnancy, making prevention preferable418.  
 
Afghanistan has received considerable international attention and support since the Taliban 
government ended in 2001, but remains a fragile country419, 420. The estimated maternal 
mortality ratio reduced from 1,300/100,000 in 2000 to 460/100,000 in 2010, but disparities 
between urban and rural areas remain stark (e.g. maternal mortality ratio of 166/100,000 in 
Kabul versus 713/100,000 in Badakhshan)421, 422. Similarly, the infant mortality rate reduced from 
153/1,000 to 74/1,000 in 2011423-425. However, indicators remain poor. An estimated 16 million 
people are at risk of malaria in Afghanistan and it remains a public health concern160, 235, 426. 
Transmission is unstable and seasonal, and a significant cause of morbidity in lowland and rice 
irrigation areas 426.  
 
No publications were found on malaria epidemiology in pregnancy in Afghanistan. This study 
aimed to assess the contribution of malaria to maternal anaemia and birth outcomes in eastern 
Afghanistan. Objectives were to assess: (i) prevalence of malaria and anaemia among pregnant 
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women, (ii) risks of malaria in pregnancy, and (iii) malaria awareness and reported behaviours 
during pregnancy. 
 
Methods 
Study site and population 
Studies were conducted in Ghani Khel District Hospital, a secondary-level facility in rural 
Nangarhar province, and primary-level facilities (i.e. BHCs) and communities within its 
catchment area. The target population was women of reproductive age (WRA; aged 15-49) from 
among an estimated population of 500,000 women accessing health services subcontracted to 
an NGO provider, HNTPO, through Afghanistan’s Basic Package of Health Services186, 235. Malaria 
transmission is moderate and seasonal, vivax peaking May-August and causing 70-95% of 
malaria, and falciparum predominantly in October-November246. Main vectors are Anopheles 
stephensi, An. superpictus, and An. culicifacies246, 426. At the time of this study, the National 
Malaria and Leishmaniasis Control Programme worked to prevent malaria through insecticide-
treated nets (e.g. ITNs/LLINs) - targeted preferentially to pregnant women - distributed at 
subsidised prices through primary-level BHCs52, 115, 236. Antenatal services during the four 
recommended visits followed WHO guidelines427. Unicef supported prevention of maternal 
anaemia by providing iron/folate tablets during antenatal care visits428.   
 
Study design and data collection  
Three complementary studies were conducted: (i) a clinical survey of maternal malaria, maternal 
anaemia, and neonatal birthweight in the district hospital (ii) a case-control study of malaria risk 
factors among WRA attending nearby primary-level facilities, and (iii) a two-round community 
survey of malaria and anaemia prevalence, socioeconomic status and related knowledge, 
attitudes and practices among pregnant women in four nearby districts.  
 
Delivery-ward survey: Women delivering between February and December were enrolled and 
examined on giving informed consent: (i) thick and thin Giemsa-stained blood smears of 
peripheral, cord and placental blood were tested for malaria; (ii) maternal blood tested for 
haemoglobin; (iii) stool tested for intestinal parasites; and (iv) neonate and placenta weighed at 
delivery. Blood slides were collected by a trained midwife, stained and examined the same day 
by a trained microscopist at 100x magnification, with 200 fields checked before recording a 
negative result. All slides were re-read by an experienced microscopist, blinded to original 
diagnosis. Haemoglobin was measured by attending midwife using a HemoCue point-of-care 
test (Ängelholm, Sweden). Stool was examined for helminths and intestinal protozoa by trained 
microscopists, using duplicate Kato-Katz thick smears prepared shortly after collection and 
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allowed to clear for 45-60 minutes before examination429. Participants found positive were 
treated according to national guidelines, e.g. Albendazole 400mg PO for helminths; CQ 25mg/kg 
x 3 days for uncomplicated malaria; quinine IV 20mg/kg loading dose, then 10mg/kg t.i.d x 7 
days for severe malaria; daily iron (120mg of elemental iron) and folic acid (400µg) 
supplementation until haemoglobin concentration rises to normal for mild-moderate anaemia; 
whole blood or packed red cells 10 ml/kg over 3 hours for severe anaemia343, 430, 431. Birthweight 
was measured by attending midwife for all births within one hour of delivery, using an electronic 
scale (Salter, Birmingham UK) accurate to ±10g and calibrated weekly432. Fresh placentas were 
weighed by attending midwife, untrimmed and without blood expressed, using the same 
procedure433. Data were double-entered into Microsoft® Access 2000, with range and 
consistency checks to reduce transposition errors. 
 
Case-control study: All reproductive-age female outpatients presenting with suspected malaria 
(i.e. fever or history of fever suspected to be malaria) and providing informed consent, were 
enrolled between September and January at basic health facilities with malaria diagnostics and 
staff willing to participate in a study. All patients were examined by clinic doctors and clinical 
diagnosis, age, marital status, number of children, and number of previous pregnancies recorded 
on standardised forms. Controls were defined as WRA with clinically-suspected malaria, 
negative blood slides and no recent history of malaria (i.e. to exclude recently treated patients). 
Cases were defined as WRA with microscopically confirmed malaria and categorised according 
to malaria species and severity. Severe cases were defined as parasitaemic, with one or more 
WHO indicators for severe malaria and absence of identified alternative causes434. Microscopy, 
treatment, and data entry replicated delivery survey protocols. 
 
Community survey: Multi-stage sampling was used: (i) four districts were selected with 
functioning community health infrastructure (i.e. Shinwar, Mohmand Dara, Batikot, Nazian); (ii) 
villages were identified within each district that were malaria-endemic, with antenatal services, 
and accessible by four-wheel drive vehicle; (iii) all pregnant women in each village were invited 
to participate. Sample size was calculated to detect a malaria prevalence of 5% with 80% power 
and 95% confidence. Two collection periods, May-June and December, incorporated seasonal 
peaks of vivax and falciparum transmission respectively. Those providing informed consent were 
tested for malaria and anaemia and answered a structured questionnaire (Annex 3). Adapted 
from previous research115, the questionnaire was back-translated in Pashtu and piloted in a non-
participating district. Literate female interviewers were recruited from local communities and 
trained over three days on privacy, prompting, and questionnaire completion. Microscopy, 
treatment, and data entry replicated delivery survey protocols.   
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Analysis 
Data were analysed using Stata/IC13.1. 
 
Delivery-ward survey: Malaria infection was categorised as negative (i.e. negative peripheral, 
umbilical, and placental slide result) or positive (i.e. any positive result). Anaemia was 
categorised as non-anaemic (i.e. 110g/l or above) or anaemic (i.e. below 110g/l) if anaemia was 
mild (100-109g/l), moderate (70-99g/l), or severe (<70g/l)435, 436. Birthweight was categorised as 
non-LBW (i.e. 2,500g or above) or LBW (i.e. below 2,500g). Intestinal parasites were categorised 
as absent (i.e. none detected) or present (i.e. detection of any helminth or protozoa). Logistic 
regression was used to calculate odds ratios of anaemia or LBW outcomes, with univariate 
regression providing crude estimates and multivariate regression adjusting for a priori 
confounders (i.e. age, gravidity, presence of intestinal parasites). Cell sizes below 30 prompted 
exact logistic methods. Effect modifiers (i.e. significant likelihood ratio test) were reported 
individually.  
 
Case-control study: Categorisation and analysis replicated delivery survey protocols. 
Additionally, ITN usage was defined as reporting sleeping under ITNs the previous night. Logistic 
regression calculated odds ratios of exposures. A priori confounders were district, facility, age, 
and parity.  
 
Community survey: Categorisation and analysis replicated delivery survey protocols. 
Additionally, participant age, education, housing, and household asset variables were weighted 
and scored within a socioeconomic status (SES) index using principal components analysis 115, 210. 
Logistic regression calculated odds ratios of anaemia. A priori confounders were SES, district, 
age, parity, trimester, and season.   
 
Ethics 
Approval was provided by the Ministry of Public Health in Afghanistan and the LSHTM Research 
Ethics Committee in the United Kingdom (reference 5508). All participants were informed about 
the study purpose, content and potential publication and written or verbal informed consent 
was recorded. Data were coded anonymously and stored in password-protected hard-drives.  
 
Results  
Delivery-ward survey 
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In total, 517 patients agreed to participate. Average age was 25 years (range 16-40). 
Approximately 35% were primigravida, 31% multigravida (2-4 pregnancies) and 33% grand-
multigravida (5+ pregnancies). Among 38 women with intestinal parasites (prevalence 74/1,000, 
95%CI 54-99), most frequent were Entamoeba histolytica (47%), Giardia lamblia (26%) and 
Ascaris lumbricoides (16%). One malaria case, asymptomatic at delivery and detected in 
peripheral blood only (prevalence 1.9/1,000, 95%CI 0.3-13.7); 179 anaemia cases (prevalence 
346/1,000, 95%CI 306-388), 12 of them severely anaemic (23/1,000, 95%CI 20-25); and 59 LBW 
deliveries (114/1,000, 95%CI 89-115) were recorded. 
 
As only one malaria case was detected, further analysis only compared factors associated with 
anaemia and LBW (Table 15). Anaemia presence was not associated with age, gravidity, 
presence of intestinal parasites, or LBW delivery. LBW delivery was not associated with intestinal 
parasite or anaemia presence, though it was associated with gravidity in multivariate analysis.  
 
Table 15. Associations of demographic and clinical variables with maternal anaemia and low-
birthweight delivery among 517 delivery-ward patients in eastern Afghanistan 
Associations with anaemia Anaemic, n (%)  Non-anaemic, n (%)  OR (95%CI) AOR (95%CI) 
 (N=179) (N=338)   
Age group     
15-20 66 (36.9) 143 (42.3) Ref. Ref. 
21-30 84 (46.9) 154 (45.6) 1.18 (0.80-1.75) 1.00 (0.63-1.60) 
31-49 29 (16.2) 41 (12.1) 1.53 (0.88-2.68) 1.20 (0.59-2.44) 
Gravidity     
Primigravidous 54 (30.2) 129 (38.2) Ref. Ref. 
Multigravidous (2-4) 58 (32.4) 104 (30.8) 1.33 (0.85-2.09) 1.32 (0.81-2.17) 
Grand-multigravidous (5+) 67 (37.4) 105 (31.1) 1.52 (0.98-2.37) 1.42 (0.80-2.53) 
Intestinal parasites     
No 167 (93.3) 312 (92.3) Ref. Ref. 
Yes 12 (6.7) 26 (7.7) 0.86 (0.42-1.75) 0.82 (0.40-1.67) 
LBW     
No 159 (88.8) 229 (88.5) Ref. Ref. 
Yes 20 (11.2) 39 (11.5) 0.96 (0.54-1.71) 1.09 (0.60-1.97) 
Associations with LBW LBW, n (%) Non-LBW, n (%)  OR (95%CI) AOR (95%CI) 
 (N=59) (N=458)   
Age      
15-20 33 (55.9) 176 (38.4) Ref. Ref. 
21-30 21 (35.6) 217 (47.4) 0.52 (0.29-0.92)* 1.13 (0.57-2.22) 
31-49 5 (8.5) 65 (14.2) 0.41 (0.15-1.10) 2.17 (0.55-8.49) 
Gravidity     
Primigravidous 38 (64.4) 145 (31.7) Ref. Ref. 
Multigravidous (2-4) 13 (22.0) 149 (32.5) 0.33 (0.17-0.64)** 0.31 (0.15-0.64)** 
Grand-multigravidous (5+) 8 (13.6) 164 (35.8) 0.19 (0.08-0.41)** 0.13 (0.04-0.39)** 
Intestinal parasites     
No 55 (93.2) 424 (92.6) Ref. Ref. 
Yes 4 (6.8) 34 (7.4) 0.90 (0.31-2.65) 1.04 (0.34-3.14) 
Anaemia      
No 39 (66.1) 299 (65.3) Ref. Ref. 
Yes 20 (33.9) 159 (34.7) 0.96 (0.54-1.70) 1.09 (0.60-1.96) 
NB: *p<0.05; **p<0.001; AOR adjusted for age, gravidity, intestinal parasite presence. Cell sizes below 30 use exact 
logistic methods.   
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Case-control study 
In total, 141 malaria cases and 1,010 controls were enrolled from reproductive-age women 
attending eight district clinics (Table 16). Most were resident in Jalalabad (40%), Shinwar (23%) 
and Momand Dara (15%) districts. Average age was 28 (range 15-45). Most (81%) were married. 
Approximately 25% were nulliparous, 38% had delivered 1-5 times, and 36% more than five 
times. Parous women averaged 4.6 children (range 1-13). Approximately 25% of women were 
pregnant and 23% anaemic. P. falciparum infection accounted for 37% (52/141) of malaria cases, 
25% (13/52) of which were assessed as severe. Among pregnant women, 11% (31/286) had 
malaria infection compared to 15% (110/755) of non-pregnant women. Among pregnant 
women with malaria, 35% (11/31) were infected with P. falciparum, of which 1 was severe. 
 
Reported ITN usage was 32% (45/141) among cases and 43% (431/1,010) among controls, giving 
a protective 40% lower odds of malaria infection (AOR 0.60; 95%CI 0.40-0.91). None of age, 
pregnancy status, parity, or anaemia were associated with malaria infection in univariate or 
multivariate analyses (Table 16). 
 
Table 16. Associations between demographic and clinical exposures and malaria, among 1,150 
case-control study participants in eastern Afghanistan 
Variables Cases, n (%) Controls, n (%)  OR (95%CI) AOR (95%CI) 
 (N=141) (N=1,010)   
Age group     
15-20 32 (22.7) 286 (28.3) Ref. Ref. 
21-30 62 (44.0) 437 (43.3) 1.27 (0.81-1.99) 1.36 (0.74-2.49) 
31-49 47 (33.3) 287 (28.4) 1.46 (0.91-2.36) 1.49 (0.75-2.97) 
Pregnant 31 (22.0) 255 (25.3) 0.83 (0.55-1.27) 0.89 (0.56-1.42) 
Parity      
Nulliparous (no births) 36 (25.5) 256 (25.4) Ref. Ref. 
Parous (1-5 births) 55 (39.0) 389 (38.5) 1.01 (0.64-1.57) 0.84 (0.47-1.52) 
Grand-multiparous (6+ births) 50 (35.5) 365 (36.1) 0.97 (0.62-1.54) 0.68 (0.35-1.31) 
Anaemic  33 (23.4) 230 (22.8) 1.04 (0.68-1.57) 1.00 (0.65-1.54) 
ITN usage 45 (32.0) 431 (42.7)  0.63 (0.43-0.92)* 0.60 (0.40-0.91)* 
NB: *p<0.05; **p<0.001; AOR adjusted for district, facility, age, parity.   
 
Community survey 
Socioeconomic and clinical variables: In total, 530 pregnant women participated. Mean age was 
28 (range 15-45) and 80% had no formal education. Most households averaged 9.8 members 
(range 1-39), 2.6 under age five (range 0-18), living in three rooms (range 1-12). Most had no 
electricity (73%; 387/530), while 48% owned land (255/530).  
 
Table 17 shows education, employment and household assets used for principle components 
analysis, disaggregated by socioeconomic quartile.  
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Table 17. Factors used in principle components analysis to define socioeconomic quartiles 
among 530 community survey participants in eastern Afghanistan 
Socioeconomic variables Socioeconomic quartile, n (%) 
 
1. Poorest 
(N=133)  
2. Poor  
(N=132) 
3. Less poor 
(N=133) 
4. Least poor 
(N=132) 
Education      
None 128 (30.2) 109 (25.8) 100 (23.6) 87 (20.5) 
Religious/Informal 3 (5.4) 15 (26.8) 18 (32.1) 20 (35.8) 
Primary-school 2 (9.1) 6 (27.3) 3 (13.6) 11 (50.0) 
Middle-school 0 (0) 1 (8.3) 4 (33.3) 7 (58.3) 
High-school 0 (0) 1 (6.7) 8 (53.3) 6 (40.0) 
University/Technical 0 (0) 0 (0) 0 (0) 1 (100) 
Primary earner’s employment     
Not working  2 (40.0) 2 (40.0) 1 (20.0) 0 (0) 
Manual labour 70 (37.6) 46 (24.7) 43 (23.1) 27 (14.5) 
Farming 35 (22.0) 48 (30.2) 34 (21.4) 42 (26.4) 
Trade/Market 14 (18.0) 22 (28.2) 20 (25.6) 22 (28.2) 
Driver 8 (18.1) 10 (22.7) 11 (25.0) 15 (34.1) 
Office/Similar 4 (7.0) 4 (7.0) 24 (41.4) 26 (44.9) 
Household assets     
Guestroom 28 (9.3) 70 (23.3) 91 (30.2) 112 (37.2) 
Electricity 11 (7.4) 29 (19.7) 43 (29.3) 64 (43.5) 
Land ownership 33 (13.0) 64 (25.1) 61 (24.0) 97 (38.0) 
Car/Truck 0 (0) 2 (4.0) 12 (24.0) 36 (72.0) 
Radio/Music-player 5 (4.2) 15 (12.7) 30 (25.4) 68 (57.6) 
Rug 12 (6.6) 33 (18.2) 60 (33.2) 76 (42.0) 
Curtains 18 (7.1) 57 (22.4) 71 (28.0) 108 (42.5) 
Bicycle 25 (12.1) 38 (18.4) 60 (29.0) 84 (40.6) 
Pressure-cooker 27 (8.3) 79 (24.2) 101 (31.0) 119 (36.5) 
ITNs 9 (4.5) 31 (15.6) 65 (32.7) 94 (47.2) 
 
Malaria point prevalence was 3.8/1,000 (95%CI 0.9-15.0), anaemia was 277/1,000 (95%CI 241-
317), and severe anaemia 34/1,000 (95%CI 21-53), similar to delivery-ward survey findings. As 
only two malaria cases were detected, analysis of effects on maternal haemoglobin 
concentration was conducted for anaemia instead. Table 18 shows none of age, parity, 
trimester, malaria infection, iron/folate usage, antenatal attendance, ITN usage, or SES were 
associated with anaemia in multivariate analysis.   
 
Table 18. Associations of socioeconomic, clinical and behavioural responses with anaemia 
among 530 community survey participants in eastern Afghanistan 
Variables Hb  Anaemic, n 
(%) 
Non-
anaemic, n 
(%)  
OR (95%CI) AOR (95%CI) 
 mean±SD (range) (N=147) (N=383)   
Age      
15-20 11.4±1.9 (7.3-19.3) 22 (15.0) 78 (20.4) Ref. Ref. 
21-30 11.0±1.7 (6.5-17.5) 81 (55.1) 223 (58.2) 1.29 (0.75-2.20) 1.35 (0.71-2.57) 
31-45 10.7±1.7 (6.5-15.5) 44 (29.9) 82 (21.4) 1.90 (1.05-3.46)* 1.89 (0.85-4.20) 
Parity      
Nulli/Primiparous (0-1 
births) 
11.1±1.8 (6.8-17.5) 35 (23.8) 103 (27.0) Ref. Ref. 
Multiparous (2-5 
births) 
10.9±1.7 (6.5-19.3) 76 (51.7) 187 (48.8) 1.20 (0.75-1.90) 0.99 (0.57-1.72) 
Grand-multiparous (6+ 
births) 
10.9±1.7 (6.5-14.7) 36 (24.5) 93 (24.3) 1.14 (0.67-1.96) 0.76 (0.38-1.52) 
Trimester       
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1st 10.9±2.1 (8.0-14.0) 3 (2.0) 6 (1.58) Ref. Ref. 
2nd  11.3±1.7 (7.0-17.5) 57 (38.8) 188 (49.1) 0.61 (0.15-2.50) 0.53 (0.12-2.41) 
3rd  10.7±1.7 (6.5-19.3) 87 (59.2) 189 (49.4) 0.92 (0.22-3.77) 0.76 (0.17-3.41) 
Malaria infection      
No 11.0±1.7 (6.5-19.3) 147 (100) 381 (99.5) .. .. 
Yes 12.5±1.4 (11.5-14) 0 (0) 2 (0.5) .. .. 
Iron/Folate usage      
No 10.9±1.7 (6.5-19.3) 108 (73.5) 277 (72.3) Ref. Ref. 
Yes 11.1±1.7 (6.7-15.5) 39 (26.5) 106 (27.7) 0.94 (0.61-1.44) 1.16 (0.73-1.84) 
Antenatal attendance (at least once)     
No 11.0±1.4 (6.9-17.5) 20 (13.6) 54 (14.1) Ref. Ref. 
Yes 11.0±1.7 (6.5-19.3) 127 (86.4) 329 (85.9) 1.04 (0.60-1.81) 1.03 (0.57-1.87) 
Household ITN ownership     
No 11.0±1.8 (6.5-19.3) 91 (61.9) 240 (62.7) Ref. Ref. 
Yes 11.1±1.7 (6.5-15.5) 56 (38.1) 143 (37.3) 1.03 (0.70-1.53) 1.74 (0.99-2.90) 
Slept under ITN last night     
No 11.0±1.4 (6.5-19.3) 134 (91.2) 357 (93.2) Ref. Ref. 
Yes 10.8±1.4 (8.6-14.2) 13 (8.8) 26 (6.8) 1.33 (0.66-2.67) 1.71 (0.82-3.64) 
Socioeconomic status      
1.Poorest  10.8±1.9 (6.5-17.5) 47 (32.0) 86 (22.5) Ref. Ref. 
2.Poor 10.9±1.8 (6.8-19.3) 35 (23.8) 97 (25.3) 0.66 (0.39-1.12) 0.72 (0.41-1.26) 
3.Less poor 10.9±1.7 (6.5-14.3) 39 (26.5) 94 (24.5) 0.76 (0.45-1.27) 0.95 (0.53-1.71) 
4.Least poor 11.4±1.6 (7.5-15.5) 26 (17.7) 106 (27.7) 0.45 (0.26-0.78)* 0.57 (0.29-1.10) 
NB: *p<0.05; **p<0.001; AOR adjusted for survey, age, parity, trimester, SES, district; Cell sizes below 30 use exact 
logistic methods. 
 
Knowledge/perceptions: Malaria knowledge was high, with 99% reporting fever, shivering/chills, 
headache, weakness or joint pain as symptoms, 97% reporting mosquito bites transmit malaria, 
70% reporting diagnosis by blood test, and 81% reporting ITN usage as the best available 
prevention. Risk perception was also high, with 85% identifying malaria as their community’s 
‘worst health problem,’ 90% as common in their community, and 38% reporting they had 
experienced ‘malaria’ during their present pregnancy. In contrast, only 6% identified either 
diarrhoeal disease or acute respiratory tract infections as concerns, despite high frequency of 
both (Table 19).  
 
Table 19. Associations of knowledge and behavioural responses with socioeconomic status 
among 530 community survey participants in eastern Afghanistan 
Response variables Poorer# Wealthier# OR (95%CI) AOR (95%CI) 
  (N=265)  (N=265)   
Primary source of healthcare     
NGO/government health facility 217 (81.9) 184 (69.4) Ref. Ref. 
Private health facility 43 (16.2) 67 (25.3) 1.84 (1.19-2.82)* 1.30 (0.77-2.21) 
Traditional/Self-treat 5 (1.9) 14 (5.3) .. .. 
Attended antenatal services at least 
once 
228 (86.0) 228 (86.0) 1.00 (0.61-1.63) 1.38 (0.75-2.54) 
Uses iron/folate supplements 54 (20.45) 91 (34.3) 2.34 (1.55-3.53)* 1.90 (1.17-3.09)* 
Greatest health concern     
Other 3 (1.1) 10 (3.8) .. .. 
Diarrhoea 18 (6.8) 14 (5.3) Ref. Ref. 
ARI 12 (4.5) 21 (7.9) 0.53 (0.12-2.29) 0.53 (0.09-3.03) 
Malaria 232 (87.6) 220 (83.0) 0.28 (0.77-1.05) 0.43 (0.91-2.00) 
How common is malaria     
No malaria/Infrequent 22 (8.3) 29 (10.9) Ref. Ref. 
Common 243 (91.7) 236 (89.1) 0.74 (0.41-1.32) 0.73 (0.36-1.48) 
Best malaria prevention in pregnancy      
Nothing works 29 (10.9) 24 (9.1) Ref. Ref. 
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ITNs 212 (80.0) 219 (82.6) 1.25 (0.70-2.21) 1.26 (0.64-2.46) 
Rapid diagnosis/treatment 1 (0.4) 1 (0.4) .. .. 
Burning/Smoke 8 (3.0) 9 (3.4) .. .. 
Clean house/area 15 (5.7) 12 (4.5) 0.97 (0.38-2.46) 0.53 (0.17-1.64) 
Preferred malaria diagnosis     
Self/Informal 31 (11.7) 48 (18.1) Ref. Ref. 
Facility (clinical) 50 (18.9) 29 (10.9) 0.37 (0.20-0.71)* 0.43 (0.19-0.96)* 
Facility (blood test) 184 (69.4) 188 (70.9) 0.66 (0.40-1.08) 0.91 (0.48-1.72) 
Preferred malaria treatment     
NGO/government health facility 214 (80.8) 198 (74.2) Ref. Ref. 
Private health facility/Other 51 (19.2) 67 (25.3) 1.42 (0.94-2.14) 0.86 (0.51-1.44) 
Would use malaria-preventive drugs in pregnancy    
Never 232 (87.6) 204 (77.0) Ref. Ref. 
Yes/Maybe 33 (12.5) 61 (23.0) 2.10 (1.32-3.34)* 1.69 (0.98-2.91) 
Why use ITNs     
Avoid mosquitoes  169 (63.8) 167 (63.0) Ref. Ref. 
Prevent insect bites 49 (18.5) 43 (16.2) 0.89 (0.56-1.41) 1.15 (0.65-2.02) 
Prevent malaria 40 (15.1) 51 (19.3) 1.29 (0.81-2.06) 1.92 (1.07-3.43)* 
Other/Don’t know 7 (2.6) 4 (1.5) .. .. 
ITN-owners only n=40 (%) n=159 (%)   
Which family members use ITNs     
Nobody/Unknown 11 (27.5) 41 (25.8) Ref. Ref. 
All 9 (22.5) 61 (38.4) 1.82 (0.69-4.78) 1.23 (0.37-4.04) 
Children 20 (50.0) 43 (27.0) 0.58 (0.24-1.35) 0.48 (0.16-1.40) 
Women 0 (0) 11 (6.9) .. .. 
Men/Elderly 0 (0) 3 (1.9) .. .. 
Participant used ITN last night 7 (17.5) 32 (20.1) 1.19 (0.48-2.93) 3.09 (1.01-9.51)* 
Reasons for not using ITN last night n=33 (%) n=127 (%)   
No mosquito nuisance 11 (33.3) 35 (27.6) Ref. Ref. 
ITN used by others  12 (36.4) 26 (20.5) 0.68 (0.26-1.78) 2.87 (0.42-19.8) 
No reason provided 10 (30.3) 66 (52.0) 2.07 (0.80-5.36) 4.65 (1.09-19.8)* 
NB: *p<0.05; **p<0.001; AOR adjusted for survey, age, parity, trimester, district; #Poorer merges SEQ 1 and 2, 
Wealthier merges SEQ 3 and 4. 
 
Reported practices: Most (76%) reported NGO-run public-sector facilities as their primary source 
of healthcare and 86% reported attending antenatal services at least once during pregnancy. 
Only 27% reported taking iron/folate during pregnancy, with 55% reporting no use of dietary 
supplements. However, this differed by SES, with wealthier women having almost double the 
odds of taking iron/folate (AOR 1.90; 95%CI 1.17-3.09).  
 
Most (78%) reported using public facilities for malaria treatment, primarily due to affordability 
(45%) and effectiveness (40%), with no differences by SES. Most (82%) reported they would 
never take drugs to prevent malaria during pregnancy. Of almost half (43%) reporting avoiding 
all medicines during pregnancy, 55% reported doing so because they might feel sick and 32% 
because drugs - including antimalarials - might be dangerous during pregnancy. Although most 
(81%) recommended ITNs for malaria prevention, only 17% reported this as their major 
advantage and most (81%) identified avoiding nuisance biting as most important. Approximately 
38% reported household ownership of at least one ITN. Most women in ITN-owning households 
reported that everyone (35%) or children (32%) usually slept under ITNs. While 80% reported 
not using an ITN the previous night, wealthier women had three times higher odds of having 
slept under one (AOR 3.09; 95%CI 1.01-9.51).  
Howard N: Malaria control for Afghans (1990-2005) 115 Chapter 6 
 
Discussion 
Prevalence and perceptions 
This study design, by using three distinct data sources to examine the scope of the problem in 
Afghanistan, provides a broad view of malaria and anaemia in pregnancy. Malaria prevalence of 
only 3.9/1,000 among pregnant women in communities and 1.9/1,000 in a delivery-ward 
appears to reflect a genuine reduction in malaria transmission rates in Afghanistan246. A decade 
previously, community surveys among all age groups in this province typically recorded a 
prevalence of 7-10% for vivax and 2-5% for falciparum malaria52. Reasons for this reduction 
could include expansion of health services186, 419, increased availability of malaria diagnosis and 
treatment91, enhanced control activities12, 152, improved political stability and socioeconomic 
development186, and/or changing environmental conditions and improved agricultural 
practices160. 
 
While recorded malaria prevalence was low, the high prevalence of maternal anaemia - 
consistent with a reported national prevalence of 40.3% among WRA - is a concern428. 
Associations between anaemia and malaria were not observed, and it is clear that factors other 
than malaria are chiefly responsible for the high prevalence of maternal anaemia detected in 
delivery-ward and cross-sectional surveys. More likely contributors were poor diet, lack of 
access to nutritional supplements during pregnancy, poor spacing and high frequency of 
pregnancies, and possible genetic traits11, 428, 437. South Asia generally has high anaemia levels, 
accounting for 37.5% of the entire global anaemia years lost to disability in 2010, down from 
39.8% in 1990438. Over 50% of this was iron-deficiency anaemia, which was higher in females 
than males, and compared to rates of less than 25% in sub-Saharan Africa and all high-income 
countries438. South Asia also has the highest anaemia prevalence among pregnant women, 
which has changed little since 1995437. Anaemia prevalence among pregnant women aged 15-
49 in South Asia reduced marginally from 53% in 1995 to 52% in 2011, while severe anaemia in 
this group reduced from 2.9% to 1.3%437. This compared with global rates of 48% in 1995 and 
33% in 2011 (2% and 0.9% severe anaemia) and high-income region rates of 23% and 22% (0.5% 
and 0.2% severe anaemia)437. Low haemoglobin concentrations can be caused by a range of 
factors, including genetic traits, e.g. sickle-cell anaemia and thalassaemia; inadequate 
bioavailability of dietary iron, folate, or vitamin B12; infectious diseases, e.g. malaria, 
schistosomiasis, and HIV; hookworm infection; and some non-communicable diseases437. It was 
beyond the scope of this study to identify the reasons for the high anaemia and severe anaemia 
prevalence detected. Research indicates that sickle-cell traits and thalassaemias may be 
important contributors in parts of South Asia439. However, it was apparent that anaemia results 
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(i.e. 34% at hospital, 28% in communities) were not unusually high regionally, while severe 
anaemia results (i.e. 2.3% at hospital and 3.4% in communities) appeared high even for the 
region. Intestinal parasite prevalence was higher than the 3.8% reported among pregnant 
women in the 2013 National Nutrition Survey, but did not appear to be associated with anaemia 
(OR 0.82; 95%CI 0.40-1.67)428. LBW prevalence was lower than the Unicef estimate of 28% for 
the South Asia region, though comparable data were unavailable for Afghanistan440.  
 
Perceptions of malaria risk appeared higher than warranted by a prevalence of 1.9-3.8/1,000. 
These perhaps predated health system strengthening and/or were encouraged by popular 
misconceptions that non-specific febrile illness was often malaria91, 344. Despite minimal 
educational attainment, women were knowledgeable about malaria, probably reflecting long-
running health education efforts by NGOs since the 1990s441. Growing evidence indicates 
messages have been effective, despite low literacy and cultural constraints targeting most 
efforts at men115, 441.  
 
Policy and practice implications  
This study demonstrated that the risk of malaria in pregnancy is low among Afghan women. 
However, the malaria burden among pregnant women in Afghanistan remains sufficient to 
warrant specific action. P. vivax treatment is particularly challenging in pregnancy. While blood-
borne parasites respond to CQ or SP, both safe in pregnancy 158, vivax infections often relapse 
without radical primaquine treatment442. Pregnant and lactating women cannot receive 
primaquine, due to risks of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD) 
deficient foetuses418. Pregnant women thus risk repeated clinical episodes throughout 
pregnancy and lactation, as well as pre-term, miscarried, and LBW deliveries395, 399, 401, 405-410, 415, 
416. Given the challenges of infection in pregnancy, prevention is clearly preferable. The two 
prevention approaches advocated by WHO in pregnancy are (i) ITN/LLINs, and (ii) IPTp, providing 
a full therapeutic antimalarial course during antenatal visits.  
 
Which approach would be most effective and acceptable for Afghanistan? ITN/LLINs 
demonstrated 40% malaria protection in the case-control study, similar to protection 
demonstrated for Afghan refugee populations in neighbouring Pakistan151. Additionally, the 
community survey confirmed ITN/LLINs were popular and used by all family members52, 115. 
Conversely, persuading pregnant women to take IPTp could be challenging given the perceived 
risks of taking medication during pregnancy. Weighing the limited risk of malaria in pregnancy, 
demonstrable protection and popularity of LLINs, reported avoidance of drugs during 
pregnancy, and still relatively limited data on IPTp for vivax malaria, there seems no real 
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justification to initiate an IPTp strategy in Afghanistan. ITNs/LLINs are a proven preventive 
strategy, which along with rapid diagnosis and treatment, can help protect pregnant women in 
low-endemicity countries such as Afghanistan52. Universal coverage with ITNs/LLINs, such as the 
Global Fund supported initiative providing free LLINs to pregnant women and immunised 
children, should be the preventive strategy of choice for pregnant women in Afghanistan. 
 
Less than half of community survey participants reported household ownership of any ITNs and 
only 20% reported using ITNs the previous night, irrespective of season or socioeconomic status. 
Since this study universal LLIN coverage campaigns have increased coverage to approximately 
80% of high-risk populations12. LLINs can be used for an average 3-5 year lifespan without 
retreatment, and since 2005 WHO has recommended programmes only purchase and distribute 
LLINs443. Health messages should emphasise that LLINs be used by all family members, 
particularly those at greatest risk from malaria. That over 80% of women cited prevention of 
nuisance biting as more relevant than malaria prevention is not necessarily negative, as families 
do use ITNs appropriately when given access246.  
 
Anaemia prevention and treatment policies are already in place in Afghanistan235, 236, 343. Unicef 
is particularly active in nutrition, and nutritional anaemia can be addressed through dietary 
diversification, improved access to foods with high iron bioavailability, and/or staple foods 
fortification438. Approximately 50% of anaemia and 60% of severe anaemia in pregnancy in the 
region appears amenable to iron438, suggesting increased coverage of such programmes should 
help to reduce anaemia in pregnancy. However, more research is needed to determine the 
reasons for the high rates of severe anaemia in pregnancy in this population to provide better 
guidance on other possible prevention and treatment measures.  
 
Limitations 
Low malaria prevalence limited analysis of associations. Community sampling may have 
underestimated malaria prevalence if those ill at home did not participate. However, 
comparison of facility and community samples produced no evidence of bias, indicating surveys 
reflected transmission. Use of febrile outpatient rather than community controls is a limitation, 
as controls may have been previously parasitaemic. A population control, though preferable, 
was not feasible. 
 
Conclusions 
Malaria did not appear responsible for the high prevalence of maternal anaemia detected. While 
malaria prevalence was low, the risk of severe malaria among pregnant women is sufficient in 
Afghanistan to justify specific preventive interventions. Given women’s perceptions of drug 
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usage in pregnancy and the limited transmission risk, an IPTp implementation strategy is not 
justified. Scaling-up LLINs, with increased MOPH emphasis on usage in pregnancy, is likely to be 
more successful in Afghanistan. 
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Overview 
This chapter synthesises and discusses the main research findings from the four studies included 
in this DrPH thesis. The first section synthesises primary findings under the four evaluation 
framework dimensions of: (i) effectiveness, (ii) efficiency, (iii) equity, and (iv) humanity. It draws 
from relevant literature to discuss how findings fit within the broader knowledge base, what 
insights may be possible from bringing together these studies on disparate malaria control 
topics, and how well the framework served to support analysis. The second section discusses 
implications for malaria control, focusing on potential research. The third section describes 
research limitations. The final section provides concluding reflections.  
 
Primary findings 
Results chapters 3 to 6 include four individual studies using different methods and covering 
different topics of programme cost-effectiveness (economic analysis), antimalarial regimen 
effectiveness (clinical epidemiology), malaria prevention and health education (qualitative 
analysis), and malaria in pregnancy needs and responses (clinical and social epidemiology). To 
synthesise key lessons, common themes in these studies are considered below using the ‘four-
dimensional’ framework introduced in Chapter 1 (Figure 1). 
 
Effectiveness  
Effectiveness involves the extent to which identified objectives can be shown to have been met. 
A major question asked about any disease control programme is ‘Are the interventions it 
provides effective, meaning do they achieve programmatic aims and objectives?’ Relatedly, 
what other interventions might be equally or more effective? These questions are primarily 
addressed through epidemiological analyses of statistical associations and causality. Chapters 3, 
4 and 6 included epidemiological analyses of associations between programme interventions 
and outcome indicators. Additionally, qualitative social science analyses can address questions 
about how and why programme objectives may or may not have been met, including context, 
motivations, and politics444. Chapter 5 included qualitative analysis of people’s understanding of 
health and usage of protective measures including ITNs. Thus, the majority of study data were 
related to effectiveness of interventions and all studies included effectiveness measures. This is 
perhaps unsurprising, given study data were originally operational research datasets. This also 
means it is perhaps easiest to answer whether HNTPO’s malaria control initiatives were 
effective.  
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In Chapter 3, the study aim was to determine whether adding malaria prevention using targeted 
IRS to case management using quality-assured microscopy and national first-line treatment was 
a better use of limited resources than case management alone during a prolonged epidemic in 
Afghan refugee settlements in Pakistan. Epidemiological analysis showed that targeted IRS 
averted an estimated additional average of 13,598 vivax cases, 3,716 falciparum cases, 26 
deaths, and 2,545 DALYs annually.  
 
Adding IRS thus clearly appeared effective. However, it is first necessary to consider whether 
another preventive intervention (e.g. ITNs) might have been more effective165, 445. While it was 
not possible to determine this with the data available, further analysis of existing operational 
datasets within Afghan refugee and returnee populations could help (e.g. Dataset 2, on the cost-
effectiveness of adding ITNs to IRS, which was not included in this thesis). However, it remains 
difficult to answer specific queries through secondary analysis of operational datasets and 
further research is warranted. For example, a Cochrane review found limited data from two 
studies in unstable transmission settings, suggesting ITNs gave better protection than IRS in India 
(i.e. malaria incidence risk ratio was 1.48) and South Africa (risk ratio was 1.34 but not significant 
at 0.05)87. Due to increasing resistance globally to the pyrethroids used in ITNs, research on both 
ITNs and IRS is still needed to address efficacy questions. For example, Fullman and others have 
demonstrated additional benefits from combining ITNs with IRS using non-pyrethroid 
insecticides445-447. Further research is thus needed on ITN and IRS effectiveness in the context of 
potential insecticide resistance in Afghanistan and Pakistan93, 448-450. Secondly, findings assumed 
no protective effect of prompt and effective malaria treatment due to lack of data. This 
assumption may be incorrect, in which case IRS results would become comparably less effective 
(e.g. as shown in the sensitivity analysis in Table 6). Further research is needed on the protective 
effect of case management in South Asia and elsewhere. Finally, effectiveness findings alone do 
not give any indication of the costs of IRS or comparable preventive intervention and cost-
effectiveness analysis is necessary. 
 
In Chapter 4, the study aim was to determine whether extended five-day CQ treatment was 
more effective than standard three-day CQ treatment for uncomplicated falciparum malaria 
among Afghan refugees in Pakistan. The study was justified because national treatment 
guidelines recommended extended treatment for all refugee patients returning with symptoms 
within a few weeks of initial three-day treatment, despite increasing CQ resistance in Pakistan 
and a lack of in vivo testing. Thus, HNTPO staff were required to provide a treatment regimen 
that lacked any research evidence to support its usage. Epidemiological analysis showed that 
84% of patients receiving three-day treatment versus 51% of patients receiving five-day 
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treatment experienced parasite recrudescence during follow-up (AOR 0.17, 95%CI 0.08-0.38). 
Thus, cure rates were significantly improved with the five-day regimen, particularly among 
adults, though fever and parasite clearance times and proportions gametocytaemic post-
treatment were similar between treatment groups. As second-line, the five-day regimen 
resulted in higher failure rates than as first-line. Finding the CQ-resistance marker pfcrt 76T in 
all isolates analysed, and pfmdr1 86Y and 184Y in 18% and 37% of isolates respectively, indicated 
that CQ resistance would worsen321, 331.  
 
Implementing the extended-dose regimen was thus demonstrated to be ineffective, indicating 
an urgent need to consider and potentially revise national malaria treatment policy. In this case, 
HNTPO took on the role of advocating for changes in first-line treatment policy, which occurred 
regionally around 2006, and for improvements in policy uptake, which has been slower and is 
still ongoing in South Asia91, 451-453.  
 
In Chapter 6, the study aim was to determine whether malaria in pregnancy was a significant 
enough concern for Unicef and WHO, the study funders, to recommend chemoprevention for 
pregnant women in Afghanistan in addition to prioritised ITN usage. Clinical and social 
epidemiological analyses of data in the three chapter sub-studies provided a coherent picture. 
First, among 517 delivery-ward participants, one malaria case (prevalence 1.9/1,000), 179 
anaemia cases (prevalence 346/1,000), with 12 severely anaemic (prevalence 23/1,000), and 59 
LBW deliveries (prevalence 107/1,000) were detected. Second, among 141 malaria cases and 
1,010 controls, no association was found between malaria infection and pregnancy (AOR 0.89; 
95%CI 0.57-1.39), parity (AOR 0.95; 95%CI 0.85-1.05), age (AOR 1.02; 95%CI 1.00–1.04), or 
anaemia (AOR 1.00; 95%CI 0.65-1.54). However, 45/141 (32%) cases and 431/1,010 (43%) 
controls reporting ITN usage indicated ITNs provided 40% reduced odds of malaria infection 
(AOR 0.60; 95%CI 0.40-0.91). Third, among 530 community survey participants, malaria and 
anaemia prevalence were 3.9/1,000 and 277/1,000 respectively, with 34/1,000 experiencing 
severe anaemia. While RDTs may have detected sub-microscopic infections, it is not clear, given 
the low levels of malaria detected overall and lack of malaria immunity in study areas, whether 
using RDTs would have increased numbers significantly. However, Leslie et al showed that RDTs 
could improve malaria diagnosis in low transmission areas in Afghanistan92. Despite most 
women having no formal education, malaria knowledge was high, but most expressed 
reluctance to take malaria preventive medication during pregnancy as they considered it 
potentially unsafe.  
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Implementing chemoprevention was thus demonstrated to be unnecessary and therefore 
ineffective. In this case, HNTPO control programme staff advocated for a nuanced and 
contextually-appropriate approach to IPT roll-out globally and that IPTp not be implemented in 
Afghanistan. WHO now only recommends chemoprevention in areas of moderate-to-high 
malaria transmission in sub-Saharan Africa10. Less progress has been apparent in anaemia 
prevention, which remains ‘one of the most intractable public health challenges in South Asia’454. 
Anaemia is typically due to nutritional deficiencies, infectious diseases, or genetic haemoglobin 
disorders. While relatively little of the anaemia detected in Chapter 6 appeared to be due to 
common infections (i.e. malaria, worms), it seemed probable that a significant proportion was 
due to undernutrition or genetic disorders, which  were not normally diagnosed in these remote 
and resource poor areas454. While both countries have made progress with iron 
supplementation programmes, the minimal improvements demonstrated suggest that these 
have either been insufficiently implemented or that genetic causes are a more significant 
contributor454. For example, β-thalassemia is one of the most common haemoglobin disorders 
in Pakistan, with a carrier rate of 5-8%455, 456.  
 
Generally, research questions related to how and why interventions succeed or fail draw from 
social science approaches. Chapter 5 included social science analysis that allowed for qualitative 
assessment of the effectiveness of programme interventions225. The study was conducted as 
part of efforts to identify and explore socioeconomic determinants of ITN purchasing and usage 
so as to help increase ITN coverage, as ITN social-marketing was the primary malaria prevention 
intervention in Afghan communities115. Qualitative analysis indicated that health education 
interventions had increased malaria knowledge and motivation to purchase ITNs, though there 
remained some confusion about different prevention initiatives (e.g. the common perception 
that the reason for boiling water was to kill the mosquitoes breeding in it and thus prevent 
malaria and typhoid).  
 
Implementing behaviour-change communication, through health education sessions and social-
marketing of ITNs, was thus shown to be effective in improving malaria-related knowledge and 
the desire to own ITNs among targeted communities. It is worth noting, that while Chapter 6 
included social epidemiology – which quantitatively analyses social determinants and the 
dynamics between social context and health457 – only one of the four studies (Chapter 5) 
included data that allowed for qualitative social science analysis. HNTPO set-up a social research 
unit in 2001, though organisational expertise was generally stronger in quantitative research. 
This may have had implications for other interventions. For example, a qualitative component 
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could have helped determine the value of women’s unpaid work in Chapter 3 or explore reasons 
for the fear of chemoprevention reported by women in Chapter 6.  
 
Efficiency 
The second question usually asked about a programme is ‘Do the interventions provide value-
for-money?’ Such questions are addressed through economic analysis of intervention costs per 
outcome of interest. As with qualitative analysis, only one of the four studies (Chapter 3) 
included data that allowed for economic analysis. However, in this case it was not due to the 
lack of other economic datasets but rather a pragmatic decision to include only the largest and 
most relevant economic dataset.  
 
Chapter 3 included economic assessment of the cost-effectiveness, or economic efficiency, of a 
programme intervention224. Economic analysis showed that the additional cost of including IRS 
over five years per case averted was US$39; US$50 for vivax (US$43 in years 1-3, US$80 in years 
4-5) and US$182 for falciparum (US$139 in years 1-3 and US$680 in years 4-5). Per DALY averted 
this was US$266 (US$220 in years 1-3 and US$486 in years 4-5). Cost-effectiveness thresholds 
used were the somewhat aspirational WHO threshold of 1 and 3 times GDP per capita and the 
lower but less well-known threshold proposed by Woods et al of US$87-669 for Pakistan296, 299. 
 
Adding targeted IRS to routine case management was thus shown to be cost-effective using both 
WHO and comparison thresholds. The intervention was ‘highly cost-effective’ using the WHO 
threshold of 1xGDP per capita (i.e. US$479 for Pakistan in year 0) per DALY averted when 
averaged over five years and in years 1-3. This reduced in years 4-5, as the epidemic came to an 
end, but remained cost-effective at the WHO threshold of 3xGDP per capita (i.e. US$1,436 for 
Pakistan) per DALY averted296. The intervention remained cost-effective over all time-periods 
using Woods et al’s threshold299. However, as noted in the Effectiveness sub-section above, it is 
necessary to consider whether another preventive intervention (e.g. ITNs) might have been 
more cost-effective. For example, in a systematic review White et al found the median 
incremental cost effectiveness ratio per DALY averted was $27 (range $8.15-$110) for ITNs 
versus $143 (range$135-$150) for IRS, indicating ITNs are more cost-effective in some 
contexts303. Secondly, findings assumed no protective effect of prompt and effective malaria 
treatment, which may have overestimated IRS cost-effectiveness. Sensitivity analysis showed 
that increasing cases averted by case management from zero to 30% and 50% increased ICER 
costs from US$39 to US$56 and US$78 respectively, while reducing cases prevented by 50% 
increased ICER costs to US$79, which were notable reductions in cost-effectiveness.  
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Equity 
A third question that is often asked about an intervention is ‘Is it equitable?’, or more 
specifically, ‘How well does the intervention address principles of equality, fairness, and 
distributive justice?’ The principle of fairness is sometimes explained in terms of equality (i.e. 
uniform distribution), in which everyone has equal access to healthcare resources, but is more 
accurately explained in terms of equity, in which socially marginalised individuals are provided 
with additional opportunities to help redress chronic disparities458. Cromwell notes that while 
equality is a descriptive concept (i.e. two or more groups are equivalent when compared by one 
or more measure), equity is a moral concept that requires adoption of an explicitly ethical 
framework for its evaluation459. Thus, Braveman and Gruskin consider equity inherently 
normative120, 460. Distributive or social justice, the principle that costs and benefits are allocated 
fairly according to either contribution or need, is increasingly important in the bioethics and 
healthcare literature125, 461-463. It is commonly referred to in terms of horizontal equity, i.e. people 
in equivalent circumstances are treated equally, and vertical equity, i.e. people in different 
circumstances are treated differently to improve fairness125.  
 
Arguably, the two most common measures used in assessing equity of health interventions are 
equality of access (e.g. equal access to an intervention among groups) and equality of usage (i.e. 
equal provision and usage of an intervention among groups). The social variable that was both 
considered relevant and with data available from which to consider equality of access was 
socioeconomic status. Chapters 5 and 6 included some examination of equality of access to 
programme interventions.  
 
Quantitative data analysis, conducted previously by the investigator, demonstrated that Afghan 
households in the richest socioeconomic quartile had 4.5 times higher odds of owning ITNs than 
those in the lowest quartile115. Qualitative analysis in Chapter 5 supported quantitative findings 
that the poorest struggled to afford ITNs, even at subsidised prices. Thus, findings demonstrated 
that equality of access to ITNs through social-marketing was not sufficient to enable distributive 
justice for the poorest and that alternative or additional distribution strategies that contributed 
to vertical equity in relation to socioeconomic status (e.g. additional targeted subsidy) were 
needed. Alternatively, free mass distribution of ITNs - as a means of increasing horizontal equity 
- would also likely improve access for the poorest.  
 
Chapter 6 used a similar asset index to show that women from poorer and wealthier households 
had similar malaria knowledge and reported behaviours (Table 19). This suggested that equality 
of access and usage in relation to socioeconomic status were sufficient for health education and 
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case management interventions, both of which were free to service-users. Thus, these 
horizontal equity initiatives (i.e. in that all had access to free health education and case 
management, regardless of socioeconomic status) appeared effective, in that they appeared to 
work as intended and not exclude any of the socioeconomically marginalised groups included in 
assessment.    
 
It is perhaps worth noting that Table 19 shows children were prioritised for sleeping under ITNs 
among lower-income households where ITNs were insufficient to cover everyone, while other 
age groups were not. This may indicate that children were considered most vulnerable and/or 
most valued in households. Health education messages encouraged prioritisation of under-five 
children and pregnant women to sleep under ITNs. However, though numbers were too small 
to determine significance, Table 19 gives no indication that women were prioritised to sleep 
under available ITNs in poorer households when ITNs were insufficient to cover everyone (i.e. 
no women, or 0%, in poorer households versus 11 women, or 6.9%, in wealthier households). 
Therefore, though data were insufficient to be definitive, it appears that health education 
interventions contributed to age-related vertical equality of ITN usage in relation to children, 
though not necessarily to gender-related equality of usage. 
 
ITN social-marketing was thus not equitable according to the equality of access measure, as 
poorest households were less likely to have enough ITNs to cover all household members. 
Conversely, health education and case management appeared to contribute to horizontal equity 
using the same equality of access measure. HNTPO had initially selected a social-marketing 
approach for ITNs, as a means of maximising coverage due to low funding levels115. On finding 
that social-marketing did not reach the poorest, HNTPO began experimenting with targeted 
subsidies. However, national policy has since changed to free mass distribution of ITNs in both 
Afghanistan and Pakistan, primarily enabled by significantly increased international funding due 
to the launch of GFATM. Thus, there was no opportunity to test the effectiveness of these 
subsidies and research is needed to determine whether mass interventions intended to improve 
horizontal equity (e.g. free IRS and ITN distribution) are able to sufficiently improve equality of 
access and usage of malaria control interventions among the most marginalised Afghan refugees 
and returnees or whether additional vertical approaches are needed.  
 
As the global universal health coverage movement gains momentum and countries work to 
achieve the SDG3 target on ‘universal health coverage, financial risk protection, and access to 
quality essential healthcare services, safe, effective, quality, and affordable essential medicines 
and vaccines’464 greater efforts will be required to address health equity in redistributive rather 
Howard N: Malaria control for Afghans (1990-2005) 127 Chapter 7 
than merely equivalent ways113, 122-124. For example, this might require more engagement 
between health and non-health sectors (e.g. education, labour) to address the root causes of 
the income inequities that contribute to health inequities.  
 
Humanity 
A fourth question is ‘Are interventions humane (e.g. do they support the humanity of 
participants)?’, or more specifically, ‘How well does the intervention address the principles of 
autonomy, justice, beneficence, and dignity?’ Smith et al noted that exploring humanity in public 
health interventions involves assessing the “social, psychological, and ethical acceptability of the 
way people are treated”198. As described in Chapter 1, the five generally agreed principles of 
humanity are autonomy, the right to informed choice; beneficence, choosing to do good; non-
maleficence, avoiding harm; dignity, the right to respect; and justice, the right to fair 
treatment138, 217, 465. Humanity principles are not routinely measured in public health 
interventions in low and middle-income countries, which is unfortunate given their 
importance142, 466. As Smith et al noted, the humanity of programme interventions is most 
obvious in its absence198.  
 
One reason humanity principles are seldom included explicitly may be that their assessment still 
requires further development. Early assessments of humanity relied on satisfaction surveys, but 
these were criticised both methodologically (because survey instruments had poor 
psychometric properties and satisfaction correlated poorly with humane treatment) and 
theoretically (because satisfaction is poorly defined)465. Humanity is now most commonly 
assessed through data on service-user perspectives and experiences, using surveys, in-depth or 
semi-structured interviews, and observation. A second reason may be that the role of humanity 
still lacks consensus among public health practitioners, particularly individual autonomy versus 
communal health benefit467, 468. As Kass indicated, autonomy cannot be assumed as a priority 
for public health in the same way that it is for biomedical practice467. For example, interventions 
that require sufficient coverage to provide communal benefit (e.g. vaccination, ITNs) work best 
when all those at risk access and use them. However, while compulsory vaccination has been 
debated, and enacted in some countries (e.g. in the UK against smallpox in 1853), no similar 
debate on enforcing ITN usage seems likely469, 470. Malaria control interventions are not generally 
conducive to legal mandate and rely on informed choice among community members to be 
implemented effectively. Additionally, malaria control and research generally occurs in low-
income settings, often conducted or overseen by those from very different socioeconomic and 
cultural backgrounds, which could allow opportunities for mistakes or even exploitation if 
providers were given powers to enforce usage. Therefore, autonomy and other humanity 
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considerations remain relevant to malaria control programmes. Malaria control, as a public 
health intervention, should ‘minimise unnecessary burdens on the population while fulfilling the 
mandate to improve population health and reduce social health inequalities’471.   
 
As assessment of the humanity of interventions is not routinely or explicitly included in research, 
it was more challenging to examine retrospectively than other dimensions and findings were 
more ambiguous. The investigator did not have the opportunity to include humanity assessment 
measures in survey questionnaires and interview guides. Additionally, and perhaps more 
relevantly, the literature provided limited guidance on how to correlate service-user experience 
with humanity principles or determine thresholds of humanity in health interventions465. Based 
on available guidance, the investigator correlated humanity principles with the following 
measures: (i) autonomy with measurements of perceived independence and informed choice; 
(ii) beneficence with provision of the best available interventions; (iii) non-maleficence with 
service-user safety; (iv) dignity with perceived respectful treatment; and (v) justice with equality 
of access or usage, as described above under Equity, and reciprocity in providing benefits to 
those being studied125, 466. Chapters 5 and 6 included elements of the humanity of programme 
interventions223, 472.  
 
Consideration of autonomy was most feasible in terms of gender and socioeconomic status, and 
consisted of determining whether men and women of all socioeconomic levels perceived 
themselves able to make informed choices about accessing and using prevention and treatment 
interventions. Quantitative analysis of survey data in Chapter 6 showed most women service-
users (78%) said they preferred malaria treatment at ‘NGO/government’ facilities run by HNTPO 
and preferred a malaria blood test (70%), as opposed to the clinical diagnoses often provided at 
private facilities (Table 19). Another indication of malaria services at HNTPO-supported facilities 
being valued was that wealthier women were somewhat less likely to seek treatment for non-
malaria issues at these facilities (e.g. 69% of wealthier versus 82% of poorer women). Most (81%) 
also identified ITNs as the best malaria prevention intervention during pregnancy. This 
suggested that both lower-income and higher-income women considered themselves able to 
choose appropriate case management and prevention interventions, though not necessarily to 
access or use them. Qualitative analysis of interview data in Chapter 5 showed that men and 
older women often made access and usage decisions for other household members. Thus, 
younger women had less autonomy than men and some older women in terms of choosing how 
to prevent or treat malaria. However, data were insufficient for further interpretation or to 
suggest any action that HNTPO might have taken to mitigate this.  
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Beneficence and non-maleficence related to HNTPO policy and practices and could not be 
considered through the available data on service-user perspectives. Consideration of 
beneficence consisted of determining whether HNTPO ensured provision of the best available 
interventions. Critical comparison of WHO global and regional guidelines and HNTPO research 
outputs indicated that operational research had been conducted on all major and some 
relatively obscure (e.g. cattle sponging) malaria control interventions to determine the most 
effective interventions for populations served. Assessment of non-maleficence consisted of 
determining that HNTPO only implemented prevention and treatment interventions that were 
deemed safe according to national and international standards. Economic analysis of HNTPO 
costs indicated that routine procurement of prevention, diagnostic, and treatment equipment 
and supplies adhered to standard practice and nothing was deemed to be unusual or worthy of 
particular concern.   
 
Consideration of dignity consisted of determining whether men and women perceived that their 
choices about whether and how to engage with malaria control interventions were respected. 
Data were insufficient and qualitative analysis did not provide any findings in relation to 
perceived dignity. However, it additionally did not raise any concerns around this issue.   
 
Consideration of justice first consisted of determining whether men and women of all 
socioeconomic levels experienced equality of access to prevention and treatment interventions. 
Thus, qualitative analysis of interview data suggested concerns around justice, due to difficulties 
expressed by the poorest in affording ITNs (discussed above under Equity), though no similar 
concerns were expressed by participants about IRS, which was free to service-users. Both 
qualitative and quantitative data indicated that participants were satisfied with malaria 
prevention, whether using IRS or ITNs, if the costs of ITNs were to be addressed. No data were 
available related to the justice of case management interventions. Second, consideration of 
justice consisted of determining whether reciprocity for study participants (e.g. non-financial 
tokens of appreciation for their contributions) was discussed or practiced. This did not seem to 
be HNTPO policy, which instead appeared to favour an ‘ethic of the common good’ (e.g. 
participant cooperation and short-term sacrifice so as to increase community health benefits in 
the longer-term)473, 474. However, to avoid any accusations of paternalism or lack of pluralism 
and increase opportunities for community ownership and perceived justice, this is something 
that could be debated explicitly in future475, 476.   
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Available data thus indicated that interventions partially addressed humanity and appeared 
generally humane, though more data were needed to allow explicit assessment of one or more 
humanity principle.    
 
HNTPO interventions and the evaluation framework 
Synthesising results from the four studies and relevant literature raised three issues. First, it 
indicated that HNTPO interventions could be related to and potentially score well on all 
dimensions of the evaluation framework. Second, it suggested that while the framework was 
useful, further development of tools and consensus on measurement and thresholds would 
make it more useful for use by implementing agencies. Third, it demonstrated that operational 
research could be used to address academic research questions.  
 
Considering each dimension of the framework appeared to be a useful exercise in that it helped 
delineate and provide greater depth to evaluation aspects such as equity and humanity that 
were not explicitly considered within individual studies. However, the framework did not 
provide guidance on measurement methods or achievement thresholds and therefore analysis 
remained overly subjective.  While this framework is not new, further research is clearly needed 
for the framework to be useful and useable. First, only the efficiency dimension includes a 
measurable threshold and even these widely used cost-effectiveness thresholds are the subject 
of ongoing debate299. Second, more evidence is needed on evaluating the five aspects of 
humanity in terms of: (i) whether these can be ranked/prioritised or should always be included 
and weighted equally; (ii) measurable thresholds; and (iii) systematic and more easily replicable 
methods to gauge relevant participant experiences and correlate them with the different 
elements of humanity. The principles of humanity are not new either198. However, no articles 
were found that included the five principles explicitly in a low or middle-income country 
healthcare intervention evaluation context.  
 
Other evaluation frameworks were considered, as discussed in Chapter 2, particularly that of 
Reeve et al, which looks promising for adaptation in future research (Figure 12). An strength of 
Reeve et al’s framework over Black and Gruen’s used here, is that it explicitly considers external 
factors affecting the programme such as donor interest and funding availability, national policy, 
and global priorities (e.g. Key Foundations, Fundamental Enablers in Figure 12).   
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Figure 12. Reeve et al’s health service evaluation framework 
 
Source: Reeve et al261 
 
External factors affected the malaria control programme significantly, including the chronic 
conflict in Afghanistan, governance issues, constrained donor funding during the study period, 
and competing health priorities (e.g. maternal health, leishmaniasis). While these effects could 
not easily be measured, they could be considered qualitatively.  However, while interesting for 
future research, Reeve et al’s framework was deemed overly complex and possibly inflexible for 
secondary analysis of operational datasets and did not explicitly include either equity or 
humanity. Both equity and humanity seem particularly important evaluation concerns when 
working with vulnerable populations in conflict-affected and resource-constrained settings, such 
as Afghan refugee camps and returnee villages. None of the other frameworks considered 
appeared better (Table 2).  
 
Black and Gruen’s framework, despite its overall simplicity, enabled deeper analysis of these old 
operational datasets and discussion of equity and humanity issues not routinely considered in 
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public health interventions. This supports the potential for even relatively simple evaluation 
frameworks to guide and support secondary analyses of operational data.   
 
A number of public health ethics frameworks and guidance questions (e.g. Table 20) have been 
developed to support equity and humanity considerations within public health467, 468, 471, 477. 
These can be used to guide future malaria control programme development, and thus improve 
implementation and evaluation of equity and humanity considerations. Table 20, for example, 
provides a list of ethics questions for public health interventions – including autonomy, justice, 
beneficence, and non-maleficence - to help ensure they are equitable and humane.  
 
Table 20. Public Health Ontario public health ethics questions 
No Question 
1 What are the objectives of the initiative? How are they linked to potential improvements in public 
health?  
 − A clear link must be provided between the initiative and potential public health improvements; 
potential benefits may be immediate or future. Collection of data where public health value is more 
speculative may be permissible with justification. 
 − This question serves as an anchor for review, as many of the questions below relate back to the original 
objectives. 
2 Can the objectives be achieved using the proposed methods? 
 − Initiatives lacking sufficient methodological rigour may lead to data that is of poor quality or invalid, 
wasting resources and potentially causing potential harm through misinformation. 
 − Requirements for scientific rigour must be balanced with sensitivity to the context in which an activity 
is implemented. 
 − Judgment regarding the design of an initiative requires relevant methodological expertise as well as 
some knowledge about the participating populations and other contextual details, as relevant. 
3 Who are the expected beneficiaries of the knowledge gained or other benefits?  
 − Beneficiaries may include individuals and/or communities, whether or not they are directly 
participating in the proposed initiative. 
 − Individual and collective interests may be shared or competing, or both, depending on the 
circumstance. 
4 What are the burdens and potential harms associated with the proposed initiative? Who bears them?  
 − Harms associated with evidence generation in public health frequently arise from collection, use or 
disclosure of information; potential consequences include stigmatization, discrimination, psychological 
distress or economic loss. Other harms, such as threats to health, may also occur. 
 − Burdens generally are borne by those participating in an initiative. Harms may affect individuals and/or 
communities, whether or not they are directly participating in the proposed initiative. 
 − Potential harm to relationships should be considered. 
 − Where possible, an effort must be made to mitigate or minimize risks and burdens, balancing against 
any loss in potential benefit. 
5 Are burdens and potential harms justified in light of the potential benefits to participants and/or to 
society?  
 − Burdens and potential harms should be weighed against not only potential benefit from conducting an 
inquiry, but the harm in not carrying out that inquiry. 
 − Burdens or harms may accrue to different individuals/groups than those receiving the benefit but, 
where this is the case, there should be some justification. 
 − “Fair procedures” such as transparency and stakeholder participation should be used to guide decision 
making regarding balancing of burdens, harms and benefits. 
6 Is selection of participants fair and appropriate?  
 − Fair distribution of burdens, risks and potential benefits includes paying special attention to vulnerable 
or disadvantaged populations, to be included where there is potential benefit, excluded where certain 
groups face greater burden or risk, or preferentially included because of increased probability or 
magnitude of benefit. 
 − The principle of reciprocity requires finding ways to give back to individuals or communities that bear a 
disproportionate share of burden or risk for the benefit of others. 
7 Is individual informed consent warranted? Is it feasible? Is it appropriate? Is it sufficient?  
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 − While important, individual autonomy does not always take priority over other ethical concerns, such 
as welfare of populations. 
 − For many public health initiatives, obtaining individual consent may not be required, feasible or 
appropriate. Where departure from individual informed consent is proposed, consider alternatives such 
as broad consent, notice with opt out, and consultation with a representative sample of the population 
of interest. 
 − In certain cases, such as examination of illegal behaviour, alternative approaches such as use of verbal 
consent or pseudonyms may be appropriate. 
8 Is community engagement warranted? Is it feasible? What level of engagement is appropriate?  
 − Community engagement is encouraged where feasible and might be used in lieu of, or in addition to 
individual consent. 
 − Engagement may range from informing to consultation, collaboration and empowerment. 
 − Community engagement may include some form of collective consent or consensus process authorizing 
the initiative in the community. 
 − Challenges include determining what level of engagement is appropriate, what counts as a community, 
and who the appropriate representatives are. 
9 What are the social justice implications of this initiative?  
 − Projects that reinforce existing inequities should be avoided and opportunities to promote social justice 
should be considered where possible. 
 − Extra resources or special measures may be needed to promote social justice, for example to ensure 
that disadvantaged groups are appropriately considered in the development of project objectives, or to 
remove barriers to their participation in public health initiatives. 
10 What are the potential longer-term consequences?  
 − Where possible, potential negative long-term consequences of an initiative should be considered and 
plans for mitigating these risks should be developed prior to implementation. 
 − Community engagement can be helpful both in identifying potential long-term harms, and in devising 
methods to address them. 
Source: Willison et al466 
 
Operational research was shown here to have considerable value, as even these old datasets 
maintained relevance for today. Operational research needs to demonstrate relevance and 
value by improving policy and practice221. It is particularly useful in settings often considered too 
challenging for academic research, e.g. Afghanistan, which was affected by ongoing conflict at 
the time of data collection220. Good quality operational research is not only relevant to public 
health but can support academic enquiry, by: (i) improving the quality and effectiveness of 
existing treatment or prevention outcomes, (ii) assessing the feasibility of new approaches or 
interventions in specific settings or populations, and (iii) advocating for policy change based on 
findings218. HNTPO malaria research was robust enough to be able to do these three things.   
 
Implications and recommendations   
While the studies in this thesis covered disparate topics, all were conducted as part of 
operational research for HNTPO’s malaria control programme for Afghans living in northwest 
Pakistan and Eastern Afghanistan and contribute to a coherent body of research on malaria 
control in the two countries. Specific implications for policy and practice have already been 
discussed within each study chapter. Therefore, this section focuses on research implications in 
relation to the four evaluation dimensions.   
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Effectiveness  
Findings contribute to the knowledge base on effectiveness of targeted IRS, ineffectiveness of a 
five-day treatment regimen against pfcrt 76T allele-related CQ resistance, and the effectiveness 
of locally relevant health education and behaviour change communication. Implications of these 
findings for both policy-makers and practitioners include the importance of relying on data 
rather than assumptions (e.g. that refugees would not take the correct antimalarial dosages) 
when determining treatment policy, the need to ensure effective drug resistance surveillance, 
and the potential benefits of long-term health education initiatives. The diversity of implications 
related to effectiveness, that cannot all be included here, is partially an indication of the 
prominence of effectiveness research in comparison to other dimensions. While more research 
can certainly be recommended, it appears particularly relevant to recommend a balance of 
research efforts between the four dimensions.   
 
Efficiency  
Findings contribute to the knowledge base on cost-effectiveness of targeted IRS in low-
endemicity vivax-dominant settings in South Asia. As national policy already includes the usage 
of targeted IRS, the main implications of these findings involve the need for additional research, 
particularly to determine whether ITNs might provide more cost-effective prevention than IRS 
does in these countries. Analysis of existing HNTPO economic datasets comparing ITNs to IRS 
and different insecticide formulations in Pakistan, and static versus mobile distribution of ITNs 
in Afghanistan, is needed to provide a more comprehensive understanding of programme 
efficiency.   
 
Equity  
Findings contribute to the knowledge base on equality of access to ITNs, case management, and 
health education. These findings supported earlier socioeconomic findings115 in implying that 
the primary barrier to ITN purchasing and usage in these Afghan communities was price, 
indicating that social-marketing could not effectively distribute ITNs to the poorest and free or 
more affordable targeted mechanisms were likely necessary to increase coverage. Since the 
time of the study, mass distribution of ITNs free to high-risk service-users has become national 
policy. Therefore, instead of recommending increased access it would be worthwhile to evaluate 
the equity of existing ITN distribution initiatives to ensure that all those in need at all 
socioeconomic levels can access effective malaria prevention under existing policies121. 
Additionally, it would be useful to collect and analyse data on Mooney’s other measures of 
equity, for example: (i) equality of expenditure per capita, (ii) equality of inputs per capita, (iii) 
equality of input for equal need, (iv) equality of marginal met need, and (v) equality of health212. 
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All, except perhaps the last of these, would require economic data, which supports the need for 
explicitly considering equity in economic analyses of malaria control interventions.  
 
Humanity  
Findings contribute to the knowledge base on the humanity of malaria control interventions 
through an initial attempt to correlate five principles of humanity with measurable aspects of 
service-user experience and provider action. These include: (i) autonomy with perceived 
independence and informed choice; (ii) beneficence with provision of the best available 
interventions; (iii) non-maleficence with service-user safety; (iv) dignity with perceived 
respectful treatment; and (v) justice with equality of access and usage125. Further research is 
needed to test and improve upon this initial attempt. The main recommendation is that 
individuals and organisations engaged in research, particularly in low-income and conflict-
affected countries where issues of humanity can be particularly crucial, strengthen the 
knowledge base by incorporating measurement and analysis of humanity and equity indicators 
within their studies.  
 
Limitations 
General limitations  
A major limitation of using secondary data was that data did not always answer specific research 
questions directly478. Since the DrPH investigator did not collect data for all of the studies 
included (i.e. studies in Chapters 3,4, components of Chapter 6), she had minimal control over 
variables included in the datasets or how these were initially categorised. Thus, there were gaps 
in some datasets (e.g. particularly those used in Chapter 3) that could not be reconstructed 
retrospectively. This limitation was mitigated by adjusting analytical approaches where 
necessary and excluding variables or categorisations that could not be interpreted or replicated. 
 
A second major limitation was that the DrPH investigator could not always determine how or 
how well data had been collected478. For example, it was not always apparent how quantitative 
socioeconomic data might have been affected by observer or responder biases, such as 
participant misunderstanding of interview questions or assumptions about what interviewers 
were looking for (e.g. expenditure and mortality surveys in Chapter 3, community survey in 
Chapter 6). To address clarity issues, the investigator checked with field supervisors and data 
collectors where possible and made assumptions or estimations when data collectors were not 
available or did not remember. To help mitigate issues around potential information bias, results 
on perspectives and reported behaviours from studies in which the investigator did not 
supervise data collection were compared with those for which she did, and no notable 
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differences were found using this approach115, 225. Assumptions and estimations drew from the 
investigator’s own experience in Afghanistan and working with the HNTPO malaria control 
programme and discussion with senior HNTPO researchers, including Professor Mark Rowland, 
Dr Toby Leslie, and Naeem Durrani.  
 
A third general limitation was that data on equity and humanity dimensions were relatively 
minimal. As data included in this thesis had not been published previously, it was thus deemed 
requisite to focus sub-study analysis and write-up on publishing each study as a stand-alone 
article addressing original or adapted research objectives. Primarily, this meant that 
effectiveness received much greater focus than efficiency, equity, or humanity, both because 
the data were able to address this dimension most clearly and because findings that may have 
informed equity or humanity dimensions were generally less comprehensive or clear and 
therefore not included in the final versions for publication provided here as chapters. This 
limitation was mitigated somewhat through the data synthesis and interpretation included in 
this discussion chapter. However, the general lack of data that could be used to analyse equity 
and particularly humanity remains a limitation.   
 
A final general limitation is that study chapters were published in different years and therefore 
grounded in the knowledge and literature of their respective publication years. For example, 
Chapter 5 was published in 2010, Chapter 4 was published in 2011, Chapter 6 was published in 
2015, and Chapter 3 was published in 2017. This limitation was mitigated by updating the 
literature included in study chapters and inclusion of recent literature and changes in policy and 
practice in the introduction and discussion chapters.  
 
Specific sub-study limitations 
The main limitations in the economic study (Chapter 3) were the need to rely on unsprayed 
settlements as the best control available retrospectively and lack of suitable control for case 
management, which meant cases prevented by diagnosis and treatment had to be estimated at 
zero; low numbers of falciparum cases and lack of reliable mortality data, which could have 
reduced the accuracy of estimations for deaths and DALYs averted; lack of disaggregated age 
and sex data for calculating women’s time and life-years directly; and lack of agreed cost-
effectiveness thresholds299. This was the oldest data, from 1997, so it is perhaps unsurprising 
that there were several important limitations to consider. Limitation were mitigated by 
considering each in a univariate sensitivity analysis, to identify how sensitive results were to 
uncertainty and how they would be affected by changes in specified assumption or data 
parameters479, 480.   
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The main limitations in the clinical trial (Chapter 4) were relatively small sample size, lack of PCR 
genotyping to distinguish between recrudescent and new infections, and lack of adherence 
measurement. Limitations were mitigated through drawing on supportive findings from similar 
research (e.g. Leslie et al’s findings that fewer than 5% of infections were new329 and that 
Afghan’s adhered to much longer fourteen-day regimens342).  
 
The main limitations in the qualitative study (Chapter 5) were time constraints limiting the 
number of possible interviews; access restrictions (e.g. geographical, security), as roads were 
very poor and Taliban commanders had to approve travel to avoid unwanted killing or detention; 
and sensitivities around certain topics (e.g. gender, finances). Limitations were mitigated 
through meetings with commanders to discuss the study and research aims, training and close 
supervision of data collectors and interpreters, and discussing interpretations of interview data 
and socio-cultural issues with the research team.  
 
The main limitations in the epidemiological study (Chapter 6) were the low malaria incidence in 
pregnant women that restricted the type and depth of analysis that could be conducted; usage 
of febrile outpatients as controls in the case-control sub-study, as controls may have been 
previously parasitaemic; and the need to rely on prevalence rather than incidence data. 
Limitations were mitigated primarily through comparative ‘triangulation’ of results between the 
three different sub-studies included in Chapter 6. 
 
Conclusions 
First, HNTPO has supported, implemented and researched malaria control for Afghans in 
refugee settlements in Pakistan and villages in Afghanistan for over 25 years. During that time, 
staff have  conducted operational research and provided evidence-informed prevention and 
treatment services to people in desperate need. The four studies included here reflect some of 
the diversity of this body of research. While this thesis cannot, and did not aim to, draw overall 
conclusions on the effectiveness, efficiency, equity, and humanity of HNTPO’s overall 
programme, consideration within the four-dimensional framework suggests that the 
interventions included here can be considered generally successful in terms of all dimensions of 
effectiveness, efficiency, equity, and humanity. While more analysis of economic data and more 
research on aspects of equity and humanity is required, available evidence indicates solid 
achievement.  
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Second, findings clearly demonstrate that operational research, including secondary analysis of 
datasets collected by implementing organizations, can be a valuable addition to the knowledge-
base and despite limitations robust and academically-relevant findings can be made. 
 
Third, effectiveness, efficiency, equity and humanity appear to be worthwhile dimensions of 
public health intervention evaluation. However, more research is needed to make this 
framework practical and more measurable as an evaluation tool. For example, HNTPO and other 
organisations engaged in operational research in low and middle-income countries particularly, 
could further strengthen both their research and the knowledge base by incorporating 
measurement and analysis of all of these dimensions, rather than just one or two, within each 
research study. 
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Annex 1.1. Chapter 5: FGD guide for people WITH mosquito nets 
Functional Questions (to each participant) 
Names of Participants 
What is the education level of each participant? 
 
Pile Sort Exercises 
Give each of the participants a pile of the cards. 
1. Ownership: Ask each participant to make two piles, one pile of the things that they own or 
have and one pile of the things that they do not have. 
When they have each made their piles then ask them to bring them up and get the recorder to 
record the items from each pile on their record sheet. 
 
2. Ranking:  Now ask the participants to put the cards together into one pile again and to sort 
the pile into the order of the things that they would be most likely to buy if they had extra 
money (or goods to barter and exchange). 
When they have done this get the recorder to record the ranking of the items on the “rank 
order” record sheet. 
 
3. General Discussion of ranking:  Ask the participants why they have ranked the items in the 
order that they have, what are the reasons behind that order? 
 
General Discussion 
Points to Discuss: 
Are mosquitoes a problem in this area? If yes, then at what times of the year? 
What do you do to protect yourself and family from mosquitoes? 
What are the most important health problems in this area? 
Is malaria a problem?  If, yes then where does it rank (i.e., how important is it compared to the 
other common diseases)?  Why? 
How do you catch malaria ? (probe for all the possible ways) 
Who is the most vulnerable to malaria?  Why? 
How do you protect yourself from malaria? 
 
Ask each participant: 
How many nets do you own? (ask each participant individually) 
How long have you had your nets? (ask each participant) 
Who sleeps under the nets in your family? (ask each participant) 
Why is the net given to those people? 
Are the nets used every night?  If no, then when are they used and why? 
 Have you retreated your net?  
If yes, then how often and why did you decide to retreat? (probe to see if own 
decision or if prompted by other family members). 
If no, then why not? 
 
General Discussion: 
So you all own nets – How did you hear about nets? 
 What made you decided to buy the nets? (probe to see if they heard about the nets or 
if some other family member heard and told them about it) 
 Who made the decision to buy the nets? (probe to see if only they decided or if another 
family member asked them to buy the nets) 
 
Show the health education messages and ask:  Have you seen these? 
  What do they say?  What do you think of them? 
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  Do you believe them? 
In your opinion what type of people own nets? (if say rich people then ask what they mean by 
rich) 
In your opinion what sort of people won’t buy nets? 
 
Thank you very much for your time and co-operation, your answers will be very useful to us in 
helping to design better health programmes. 
Do you have any questions for us? 
 
Annex 1.2. Chapter 5: FGD guide for people WITHOUT mosquito nets 
Functional Questions (to each participant) 
Names of Participants 
What is the education level of each participant? 
 
Pile Sort Exercises 
Give each of the participants a pile of the cards. 
1. Ownership: Ask each participant to make two piles, one pile of the things that they own or 
have and one pile of the things that they do not have. 
When they have each made their piles, ask them to bring them up and get the recorder to record 
the items from each pile on their record sheet. 
 
2. Ranking:  Now ask the participants to put the cards together into one pile again and to sort 
the pile into the order of the things that they would be most likely to buy if they had extra 
money (or goods to barter and exchange). 
When they have done this, get the recorder to record the ranking of the items on the “rank 
order” record sheet. 
 
3. General Discussion of ranking:  Ask the participants why they have ranked the items in the 
order that they have, what are the reasons behind that order?  Why is a net in the position that 
it is in? 
 
 General Discussion 
Points to Discuss: 
Are mosquitoes a problem in this area? If yes, then at what times of the year? 
What do you do to protect yourself and family from mosquitoes? 
What are the most important health problems in this area? 
Is malaria a problem?  If, yes then where does it rank (i.e., how important is it compared to the 
other common diseases)?  Why? 
How do you catch malaria? (probe for all the possible ways) 
Who is the most vulnerable to malaria?  Why? 
How do you protect yourself from malaria? 
 
Ask each participant 
What do you do if someone in your household gets sick with malaria? 
Where do you go for treatment? 
What do you buy? 
How much does it cost? 
 
General Discussion:   So if treatment for malaria costs this much, how do you pay for it? If it 
costs so much to pay for treatment wouldn’t it be cheaper to buy a net for 180,000 afghanis to 
help prevent you and your families from getting sick? 
Show the health education messages and ask:  Have you seen these? 
  What do they say?  What do you think of them? 
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  Do you believe them? 
In your opinion what type of people own nets? (if say rich people then ask what they mean by 
rich.  Try to probe to find out what it is that makes these people so different from them) 
In your opinion, what sort of people won’t buy nets? 
In your opinion, is there anything (apart from making them cheaper) that would make people 
buy more nets? 
Thank you very much for your time and co-operation, your answers will be very useful to us in 
helping to design better health programmes. 
Do you have any questions for us? 
 
Annex 2.1. Chapter 5: Interview guide, Jalalabad 
Need: tape recorder, translator, driver 
1. Net Purchasers   (if possible one of each).  Reasons for purchasing (how able). 
 a)   non-landowner 
 b)   husband in Pakistan 
 
2. Net Non-purchasers   (at least one of each).  Reasons for not purchasing (unwilling, or willing 
but can’t) 
a)  widow 
b)  husband in Pakistan 
c)  husband disabled 
 
3. Salespeople  -  who purchases, how? 
 
4. Clinic sales staff   - Who are they selling to? 
1. Net Purchasers 
Why did you decide to buy bednets? 
How often do you use the bednets you purchased? 
How helpful do you consider them? 
Would you like to buy more if you could?  
If yes, what is currently stopping you? 
Do you think that bednets can protect your family’s health?  Why or why not? 
What do you think is the more important problem for your family, mosquito bites or malaria? 
 
When someone in your family is sick, what do you do? 
What are the most significant health problems your family faces? 
How significant a problem is malaria for you and your family? 
Who has had malaria in your household in the past year? 
Was this before or after you purchased bednets?   
If after, where they sleeping regularly under a net? 
What causes malaria?   
What are the ways that you protect your family from malaria?   
What is your main occupation/source of income? 
Do you have other income sources? 
If so, what are they? 
 
*From whom did you buy your nets (clinic, shop, HNI team, etc) 
What was the selling procedure? 
Did everyone get a chance to buy nets that wanted one? 
How did the sellers choose whom to sell to? 
 Was there any favouritism? 
 Who got the nets? 
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Where did you learn about the programme? 
Do you listen to radio? 
 Did you learn anything about it from radio? 
 What can you remember about malaria or nets from the radio programme? 
  Health messages? 
  Story line? 
How would you improve the sales system? 
Did you receive any health messages from sellers? 
 Can you remember them? 
Did you retreat your nets? 
 If not, why not? 
Any problems with the nets or the programme? 
How would you improve the programme/retreatment programme? 
 
2. Net Non-purchasers 
When someone in your family is sick, what do you do? 
What are the most significant health problems your family faces? 
Do you consider malaria to be a significant problem for you and your family? 
Who has had malaria in your household in the past year? 
What causes malaria?   
How do you protect your family from malaria?   
*If you were able to purchase malaria protection for your family, would you do so? 
*What would you like to purchase and why? 
Are mosquitoes a problem for your family? 
How do you protect yourselves against biting insects? 
Do you think bednets are useful?  In what way? 
 
What is your main occupation/source of income? 
Do you have other income sources? 
If so, what are they? 
 
3. Salesmen 
How many bednets have you sold in the past month? 
Who usually buys bednets (what kind of people)? 
What do you think are the main reasons people buy bednets? 
What do you think about the prices that are being charged for bednets? 
Do you own any bednets? 
What do you think is the best reason to have a bednet? 
Do you think that bednets help in malaria prevention?  Why / why not? 
Do you think it makes a significant difference to the bednet if it has been treated with 
insecticide?  Why/ why not? 
What sorts of information if any do you give people when they buy bednets? 
How many people do you think retreat their nets regularly? 
Do you let people purchase items from your store on credit?   
If so, who and what type of items? 
Would someone be able to purchase a bednet on credit? 
 
4. Clinic sales staff 
How many bednets have you sold in the past month? 
Who do you usually sell bednets to? 
What do you think are the main reasons people buy bednets? 
What do you think about the prices that are being charged for bednets? 
Do you own any bednets? 
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What do you think is the best reason to have a bednet? 
Do you think that bednets help significantly in malaria prevention?  Why / why not? 
Are there more effective or cheaper ways to prevent malaria? 
What are the advantages/disadvantages of bednets? 
How much information/explanation do you usually give when someone comes to buy a net? 
How many people do you think retreat their nets regularly? 
Do you think people prefer to buy a net from the clinic or from a private shop?  Why/why not? 
 
What do you tell buyers of nets? 
 What are the health messages? 
 What are the essential messages? 
 How do you deliver these messages? 
Did you receive instructions about how to implement net sales? 
 From whom? 
 When (what year)? 
Who do you sell nets to? 
Do you always have enough nets to satisfy demand? 
How do you prioritise net sales-who is included, who is left out? 
How do you retreat nets-how do you notify people? 
 When-which month? 
Do you have enough insecticide to satisfy demand? 
What comments/ideas do you have about treatment and net sales? 
 
Health Ed: 
Where did you learn about the net programme? 
What messages where given to you? 
Have you seen this health education material before? 
Was it explained to you? 
Can you understand what is being explained in the leaflets? 
Can you explain the leaflets to me? 
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Annex 2.2. Chapter 5: Mosquito net questionnaire, Jalalabad 
 
*NB: formatting and font size have been adjusted. 
Coding: (yes =1, no = 0, I don’t know = 9) 
Questionnaire number: _________ 
Date: __/___/___ 
Interviewer initials: _________ 
 
Village: _________ 
Compound: _________ 
ITN Purchaser / Non-purchaser  
Male / Female head of household 
Name of HH: _________ 
Respondent initials/sex: ____/____ 
Respondent relationship to HH: ________ 
 
1.  SOCIO-DEMOGRAPHIC VARIABLES: 
1.1  Age of head of household:  _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _       _______ 
1.2 Education level of head of household:  _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _       _______ 
 Number of years of primary school?      _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _       _______ 
 Number of years of secondary school?    _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  _      _______ 
 Number of years of university or additional technical training?  _ _ _ _ _ _ _ _ _ _  _ _ _ _ _      _______ 
       1.3 What is the number of occupants in the house? _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _     _______ 
1.4 How many children under age 5 in the house?  _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _      _______ 
1.5  Has your family emigrated, and if so when?                                                                                                                           -
_______   
 
2. SOCIO-ECONOMIC VARIABLES 
2.1  How many rooms in the house?  _______ 
2.2  Does it have a guestroom?          ____ 
 If yes, is it carpeted? ____ 
2.3 Is your house owned or rented? _______ 
2.4 Does the house have electricity?       ____ 
 If yes, do you have a fan? ____ 
2.5 Does the compound have a well?  ____ 
2.6  How many members of the household work? ____ 
2.7 Does anyone in the house own (and if yes, how many?): ____ 
Bicycle____ / Motorcycle____ / Carpet____ / Radio____  
Gold Jewellery____ / Teapot____ / Lamp____ / Pressure cooker____  
2.8 Do you support any family members beyond your parents, spouse and children? ____ 
If yes, how many? _______ 
2.9 Do you employ staff? ____ 
If yes, how many? ____ 
How many months of the year do they work for you?  _______ 
2.10 Do you own land? ____ 
If yes, how many jerebs? _______ 
2.11 Do you rent any land? ____ 
If yes, how many jerebs? _______ 
2.12 Do you lease land to others?  ____ 
If yes, how many jerebs? _______ 
2.13 Does any family member work on someone else’s land? ____ 
 Never / Sometimes (seasonal) / Always   
2.14 What are the three main crops that you grow?  
1.  ____________________ 
2.  ____________________ 
3.  ____________________ 
2. 15 Is the food you grow enough to support your family? ____ 
2.16 About how much of your harvest do you sell (choose one)?  
 All / Two thirds / Half  / One third / None 
2.17 What month do you get money from the sale of crops? _______ 
2.18 Does your family own any livestock? ____ 
If yes, how many cattle/ buffalo do you own?  _______ 
How many goats/ sheep do you own? _______ 
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How many horses/ donkeys do you own? _______ 
 
3.  INCOME & EXPENDITURES 
3.1 What part of your family’s monthly income (money amount) comes from: 
Salaries _______ / Wages_______ / Rents_______ / Crop sales_______ 
Livestock sales_______ / Donations from others (family members abroad, etc.)_______ 
3.2  When does the family have spare cash? _______ 
3.3  How much do you spend per month on: 
Food?_______ / Rent?_______ / Clothing? _______ / Educational supplies? _______/ Medicine?_______ 
Other  ______ (what is it____________________________)?  
3.4  Do you ever obtain anything on credit (if yes, specify)? 
Clothing / Food / Medicines / Household goods (furniture, cooking pots, etc.)/Other______________) 
3.5  Could you get a bednet on credit? ____ 
 
4.  HEALTH & MALARIA VARIABLES 
4.1 Where do you go for treatment? 
 Clinic / Pharmacy / Private doctor / Other __________________________ 
4.2  When someone in the family gets sick, who decides if they should go to the clinic? 
Father / Mother / Other ____________________  
4.3  How many of your children have been vaccinated?  (all vaccinations / some) _______ 
If not, what is the reason? (cost / availability / difficulty / not useful / other ____________________ )  
4.4 How is malaria caused? 
Dirty water / Mosquito bites / Other __________________________ 
4.5 During what season do people catch malaria?  
 Spring / Summer / Autumn / Winter / All seasons 
4.6 Who are at greatest risk from malaria? 
Men / Women / Children / Other ____________________ 
4.7 Who in your family has had malaria in the past year? 
 Men  ____ / Women ____/ Children ____/ Other ____________________  
4.8 On average, how much does it cost to treat malaria?  
 Consultation (adult) _________(child) __________  
 Drugs (adult)___________(child) ______________ 
4.9 What is the best way to treat malaria (circle best answer) ?  
Paracetomol / Antibiotics / Chloroquine / Fansidar / Other ___________________________ 
4.10 What is the best way to protect yourself from malaria (circle best answer) ? 
Bednets / Traditional method ______________ / House insecticide / Other ___________ 
4.11 During what season are mosquitoes a problem (circle best answer) ? 
Spring / Summer / Autumn / Winter 
4.12 Where do mosquitoes breed? 
 Grass / Water / Other ______________________ 
4.13 How do you protect yourselves from mosquitoes (circle best answer) ? 
Bednets / Coils / Repellent oil or cream / Aerosol Insecticide / Other _____________________ 
 
5. BEDNETS 
5.1 Does your family own any bednets (if no, go to 5.5) ____ 
5.2 If your family owns bednets, how many do you have? _______ 
Who sleeps under the net/s?  (Men / Women / Children / Other _____________)  
Are the nets treated with insecticide? ____ 
5.3 What was the source of money for the net/s (circle best answer) ? 
Savings / Loan / Gift / Crop sales / Other (specify): ______________________ 
5.4 How often does your family retreat your bednets (circle best answer) ? 
Once a year / Every 6 months / After cleaning / Never / Other _____________________ 
5.5 Are you planning to buy any bednets? ____ 
If yes, when are you planning to buy any? _______ 
What makes you want to buy bednets (list reasons) ? 
1. ___________________ 
2. ___________________ 
3. ___________________ 
4. ___________________ 
5.6 If you are not planning to buy any, what is the main reason (circle best answer) ? 
Already have enough / Too expensive / Not necessary / Don’t like them / Other (_________________) 
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Annex 3. Chapter 6: Malaria in pregnancy survey questionnaire, Jalalabad 
Yes =1, No = 0, Do Not Know = 99, Other = 7 
No. 5 Questions Responses Coding 
1 Interviewer’s ID Number:   /____/____/____
/ 
2 Start/End time: ______: _____ ______: _____ /__ /__/ 
3 Respondent’s Name:   
4 Respondent’s Village:  /____/____/ 
5 Respondent’s District:   /____/ 
 
100.  SOCIO- ECONOMIC VARIABLES 
No. 15-16 Questions Coding Skips 
101 Approximately how old are you? |__|__|   
102 What is your husband’s approximate age? |__|__|   
103 Who is the head of your household? Father-in-Law 
Husband 
Brother-in-Law 
Other (___________________________) 
1 
2 
3 
7 
 
104 What is the highest level of education you 
have completed? 
NONE 
Religious/Informal 
Primary 
Middle 
High School  
University/Technical 
0 
1 
2 
3 
4 
5 
 
105 What is the highest level of education 
completed by anyone in your household? 
 
NONE 
Religious/Informal 
Primary 
Middle 
High School  
University/Technical 
0 
1 
2 
3 
4 
5 
 
106 How many people in the house, including 
you, can read? 
NONE    
|__|__| 
0 
1 
 
 
107 How many members of the household work?   NONE    
|__|__| 
0 
1 
 
108 What is the job of your household's primary 
wage earner? 
NONE 
Farmer 
Labourer  
Shop/Market 
Driver 
Office 
Other (___________________________) 
0 
1 
2 
3 
4 
5 
7 
 
109 How many people normally live in your 
house? 
|__|__|   
110 How many children under age 5 normally 
live in your house? 
NONE    
|__|__| 
0 
1 
 
111 How many rooms in your house? |__|__|   
112 Do you have a special room or bedding just 
for guests?   
NO 
YES 
0 
1 
 
113 Does your household own land? NO 
Number of jerebs (|__|__|)  YES 
0 
1 
 
114 Does your house have electricity? 
 
NO 
General/Purchased 
Personal Generator/Turbine 
0 
1 
2 
 
115 What is the drinking water source for the 
house? 
Stream 
Well 
Piped 
Other (__________________________) 
1 
2 
3 
7 
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No. 15-16 Questions Coding Skips 
116 Does anyone in your house own   
(If yes, how many?): 
Bicycle |__|__| 
Car/Truck |__|__| 
Cassette Player |__|__| 
 Rugs (e.g. Afghani, Iranian) |__|__| 
Curtains |__|__| 
Pressure Cooker |__|__| 
 (if no ITN, skip 500)                ITN |__|__| 
1 
2 
3 
4 
5 
6 
8 
 
 
 
200.  HEALTH VARIABLES 
No. 9-10 Questions Coding Skips 
201 What is the worst health problem in your 
community?  (Circle nearest answer) 
NOTHING 
Malaria  
Diarrhoea 
ARI 
Other (___________________________) 
0 
1 
2 
3 
7 
 
202 Where do you usually go first when someone 
in the family is sick?  (Circle nearest answer)  
Government Clinic 
Private Doctor 
Pharmacy/Drug seller 
Traditional/Self-Treatment 
Other (___________________________) 
1 
2 
3 
4 
7 
 
 
 
203 When a child in your family gets sick, who 
decides that they should go for treatment?  
(Circle nearest answer) 
Child’s Father 
Child’s Mother 
Other (___________________________) 
1 
2 
7 
 
204 As far as you know, are all of the vaccinations 
of the children in your household up-to-date?   
NO 
YES 
No children 
0 
1 
2 
 
206 
206 
205 If not, what is the reason?  (Circle all 
mentioned) 
Not Available 
Difficult/ Cannot Access 
No Benefit 
Dangerous/Do Not Trust Vaccinations 
Other (__________________________) 
1 
2 
3 
4 
7 
 
206 Have you had one or more tetanus toxoid 
(“TT”) vaccine? 
NO 
YES 
Yes, but only one 
Can’t remember 
0 
1 
2 
99 
 
208 
 
207 If not, what is the reason?  (Circle all 
mentioned) 
Not Available 
Difficult/ No Access 
No Benefit 
Dangerous/Do Not Trust Vaccinations 
Other (___________________________) 
1 
2 
3 
4 
7 
 
208 How do you protect yourselves from 
mosquitoes?  (Circle all mentioned) 
NOTHING 
ITN 
Repellent 
Burning Smoke 
Insect Spray 
Other (___________________________) 
0 
1 
2 
3 
4 
7 
 
301 
301 
301 
301 
301 
209 If you do nothing to protect yourselves from 
mosquitoes, why not?  (Circle all mentioned)   
Mosquitoes aren't a problem  
Not enough money 
Other (___________________________) 
1 
2 
7 
 
 
300.  PREGNANCY VARIABLES 
No. 18-20 Questions Coding Skips 
301 How many children, if any, have you had 
before this pregnancy? 
NONE    
|__|__| 
0 
1 
 
302 How many months pregnant do you think you 
are? 
|__|__|   
303 What foods, if any, do you avoid when you 
are pregnant? 
NONE 
Water 
Pickled Vegetables 
Meat 
Fruit 
Others (__________________________) 
0 
1 
2 
3 
4 
7 
305 
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No. 18-20 Questions Coding Skips 
304 Why do you avoid these foods? Make me feel sick 
Dangerous 
Other (___________________________) 
1 
2 
7 
 
305 What medicines or drugs do you avoid during 
your pregnancy? 
NONE, unless told to by Dr/midwife 
ALL 
Others (__________________________) 
0 
1 
7 
307 
 
306 Why do you avoid these medicines? Make me feel sick 
Dangerous 
Other (___________________________) 
1 
2 
7 
 
307 What special foods, supplements, or drugs do 
you take during your pregnancy? 
NONE 
Iron/Folate Supplement 
Malaria Chemoprophylaxis 
Extra Fruits 
Others 
(______________________________) 
0 
1 
2 
3 
7 
 
308 What kind of work/activities, if any, do you 
avoid during your pregnancy? 
NONE 
Heavy Lifting 
Travelling 
Others (__________________________) 
0 
1 
2 
7 
 
309 Where do you get advice about pregnancy 
and the delivery of your child? 
NOWHERE 
Female relative 
TBA 
Midwife 
Clinic/Hospital Staff 
Other (__________________________) 
0 
1 
2 
3 
4 
7 
 
310 Do you go to the clinic/hospital for routine 
antenatal care? 
NO 
YES 
0 
1 
312 
 
311 How often do you try to go to the ANC clinic 
during pregnancy? 
NEVER 
Only when there are problems 
Shortly before delivery 
At least 3-4 times during pregnancy 
Other (___________________________) 
0 
1 
2 
3 
7 
 
 
 
313 
 
312 If you do not regularly use ANC services, why 
not? 
Not useful/necessary 
Too expensive 
Too difficult to travel/wait, etc 
Husband does not allow it 
Other (__________________________) 
1 
2 
3 
4 
7 
 
313 Where do you expect to deliver your baby? Home 
Midwife’s Home 
Hospital/Clinic Delivery Room 
Other (___________________________) 
1 
2 
3 
7 
 
314 Why will you deliver your baby there? Feel comfortable there 
Help is available if something goes wrong 
Husband decided 
Other (___________________________) 
1 
2 
3 
7 
 
315 Who do you think will help deliver your baby? Untrained Female Relative 
TBA 
Midwife 
Doctor 
Other (__________________________) 
1 
2 
3 
4 
7 
 
316 Why do you expect this person to help you 
deliver your baby? 
Feel comfortable with them 
Help is available if something goes wrong 
Husband decided 
Other 
(______________________________) 
1 
2 
3 
7 
 
 
317 
What is your greatest worry during this 
pregnancy? 
NO SPECIFIC WORRIES 
Congenital abnormalities 
Difficult/High-Risk Delivery 
Malnourished Baby 
Other (___________________________) 
0 
1 
2 
3 
7 
401 
 
318 Why are you worried about this? Dr/Midwife has warned me 
I feel something abnormal 
Elders warned me 
Other (___________________________) 
1 
2 
3 
7 
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400.  MALARIA VARIABLES 
No. 15 Questions Coding Skips 
401 How common is malaria in your community?  
(Circle nearest answer) 
NONE/Rare 
Very common 
Somewhat common  
0 
1 
2 
 
402 What one symptom, besides fever, shows 
that someone has malaria?  (Circle two) 
Shivering/Chills 
Headache  
Weakness 
Joint Pain 
Other (__________________________) 
1 
2 
3 
4 
7 
 
403 How do you normally diagnose malaria? Self-diagnose based on symptoms 
Drug seller tells me 
Provider gives clinical diagnosis 
Provider gives blood test 
Other (__________________________) 
1 
2 
3 
4 
7 
 
404 How do you think people catch malaria?  
(Circle all mentioned) 
Mosquito bites 
Drinking dirty water 
Food (which? _____________________) 
General Weakness 
Catching a cold or Flu  
Other (__________________________) 
1 
2 
3 
4 
5 
7 
 
405 Who do you think is at greatest risk from 
malaria?  (Circle nearest answer)  
Children<5yrs 
Pregnant women 
Women 
Men 
Elderly/Sick 
Other (__________________________) 
1 
2 
3 
4 
5 
7 
 
406 Who in your family has had malaria in the 
past six months?  (estimated number of each) 
NO ONE  
Men |__|__| 
Women |__|__| 
Older Children |__|__| 
<5 Children  |__|__| 
Elderly |__|__| 
Other (_______________________)  
|__|__| 
0 
1 
2 
3 
4 
5 
7 
 
 
 
407 Have you ever had malaria while you were 
pregnant?  (Circle nearest answer) 
NEVER  
This pregnancy 
Once in previous pregnancy  
Several times in previous pregnancies 
0 
1 
2 
3 
 
408 Where do you go to treat malaria?  (Circle 
nearest answer) 
Clinic 
Private Doctor 
Drug seller 
Traditional 
Other (__________________________) 
1 
2 
3 
4 
7 
 
 
 
411 
 
409 Why do you go there for malaria? 
(Circle nearest answer) 
 
Most Affordable 
Most accessible 
Most effective 
Can get credit 
Other (__________________________) 
1 
2 
3 
4 
7 
 
410 What drugs do you usually use to treat 
malaria (Circle nearest answer)? 
Whatever the Doctor tells me 
Chloroquine 
SP 
Quinine 
Other 
(_____________________________) 
1 
2 
3 
7 
 
411 Why do you choose this treatment? Most affordable 
Most easily available 
Most effective 
Provider recommendation 
Other (__________________________) 
1 
2 
3 
4 
7 
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No. 15 Questions Coding Skips 
412 What is the best way to prevent malaria?  
(Circle nearest answer) 
NOTHING 
ITN 
Immediate treatment 
Burn smoke 
Drink clean water 
Keep house/area clean 
Eat clean food 
Prophylactic Drugs (Which? _________) 
Other (___________________________) 
0 
1 
2 
3 
4 
5 
6 
8 
7 
 
413 Do you think it is necessary to take special 
precautions against malaria while you are 
pregnant? 
NO 
YES 
0 
1 
 
414 What, if anything, are you doing to protect 
yourself from malaria while you are 
pregnant?  (Circle all mentioned) 
NOTHING 
Sleep under ITN 
Immediate diagnosis/treatment 
Burn smoke 
Keep house/area clean 
Clean food/water 
Prophylactic Drugs (Which? _________) 
Other (___________________________) 
0 
1 
2 
3 
4 
5 
6 
7 
 
501 
 
415 Would you take drugs during your pregnancy 
if they might help to prevent malaria? 
NEVER 
YES 
Maybe, if I knew enough about their 
safety 
Other 
(________________________________) 
0 
1 
2 
7 
 
 
500.  ITN VARIABLES (ITN OWNERS) 
No. 5-6 Questions Coding Skips 
501 
 
 
Who usually sleeps under ITN in your 
household?  (Circle all mentioned) 
NO, NOBODY 
All 
Children 
Women  
Elderly  
Men 
Other (__________________________) 
0 
1 
2 
3 
4 
5 
7 
 
502 If only some members use them, why? Not enough ITN 
Too hot/Uncomfortable 
Not Effective 
Other (__________________________) 
1 
2 
3 
7 
 
503 Did you sleep under ITN last night? NO 
YES 
0 
1 
 
504 If not, why not? Not bothered by mosquitoes 
Somebody else was using it  
Too hot 
Other (__________________________) 
1 
2 
3 
7 
  
505 As far as you know, how often does your 
family retreat your ITN with insecticide? 
NEVER/Less than Yearly 
Yearly or more often 
0 
1 
 
506 What do you think are the advantages of 
sleeping under ITN?  (Note all mentioned)   
Not bothered by mosquitoes 
Protection from malaria 
Prevent insect bites 
Other (__________________________) 
1 
2 
3 
7 
 2 
 2 
 2 
 2 
 
600.  ITN VARIABLES (NON-OWNERS) 
No. 1 Question Coding Skips 
601 
 
 
Why does your family not own any ITN? Too Expensive 
Not Available 
Not Useful 
Uncomfortable 
Other (__________________________) 
1 
2 
3 
4 
7 
 2 
 2 
 2 
 2 
 2 
 
-- END -- 
 
